WO2015012298A1 - キノリン誘導体 - Google Patents
キノリン誘導体 Download PDFInfo
- Publication number
- WO2015012298A1 WO2015012298A1 PCT/JP2014/069419 JP2014069419W WO2015012298A1 WO 2015012298 A1 WO2015012298 A1 WO 2015012298A1 JP 2014069419 W JP2014069419 W JP 2014069419W WO 2015012298 A1 WO2015012298 A1 WO 2015012298A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- oxy
- dioxo
- hexahydro
- quinolinyl
- Prior art date
Links
- 125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 308
- 239000003814 drug Substances 0.000 claims abstract description 25
- 201000010099 disease Diseases 0.000 claims abstract description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 18
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 16
- 201000011510 cancer Diseases 0.000 claims abstract description 14
- 125000002837 carbocyclic group Chemical group 0.000 claims abstract description 9
- 208000026278 immune system disease Diseases 0.000 claims abstract description 9
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims abstract description 8
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims abstract description 7
- 208000017169 kidney disease Diseases 0.000 claims abstract description 7
- 229940124597 therapeutic agent Drugs 0.000 claims abstract description 7
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 5
- 208000032612 Glial tumor Diseases 0.000 claims abstract description 4
- 206010018338 Glioma Diseases 0.000 claims abstract description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims abstract description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims abstract description 4
- 201000001441 melanoma Diseases 0.000 claims abstract description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims abstract description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims abstract description 4
- -1 6,7-dimethoxy-4-quinolinyl Chemical group 0.000 claims description 125
- DPWOVQNJUVKARF-UHFFFAOYSA-N n-[4-(6,7-dimethoxyquinolin-4-yl)oxy-3-fluorophenyl]-2,5-dioxo-1-phenyl-7,8-dihydro-6h-quinoline-3-carboxamide Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C(=C1)F)=CC=C1NC(=O)C(C1=O)=CC=2C(=O)CCCC=2N1C1=CC=CC=C1 DPWOVQNJUVKARF-UHFFFAOYSA-N 0.000 claims description 45
- 238000000034 method Methods 0.000 claims description 35
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 33
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 30
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 28
- 125000005843 halogen group Chemical group 0.000 claims description 26
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 25
- 150000003839 salts Chemical class 0.000 claims description 21
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 19
- 229920006395 saturated elastomer Polymers 0.000 claims description 19
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 17
- JVDSXTMARYJGHC-UHFFFAOYSA-N n-[5-[7-(3-hydroxy-3-methylbutoxy)-6-methoxyquinolin-4-yl]oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6h-quinoline-3-carboxamide Chemical compound C1=CN=C2C=C(OCCC(C)(C)O)C(OC)=CC2=C1OC(C=N1)=CC=C1NC(=O)C(C1=O)=CC=2C(=O)CCCC=2N1C1=CC=CC=C1 JVDSXTMARYJGHC-UHFFFAOYSA-N 0.000 claims description 17
- 229910052757 nitrogen Inorganic materials 0.000 claims description 17
- 229940002612 prodrug Drugs 0.000 claims description 15
- 239000000651 prodrug Substances 0.000 claims description 15
- 239000012453 solvate Substances 0.000 claims description 15
- 229910052799 carbon Inorganic materials 0.000 claims description 14
- 125000004432 carbon atom Chemical group C* 0.000 claims description 14
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 14
- 150000001204 N-oxides Chemical class 0.000 claims description 13
- 125000000217 alkyl group Chemical group 0.000 claims description 13
- 239000003795 chemical substances by application Substances 0.000 claims description 13
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 12
- 150000001721 carbon Chemical class 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 125000001424 substituent group Chemical group 0.000 claims description 12
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 11
- 125000004122 cyclic group Chemical group 0.000 claims description 11
- 125000000623 heterocyclic group Chemical group 0.000 claims description 11
- 239000003112 inhibitor Substances 0.000 claims description 10
- IZUBNVRREPKQMJ-UHFFFAOYSA-N n-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-1-(2,2-dimethylpropyl)-2,5-dioxo-7,8-dihydro-6h-quinoline-3-carboxamide Chemical compound O=C1CCCC(N(CC(C)(C)C)C2=O)=C1C=C2C(=O)NC(N=C1)=CC=C1OC1=C(C=C(C(OC)=C2)OC)C2=NC=C1 IZUBNVRREPKQMJ-UHFFFAOYSA-N 0.000 claims description 10
- FHXYADDJHWWNDR-UHFFFAOYSA-N n-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-1-(3-fluorophenyl)-2,5-dioxo-7,8-dihydro-6h-quinoline-3-carboxamide Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=N1)=CC=C1NC(=O)C(C1=O)=CC=2C(=O)CCCC=2N1C1=CC=CC(F)=C1 FHXYADDJHWWNDR-UHFFFAOYSA-N 0.000 claims description 10
- 208000035217 Ring chromosome 1 syndrome Diseases 0.000 claims description 9
- WHMMKPWGWNYYFE-UHFFFAOYSA-N n-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6h-quinoline-3-carboxamide Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=N1)=CC=C1NC(=O)C(C1=O)=CC=2C(=O)CCCC=2N1C1=CC=CC=C1 WHMMKPWGWNYYFE-UHFFFAOYSA-N 0.000 claims description 9
- GWEMOSLWOWNLBJ-UHFFFAOYSA-N n-[5-[6-methoxy-7-(3-morpholin-4-ylpropoxy)quinolin-4-yl]oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6h-quinoline-3-carboxamide Chemical compound C1=CN=C2C=C(OCCCN3CCOCC3)C(OC)=CC2=C1OC(C=N1)=CC=C1NC(=O)C(C1=O)=CC=2C(=O)CCCC=2N1C1=CC=CC=C1 GWEMOSLWOWNLBJ-UHFFFAOYSA-N 0.000 claims description 9
- 230000003449 preventive effect Effects 0.000 claims description 9
- XMFHUZWFSMNTPK-UHFFFAOYSA-N n-[4-(6,7-dimethoxyquinolin-4-yl)oxy-3-fluorophenyl]-1-(3-fluorophenyl)-2,5-dioxo-7,8-dihydro-6h-quinoline-3-carboxamide Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C(=C1)F)=CC=C1NC(=O)C(C1=O)=CC=2C(=O)CCCC=2N1C1=CC=CC(F)=C1 XMFHUZWFSMNTPK-UHFFFAOYSA-N 0.000 claims description 8
- DOMPKDJRNKHEGM-UHFFFAOYSA-N n-[5-(6,7-dimethoxyquinazolin-4-yl)oxypyridin-2-yl]-1-(4-fluorophenyl)-2,5-dioxo-7,8-dihydro-6h-quinoline-3-carboxamide Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1OC(C=N1)=CC=C1NC(=O)C(C1=O)=CC=2C(=O)CCCC=2N1C1=CC=C(F)C=C1 DOMPKDJRNKHEGM-UHFFFAOYSA-N 0.000 claims description 8
- ILYAUCKXNMUTJG-UHFFFAOYSA-N n-[5-(6,7-dimethoxyquinazolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6h-quinoline-3-carboxamide Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1OC(C=N1)=CC=C1NC(=O)C(C1=O)=CC=2C(=O)CCCC=2N1C1=CC=CC=C1 ILYAUCKXNMUTJG-UHFFFAOYSA-N 0.000 claims description 8
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 7
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 7
- CAOFMNSZQBWLPN-UHFFFAOYSA-N n-[4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]-2,5-dioxo-1-phenyl-7,8-dihydro-6h-quinoline-3-carboxamide Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1NC(=O)C(C1=O)=CC=2C(=O)CCCC=2N1C1=CC=CC=C1 CAOFMNSZQBWLPN-UHFFFAOYSA-N 0.000 claims description 7
- IMTMHQGDXCGVBB-UHFFFAOYSA-N n-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-1-(2-fluorophenyl)-2,5-dioxo-7,8-dihydro-6h-quinoline-3-carboxamide Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=N1)=CC=C1NC(=O)C(C1=O)=CC=2C(=O)CCCC=2N1C1=CC=CC=C1F IMTMHQGDXCGVBB-UHFFFAOYSA-N 0.000 claims description 7
- MTVWJVOHRAHOCE-UHFFFAOYSA-N n-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-7,7-dimethyl-2,5-dioxo-1-phenyl-6,8-dihydroquinoline-3-carboxamide Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=N1)=CC=C1NC(=O)C(C1=O)=CC=2C(=O)CC(C)(C)CC=2N1C1=CC=CC=C1 MTVWJVOHRAHOCE-UHFFFAOYSA-N 0.000 claims description 7
- 125000004043 oxo group Chemical group O=* 0.000 claims description 6
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 3
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 3
- 208000036764 Adenocarcinoma of the esophagus Diseases 0.000 claims description 3
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 3
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims description 3
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 206010014733 Endometrial cancer Diseases 0.000 claims description 3
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 3
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 3
- 206010030137 Oesophageal adenocarcinoma Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 3
- 206010039491 Sarcoma Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 3
- 201000005969 Uveal melanoma Diseases 0.000 claims description 3
- 125000003302 alkenyloxy group Chemical group 0.000 claims description 3
- 125000005133 alkynyloxy group Chemical group 0.000 claims description 3
- 239000002257 antimetastatic agent Substances 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- 208000028653 esophageal adenocarcinoma Diseases 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 201000010536 head and neck cancer Diseases 0.000 claims description 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 3
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 201000002510 thyroid cancer Diseases 0.000 claims description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 3
- 125000006701 (C1-C7) alkyl group Chemical group 0.000 claims description 2
- OYQFLSVRMQSFJI-UHFFFAOYSA-N 2,5-dioxo-1-phenyl-7,8-dihydro-6h-quinoline-3-carboxamide Chemical compound O=C1C(C(=O)N)=CC=2C(=O)CCCC=2N1C1=CC=CC=C1 OYQFLSVRMQSFJI-UHFFFAOYSA-N 0.000 claims description 2
- 125000003342 alkenyl group Chemical group 0.000 claims description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims description 2
- SWZCRBJUHYKUDR-UHFFFAOYSA-N 1,2,3,4,4a,5-hexahydroquinoline-3-carboxamide Chemical compound C1=CCC2CC(C(=O)N)CNC2=C1 SWZCRBJUHYKUDR-UHFFFAOYSA-N 0.000 claims 1
- 150000003857 carboxamides Chemical class 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 abstract description 17
- 125000002619 bicyclic group Chemical group 0.000 abstract description 3
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical group OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 abstract description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 708
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 354
- 238000005160 1H NMR spectroscopy Methods 0.000 description 185
- 238000004809 thin layer chromatography Methods 0.000 description 169
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 117
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 114
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 101
- 239000000243 solution Substances 0.000 description 73
- NEVGKHMVHTYTCD-UHFFFAOYSA-N n-[5-[7-(3-morpholin-4-ylpropoxy)quinolin-4-yl]oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6h-quinoline-3-carboxamide Chemical compound C=1C=2C(=O)CCCC=2N(C=2C=CC=CC=2)C(=O)C=1C(=O)NC(N=C1)=CC=C1OC(C1=CC=2)=CC=NC1=CC=2OCCCN1CCOCC1 NEVGKHMVHTYTCD-UHFFFAOYSA-N 0.000 description 65
- 239000000203 mixture Substances 0.000 description 62
- 238000006243 chemical reaction Methods 0.000 description 58
- 239000000377 silicon dioxide Substances 0.000 description 55
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 54
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 47
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 45
- 238000000105 evaporative light scattering detection Methods 0.000 description 38
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 37
- 239000002904 solvent Substances 0.000 description 37
- 230000014759 maintenance of location Effects 0.000 description 36
- 230000000704 physical effect Effects 0.000 description 35
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 32
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 31
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 31
- 239000012044 organic layer Substances 0.000 description 29
- 230000002829 reductive effect Effects 0.000 description 29
- 238000012360 testing method Methods 0.000 description 29
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 28
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 28
- 238000002360 preparation method Methods 0.000 description 28
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 27
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 25
- 238000010898 silica gel chromatography Methods 0.000 description 24
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 22
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 22
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 21
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 21
- 229940079593 drug Drugs 0.000 description 18
- 230000005764 inhibitory process Effects 0.000 description 17
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- 238000010511 deprotection reaction Methods 0.000 description 15
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 14
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 14
- 235000002597 Solanum melongena Nutrition 0.000 description 14
- 239000002253 acid Substances 0.000 description 14
- 239000003960 organic solvent Substances 0.000 description 14
- 239000011541 reaction mixture Substances 0.000 description 14
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 12
- 230000000052 comparative effect Effects 0.000 description 12
- 238000001914 filtration Methods 0.000 description 12
- 239000010410 layer Substances 0.000 description 12
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 11
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 11
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 11
- 235000017557 sodium bicarbonate Nutrition 0.000 description 11
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 10
- 239000012300 argon atmosphere Substances 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 9
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 9
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 9
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 8
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 102000002263 Cytochrome P-450 CYP2C8 Human genes 0.000 description 7
- 108010000561 Cytochrome P-450 CYP2C8 Proteins 0.000 description 7
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 7
- 239000012298 atmosphere Substances 0.000 description 7
- 239000002585 base Substances 0.000 description 7
- 238000010438 heat treatment Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 6
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 6
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- MGNZXYYWBUKAII-UHFFFAOYSA-N cyclohexa-1,3-diene Chemical compound C1CC=CC=C1 MGNZXYYWBUKAII-UHFFFAOYSA-N 0.000 description 6
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 6
- 150000004820 halides Chemical class 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- YSYQKADPJSFBRQ-XMMPIXPASA-N n-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-2,5-dioxo-7,8-dihydro-6h-quinoline-3-carboxamide Chemical compound O=C1CCCC(N([C@H](CO)C(C)C)C2=O)=C1C=C2C(=O)NC(N=C1)=CC=C1OC1=C(C=C(C(OC)=C2)OC)C2=NC=C1 YSYQKADPJSFBRQ-XMMPIXPASA-N 0.000 description 6
- 239000002997 ophthalmic solution Substances 0.000 description 6
- 229940054534 ophthalmic solution Drugs 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 239000011535 reaction buffer Substances 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- WRVHQEYBCDPZEU-UHFFFAOYSA-N 4-chloro-6,7-dimethoxyquinoline Chemical compound C1=CC(Cl)=C2C=C(OC)C(OC)=CC2=N1 WRVHQEYBCDPZEU-UHFFFAOYSA-N 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 5
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 5
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 5
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- LNAMMBFJMYMQTO-FNEBRGMMSA-N chloroform;(1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].ClC(Cl)Cl.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 LNAMMBFJMYMQTO-FNEBRGMMSA-N 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 229910052751 metal Inorganic materials 0.000 description 5
- 239000002184 metal Substances 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- FKJLOAZSDMFTCD-UHFFFAOYSA-N n-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-6,6-dimethyl-2,5-dioxo-1-phenyl-7,8-dihydroquinoline-3-carboxamide Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=N1)=CC=C1NC(=O)C(C1=O)=CC=2C(=O)C(C)(C)CCC=2N1C1=CC=CC=C1 FKJLOAZSDMFTCD-UHFFFAOYSA-N 0.000 description 5
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 5
- 125000006239 protecting group Chemical group 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- CZSRXHJVZUBEGW-UHFFFAOYSA-N 1,2-thiazolidine Chemical compound C1CNSC1 CZSRXHJVZUBEGW-UHFFFAOYSA-N 0.000 description 4
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 4
- YUCBLVFHJWOYDN-HVLQGHBFSA-N 1,4-bis[(s)-[(2r,4s,5r)-5-ethyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methoxy]phthalazine Chemical compound C1=C(OC)C=C2C([C@H](OC=3C4=CC=CC=C4C(O[C@H]([C@@H]4N5CC[C@H]([C@H](C5)CC)C4)C=4C5=CC(OC)=CC=C5N=CC=4)=NN=3)[C@H]3C[C@@H]4CCN3C[C@@H]4CC)=CC=NC2=C1 YUCBLVFHJWOYDN-HVLQGHBFSA-N 0.000 description 4
- QMEQBOSUJUOXMX-UHFFFAOYSA-N 2h-oxadiazine Chemical compound N1OC=CC=N1 QMEQBOSUJUOXMX-UHFFFAOYSA-N 0.000 description 4
- NWWJFMCCTZLKNT-UHFFFAOYSA-N 3,4-dihydro-2h-thiazine Chemical compound C1CC=CSN1 NWWJFMCCTZLKNT-UHFFFAOYSA-N 0.000 description 4
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 4
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 4
- 239000007821 HATU Substances 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- WYNCHZVNFNFDNH-UHFFFAOYSA-N Oxazolidine Chemical compound C1COCN1 WYNCHZVNFNFDNH-UHFFFAOYSA-N 0.000 description 4
- 108091000080 Phosphotransferase Proteins 0.000 description 4
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 4
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- 229960002537 betamethasone Drugs 0.000 description 4
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 4
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 4
- 229910000024 caesium carbonate Inorganic materials 0.000 description 4
- 239000003054 catalyst Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 4
- ZSWFCLXCOIISFI-UHFFFAOYSA-N cyclopentadiene Chemical compound C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 4
- LPIQUOYDBNQMRZ-UHFFFAOYSA-N cyclopentene Chemical compound C1CC=CC1 LPIQUOYDBNQMRZ-UHFFFAOYSA-N 0.000 description 4
- 230000032050 esterification Effects 0.000 description 4
- 238000005886 esterification reaction Methods 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- DTHHUAXKOMWYBI-UHFFFAOYSA-N oxadiazolidine Chemical compound C1CONN1 DTHHUAXKOMWYBI-UHFFFAOYSA-N 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 102000020233 phosphotransferase Human genes 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 150000003248 quinolines Chemical class 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- VNFWTIYUKDMAOP-UHFFFAOYSA-N sphos Chemical compound COC1=CC=CC(OC)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 VNFWTIYUKDMAOP-UHFFFAOYSA-N 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- RLTPJVKHGBFGQA-UHFFFAOYSA-N thiadiazolidine Chemical compound C1CSNN1 RLTPJVKHGBFGQA-UHFFFAOYSA-N 0.000 description 4
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 4
- PYOKUURKVVELLB-UHFFFAOYSA-N trimethyl orthoformate Chemical compound COC(OC)OC PYOKUURKVVELLB-UHFFFAOYSA-N 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 description 3
- OQJVXNHMUWQQEW-UHFFFAOYSA-N 1,2,3,4-tetrahydropyrazine Chemical compound C1CNC=CN1 OQJVXNHMUWQQEW-UHFFFAOYSA-N 0.000 description 3
- JQIZHNLEFQMDCQ-UHFFFAOYSA-N 1,2,3,4-tetrahydropyridazine Chemical compound C1CC=CNN1 JQIZHNLEFQMDCQ-UHFFFAOYSA-N 0.000 description 3
- OTPDWCMLUKMQNO-UHFFFAOYSA-N 1,2,3,4-tetrahydropyrimidine Chemical compound C1NCC=CN1 OTPDWCMLUKMQNO-UHFFFAOYSA-N 0.000 description 3
- RFFLAFLAYFXFSW-UHFFFAOYSA-N 1,2-dichlorobenzene Chemical compound ClC1=CC=CC=C1Cl RFFLAFLAYFXFSW-UHFFFAOYSA-N 0.000 description 3
- QYMGRIFMUQCAJW-UHFFFAOYSA-N 1,2-dihydropyrazine Chemical compound C1NC=CN=C1 QYMGRIFMUQCAJW-UHFFFAOYSA-N 0.000 description 3
- BKWQKVJYXODDAC-UHFFFAOYSA-N 1,2-dihydropyridazine Chemical compound N1NC=CC=C1 BKWQKVJYXODDAC-UHFFFAOYSA-N 0.000 description 3
- WCFAPJDPAPDDAQ-UHFFFAOYSA-N 1,2-dihydropyrimidine Chemical compound C1NC=CC=N1 WCFAPJDPAPDDAQ-UHFFFAOYSA-N 0.000 description 3
- CXWGKAYMVASWDQ-UHFFFAOYSA-N 1,2-dithiane Chemical compound C1CCSSC1 CXWGKAYMVASWDQ-UHFFFAOYSA-N 0.000 description 3
- DKYBVKMIZODYKL-UHFFFAOYSA-N 1,3-diazinane Chemical compound C1CNCNC1 DKYBVKMIZODYKL-UHFFFAOYSA-N 0.000 description 3
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 3
- VSWICNJIUPRZIK-UHFFFAOYSA-N 2-piperideine Chemical compound C1CNC=CC1 VSWICNJIUPRZIK-UHFFFAOYSA-N 0.000 description 3
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 3
- BCHZICNRHXRCHY-UHFFFAOYSA-N 2h-oxazine Chemical compound N1OC=CC=C1 BCHZICNRHXRCHY-UHFFFAOYSA-N 0.000 description 3
- AGIJRRREJXSQJR-UHFFFAOYSA-N 2h-thiazine Chemical compound N1SC=CC=C1 AGIJRRREJXSQJR-UHFFFAOYSA-N 0.000 description 3
- BOLMDIXLULGTBD-UHFFFAOYSA-N 3,4-dihydro-2h-oxazine Chemical compound C1CC=CON1 BOLMDIXLULGTBD-UHFFFAOYSA-N 0.000 description 3
- ATVJJNGVPSKBGO-UHFFFAOYSA-N 3,4-dihydro-2h-thiopyran Chemical compound C1CSC=CC1 ATVJJNGVPSKBGO-UHFFFAOYSA-N 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- LLLHRNQLGUOJHP-UHFFFAOYSA-N 4-chloro-6,7-dimethoxyquinazoline Chemical compound C1=NC(Cl)=C2C=C(OC)C(OC)=CC2=N1 LLLHRNQLGUOJHP-UHFFFAOYSA-N 0.000 description 3
- UKTYNFPTZDSBLR-UHFFFAOYSA-N 4-chloro-7-methoxyquinoline Chemical compound ClC1=CC=NC2=CC(OC)=CC=C21 UKTYNFPTZDSBLR-UHFFFAOYSA-N 0.000 description 3
- KVCOOWROABTXDJ-UHFFFAOYSA-N 6-chloropyridin-3-ol Chemical compound OC1=CC=C(Cl)N=C1 KVCOOWROABTXDJ-UHFFFAOYSA-N 0.000 description 3
- 239000005541 ACE inhibitor Substances 0.000 description 3
- 229940123413 Angiotensin II antagonist Drugs 0.000 description 3
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 3
- 101000807561 Homo sapiens Tyrosine-protein kinase receptor UFO Proteins 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 3
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 3
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 3
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 3
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Natural products P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 102000015433 Prostaglandin Receptors Human genes 0.000 description 3
- 108010050183 Prostaglandin Receptors Proteins 0.000 description 3
- 102000001253 Protein Kinase Human genes 0.000 description 3
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 3
- 239000012979 RPMI medium Substances 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 3
- JZFICWYCTCCINF-UHFFFAOYSA-N Thiadiazin Chemical compound S=C1SC(C)NC(C)N1CCN1C(=S)SC(C)NC1C JZFICWYCTCCINF-UHFFFAOYSA-N 0.000 description 3
- YPWFISCTZQNZAU-UHFFFAOYSA-N Thiane Chemical compound C1CCSCC1 YPWFISCTZQNZAU-UHFFFAOYSA-N 0.000 description 3
- 102100037236 Tyrosine-protein kinase receptor UFO Human genes 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- 150000008065 acid anhydrides Chemical class 0.000 description 3
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 229960000711 alprostadil Drugs 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 3
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 3
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 3
- 229940127218 antiplatelet drug Drugs 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- HJSLFCCWAKVHIW-UHFFFAOYSA-N cyclohexane-1,3-dione Chemical compound O=C1CCCC(=O)C1 HJSLFCCWAKVHIW-UHFFFAOYSA-N 0.000 description 3
- HTFFABIIOAKIBH-UHFFFAOYSA-N diazinane Chemical compound C1CCNNC1 HTFFABIIOAKIBH-UHFFFAOYSA-N 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000003889 eye drop Substances 0.000 description 3
- 229940012356 eye drops Drugs 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 3
- 239000003018 immunosuppressive agent Substances 0.000 description 3
- 238000004020 luminiscence type Methods 0.000 description 3
- 229960000485 methotrexate Drugs 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 3
- HJHCUWIEHYPGCH-UHFFFAOYSA-N n-[5-[6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinolin-4-yl]oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6h-quinoline-3-carboxamide Chemical compound C1=CN=C2C=C(OCCCN3CCCC3)C(OC)=CC2=C1OC(C=N1)=CC=C1NC(=O)C(C1=O)=CC=2C(=O)CCCC=2N1C1=CC=CC=C1 HJHCUWIEHYPGCH-UHFFFAOYSA-N 0.000 description 3
- 201000008383 nephritis Diseases 0.000 description 3
- PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Substances [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 3
- BVOCPVIXARZNQN-UHFFFAOYSA-N nipecotamide Chemical compound NC(=O)C1CCCNC1 BVOCPVIXARZNQN-UHFFFAOYSA-N 0.000 description 3
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- XCRJTRCPEJKXLR-UHFFFAOYSA-N oxadiazinane Chemical compound C1CNNOC1 XCRJTRCPEJKXLR-UHFFFAOYSA-N 0.000 description 3
- IVMHDOBGNQOUHO-UHFFFAOYSA-N oxathiane Chemical compound C1CCSOC1 IVMHDOBGNQOUHO-UHFFFAOYSA-N 0.000 description 3
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 229940127557 pharmaceutical product Drugs 0.000 description 3
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 3
- 150000003180 prostaglandins Chemical class 0.000 description 3
- 108060006633 protein kinase Proteins 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 3
- 238000006722 reduction reaction Methods 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 3
- 229960001940 sulfasalazine Drugs 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- KHVCOYGKHDJPBZ-WDCZJNDASA-N tetrahydrooxazine Chemical compound OC[C@H]1ONC[C@@H](O)[C@@H]1O KHVCOYGKHDJPBZ-WDCZJNDASA-N 0.000 description 3
- PGAZQSBUJDVGIX-UHFFFAOYSA-N thiazepane Chemical compound C1CCNSCC1 PGAZQSBUJDVGIX-UHFFFAOYSA-N 0.000 description 3
- NYERMPLPURRVGM-UHFFFAOYSA-N thiazepine Chemical compound S1C=CC=CC=N1 NYERMPLPURRVGM-UHFFFAOYSA-N 0.000 description 3
- AJZGFFKDLABHDD-UHFFFAOYSA-N thiazinane Chemical compound C1CCSNC1 AJZGFFKDLABHDD-UHFFFAOYSA-N 0.000 description 3
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 3
- IBBLKSWSCDAPIF-UHFFFAOYSA-N thiopyran Chemical compound S1C=CC=C=C1 IBBLKSWSCDAPIF-UHFFFAOYSA-N 0.000 description 3
- 238000002877 time resolved fluorescence resonance energy transfer Methods 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- OBETXYAYXDNJHR-SSDOTTSWSA-M (2r)-2-ethylhexanoate Chemical compound CCCC[C@@H](CC)C([O-])=O OBETXYAYXDNJHR-SSDOTTSWSA-M 0.000 description 2
- VUAFHZCUKUDDBC-SCSAIBSYSA-N (2s)-2-[(2-methyl-2-sulfanylpropanoyl)amino]-3-sulfanylpropanoic acid Chemical compound CC(C)(S)C(=O)N[C@H](CS)C(O)=O VUAFHZCUKUDDBC-SCSAIBSYSA-N 0.000 description 2
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 2
- VLSDXINSOMDCBK-BQYQJAHWSA-N (E)-1,1'-azobis(N,N-dimethylformamide) Chemical compound CN(C)C(=O)\N=N\C(=O)N(C)C VLSDXINSOMDCBK-BQYQJAHWSA-N 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 2
- 0 *[C@@]1/C=*/[C@@]2C(*)=C(*)C(*)=C(*)C2C(O)=CCC1 Chemical compound *[C@@]1/C=*/[C@@]2C(*)=C(*)C(*)=C(*)C2C(O)=CCC1 0.000 description 2
- UUZJJNBYJDFQHL-UHFFFAOYSA-N 1,2,3-triazolidine Chemical compound C1CNNN1 UUZJJNBYJDFQHL-UHFFFAOYSA-N 0.000 description 2
- AGSHYIAAUGKFEA-UHFFFAOYSA-N 1,2,5-oxadiazolidine Chemical compound C1CNON1 AGSHYIAAUGKFEA-UHFFFAOYSA-N 0.000 description 2
- LRANPJDWHYRCER-UHFFFAOYSA-N 1,2-diazepine Chemical compound N1C=CC=CC=N1 LRANPJDWHYRCER-UHFFFAOYSA-N 0.000 description 2
- CIISBYKBBMFLEZ-UHFFFAOYSA-N 1,2-oxazolidine Chemical compound C1CNOC1 CIISBYKBBMFLEZ-UHFFFAOYSA-N 0.000 description 2
- GWYPDXLJACEENP-UHFFFAOYSA-N 1,3-cycloheptadiene Chemical compound C1CC=CC=CC1 GWYPDXLJACEENP-UHFFFAOYSA-N 0.000 description 2
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 2
- IMLSAISZLJGWPP-UHFFFAOYSA-N 1,3-dithiolane Chemical compound C1CSCS1 IMLSAISZLJGWPP-UHFFFAOYSA-N 0.000 description 2
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 2
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- SCEIUGQQBYRBPP-UHFFFAOYSA-N 2,3,4,5-tetrahydro-1h-azepine Chemical compound C1CCC=CNC1 SCEIUGQQBYRBPP-UHFFFAOYSA-N 0.000 description 2
- YYVKQFQZKSLYFN-UHFFFAOYSA-N 2,3,4,5-tetrahydro-1h-diazepine Chemical compound C1CNNC=CC1 YYVKQFQZKSLYFN-UHFFFAOYSA-N 0.000 description 2
- GLCYMVDVOVIDBB-UHFFFAOYSA-N 2,3,4,5-tetrahydrooxadiazepine Chemical compound C1CC=CONN1 GLCYMVDVOVIDBB-UHFFFAOYSA-N 0.000 description 2
- ABQOPHYTASMWLA-UHFFFAOYSA-N 2,3,4,5-tetrahydrooxazepine Chemical compound C1CNOC=CC1 ABQOPHYTASMWLA-UHFFFAOYSA-N 0.000 description 2
- SOHIYESEPVZKHS-UHFFFAOYSA-N 2,3,4,5-tetrahydrooxepine Chemical compound C1CCC=COC1 SOHIYESEPVZKHS-UHFFFAOYSA-N 0.000 description 2
- WHUAPUGLAGYTQS-UHFFFAOYSA-N 2,3,4,5-tetrahydrothiadiazepine Chemical compound C1CC=CSNN1 WHUAPUGLAGYTQS-UHFFFAOYSA-N 0.000 description 2
- IFPKIMVCYSSDDJ-UHFFFAOYSA-N 2,3,4,5-tetrahydrothiazepine Chemical compound C1CNSC=CC1 IFPKIMVCYSSDDJ-UHFFFAOYSA-N 0.000 description 2
- VRKPANGTGANDRQ-UHFFFAOYSA-N 2,3,4,5-tetrahydrothiepine Chemical compound C1CCC=CSC1 VRKPANGTGANDRQ-UHFFFAOYSA-N 0.000 description 2
- OXBLVCZKDOZZOJ-UHFFFAOYSA-N 2,3-Dihydrothiophene Chemical compound C1CC=CS1 OXBLVCZKDOZZOJ-UHFFFAOYSA-N 0.000 description 2
- FJRPOHLDJUJARI-UHFFFAOYSA-N 2,3-dihydro-1,2-oxazole Chemical compound C1NOC=C1 FJRPOHLDJUJARI-UHFFFAOYSA-N 0.000 description 2
- YTQQIHUQLOZOJI-UHFFFAOYSA-N 2,3-dihydro-1,2-thiazole Chemical compound C1NSC=C1 YTQQIHUQLOZOJI-UHFFFAOYSA-N 0.000 description 2
- ZABMHLDQFJHDSC-UHFFFAOYSA-N 2,3-dihydro-1,3-oxazole Chemical compound C1NC=CO1 ZABMHLDQFJHDSC-UHFFFAOYSA-N 0.000 description 2
- OYJGEOAXBALSMM-UHFFFAOYSA-N 2,3-dihydro-1,3-thiazole Chemical compound C1NC=CS1 OYJGEOAXBALSMM-UHFFFAOYSA-N 0.000 description 2
- BEWVAZNECYSPMT-UHFFFAOYSA-N 2,3-dihydro-1h-azepine Chemical compound C1CC=CC=CN1 BEWVAZNECYSPMT-UHFFFAOYSA-N 0.000 description 2
- QHYXWSXPPUTDRA-UHFFFAOYSA-N 2,3-dihydro-1h-diazepine Chemical compound C1NNC=CC=C1 QHYXWSXPPUTDRA-UHFFFAOYSA-N 0.000 description 2
- JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 description 2
- WLGQUBABAPAJNB-UHFFFAOYSA-N 2,3-dihydrooxepine Chemical compound C1CC=CC=CO1 WLGQUBABAPAJNB-UHFFFAOYSA-N 0.000 description 2
- IZEOXCXHDBQQAP-UHFFFAOYSA-N 2,3-dihydrothiazepine Chemical compound C1NSC=CC=C1 IZEOXCXHDBQQAP-UHFFFAOYSA-N 0.000 description 2
- PZJFUNZDCRKXPZ-UHFFFAOYSA-N 2,5-dihydro-1h-tetrazole Chemical compound C1NNN=N1 PZJFUNZDCRKXPZ-UHFFFAOYSA-N 0.000 description 2
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 2
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- PYSGFFTXMUWEOT-UHFFFAOYSA-N 3-(dimethylamino)propan-1-ol Chemical compound CN(C)CCCO PYSGFFTXMUWEOT-UHFFFAOYSA-N 0.000 description 2
- YUCBLVFHJWOYDN-PPIALRKJSA-N 4-[(r)-[(2r,4s,5r)-5-ethyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methoxy]-1-[(r)-[(2r,4r,5s)-5-ethyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methoxy]phthalazine Chemical compound C1=C(OC)C=C2C([C@@H](OC=3C4=CC=CC=C4C(O[C@@H]([C@@H]4N5CC[C@@H]([C@@H](C5)CC)C4)C=4C5=CC(OC)=CC=C5N=CC=4)=NN=3)[C@H]3C[C@@H]4CCN3C[C@@H]4CC)=CC=NC2=C1 YUCBLVFHJWOYDN-PPIALRKJSA-N 0.000 description 2
- PLIKAWJENQZMHA-UHFFFAOYSA-N 4-aminophenol Chemical compound NC1=CC=C(O)C=C1 PLIKAWJENQZMHA-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- QOGPNCUTXVZQSL-UHFFFAOYSA-N 6,7-dimethoxy-1h-quinolin-4-one Chemical compound C1=CC(O)=C2C=C(OC)C(OC)=CC2=N1 QOGPNCUTXVZQSL-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229940126062 Compound A Drugs 0.000 description 2
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical class CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 102100036725 Epithelial discoidin domain-containing receptor 1 Human genes 0.000 description 2
- 101710131668 Epithelial discoidin domain-containing receptor 1 Proteins 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 101150022345 GAS6 gene Proteins 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 2
- 101000686031 Homo sapiens Proto-oncogene tyrosine-protein kinase ROS Proteins 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 2
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 2
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- PZJROHXRBWVVTE-UHFFFAOYSA-N N-[5-(7-hydroxy-6-methoxyquinolin-4-yl)oxypyridin-2-yl]-2-oxo-1-phenyl-5,6,7,8-tetrahydroquinoline-3-carboxamide Chemical compound OC1=C(C=C2C(=CC=NC2=C1)OC=1C=CC(=NC=1)NC(=O)C=1C(N(C=2CCCCC=2C=1)C1=CC=CC=C1)=O)OC PZJROHXRBWVVTE-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- VENLWXBLRNPEBX-UHFFFAOYSA-N O=C1N(C=2CCCC(C=2C=C1C(=O)NC1=CC=C(C=C1)OC1=NC=NC2=CC=CC=C12)=O)C1=CC=CC=C1 Chemical compound O=C1N(C=2CCCC(C=2C=C1C(=O)NC1=CC=C(C=C1)OC1=NC=NC2=CC=CC=C12)=O)C1=CC=CC=C1 VENLWXBLRNPEBX-UHFFFAOYSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 235000021314 Palmitic acid Nutrition 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- LRJOMUJRLNCICJ-JZYPGELDSA-N Prednisolone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O LRJOMUJRLNCICJ-JZYPGELDSA-N 0.000 description 2
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 2
- 102000009389 Prostaglandin D receptors Human genes 0.000 description 2
- 108050000258 Prostaglandin D receptors Proteins 0.000 description 2
- 102100023347 Proto-oncogene tyrosine-protein kinase ROS Human genes 0.000 description 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 108091008605 VEGF receptors Proteins 0.000 description 2
- 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 description 2
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 2
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 description 2
- 235000010724 Wisteria floribunda Nutrition 0.000 description 2
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 229940022663 acetate Drugs 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000007259 addition reaction Methods 0.000 description 2
- 239000001361 adipic acid Substances 0.000 description 2
- 235000011037 adipic acid Nutrition 0.000 description 2
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 2
- 238000007112 amidation reaction Methods 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000000340 anti-metabolite Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 239000002256 antimetabolite Substances 0.000 description 2
- 229940100197 antimetabolite Drugs 0.000 description 2
- 239000003435 antirheumatic agent Substances 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 239000003886 aromatase inhibitor Substances 0.000 description 2
- 150000004982 aromatic amines Chemical class 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- AUJRCFUBUPVWSZ-XTZHGVARSA-M auranofin Chemical compound CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O AUJRCFUBUPVWSZ-XTZHGVARSA-M 0.000 description 2
- 229960005207 auranofin Drugs 0.000 description 2
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 description 2
- XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical class NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 229960000997 bicalutamide Drugs 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 229960004272 bucillamine Drugs 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 150000004696 coordination complex Chemical class 0.000 description 2
- ZXIJMRYMVAMXQP-UHFFFAOYSA-N cycloheptene Chemical compound C1CCC=CCC1 ZXIJMRYMVAMXQP-UHFFFAOYSA-N 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- QPMLSUSACCOBDK-UHFFFAOYSA-N diazepane Chemical compound C1CCNNCC1 QPMLSUSACCOBDK-UHFFFAOYSA-N 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 239000002988 disease modifying antirheumatic drug Substances 0.000 description 2
- LOZWAPSEEHRYPG-UHFFFAOYSA-N dithiane Natural products C1CSCCS1 LOZWAPSEEHRYPG-UHFFFAOYSA-N 0.000 description 2
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- XYIBRDXRRQCHLP-UHFFFAOYSA-N ethyl acetoacetate Chemical compound CCOC(=O)CC(C)=O XYIBRDXRRQCHLP-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 150000002244 furazanes Chemical class 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hcl hcl Chemical compound Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 238000007327 hydrogenolysis reaction Methods 0.000 description 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 2
- 229940124589 immunosuppressive drug Drugs 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- GURKHSYORGJETM-WAQYZQTGSA-N irinotecan hydrochloride (anhydrous) Chemical compound Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 GURKHSYORGJETM-WAQYZQTGSA-N 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- CPJRRXSHAYUTGL-UHFFFAOYSA-N isopentenyl alcohol Chemical compound CC(=C)CCO CPJRRXSHAYUTGL-UHFFFAOYSA-N 0.000 description 2
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 2
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 229940043355 kinase inhibitor Drugs 0.000 description 2
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 2
- 229960000681 leflunomide Drugs 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 2
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 2
- 229960004584 methylprednisolone Drugs 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 125000001620 monocyclic carbocycle group Chemical group 0.000 description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 229940127084 other anti-cancer agent Drugs 0.000 description 2
- OTLYTKRAADUASA-UHFFFAOYSA-N oxadiazepane Chemical compound C1CCONNC1 OTLYTKRAADUASA-UHFFFAOYSA-N 0.000 description 2
- RYDICHIKLKVOEJ-UHFFFAOYSA-N oxadiazepine Chemical compound O1C=CC=CN=N1 RYDICHIKLKVOEJ-UHFFFAOYSA-N 0.000 description 2
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- AQNQGBUEVCAVML-UHFFFAOYSA-N oxazepane Chemical compound C1CCNOCC1 AQNQGBUEVCAVML-UHFFFAOYSA-N 0.000 description 2
- SFJGCXYXEFWEBK-UHFFFAOYSA-N oxazepine Chemical compound O1C=CC=CC=N1 SFJGCXYXEFWEBK-UHFFFAOYSA-N 0.000 description 2
- ATYBXHSAIOKLMG-UHFFFAOYSA-N oxepin Chemical compound O1C=CC=CC=C1 ATYBXHSAIOKLMG-UHFFFAOYSA-N 0.000 description 2
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 2
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 2
- 150000003058 platinum compounds Chemical class 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 229960005205 prednisolone Drugs 0.000 description 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 2
- 229960002800 prednisolone acetate Drugs 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 2
- DNXIASIHZYFFRO-UHFFFAOYSA-N pyrazoline Chemical compound C1CN=NC1 DNXIASIHZYFFRO-UHFFFAOYSA-N 0.000 description 2
- ZVJHJDDKYZXRJI-UHFFFAOYSA-N pyrroline Natural products C1CC=NC1 ZVJHJDDKYZXRJI-UHFFFAOYSA-N 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229960001674 tegafur Drugs 0.000 description 2
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 2
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 description 2
- NHVPESPHUUFULF-UHFFFAOYSA-N tert-butyl n-(5-aminopyridin-2-yl)carbamate Chemical compound CC(C)(C)OC(=O)NC1=CC=C(N)C=N1 NHVPESPHUUFULF-UHFFFAOYSA-N 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 2
- 150000003536 tetrazoles Chemical class 0.000 description 2
- ZYXWYDDFNXBTFO-UHFFFAOYSA-N tetrazolidine Chemical compound C1NNNN1 ZYXWYDDFNXBTFO-UHFFFAOYSA-N 0.000 description 2
- TVQOEGVBMRCMFR-UHFFFAOYSA-N thiadiazinane Chemical compound C1CNNSC1 TVQOEGVBMRCMFR-UHFFFAOYSA-N 0.000 description 2
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 2
- 150000003548 thiazolidines Chemical class 0.000 description 2
- JWCVYQRPINPYQJ-UHFFFAOYSA-N thiepane Chemical compound C1CCCSCC1 JWCVYQRPINPYQJ-UHFFFAOYSA-N 0.000 description 2
- BISQTCXKVNCDDA-UHFFFAOYSA-N thiepine Chemical compound S1C=CC=CC=C1 BISQTCXKVNCDDA-UHFFFAOYSA-N 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 229930192474 thiophene Natural products 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 150000003852 triazoles Chemical class 0.000 description 2
- TUQOTMZNTHZOKS-UHFFFAOYSA-N tributylphosphine Chemical compound CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 description 2
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- BWHDROKFUHTORW-UHFFFAOYSA-N tritert-butylphosphane Chemical compound CC(C)(C)P(C(C)(C)C)C(C)(C)C BWHDROKFUHTORW-UHFFFAOYSA-N 0.000 description 2
- 229940070710 valerate Drugs 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 2
- DSEKYWAQQVUQTP-XEWMWGOFSA-N (2r,4r,4as,6as,6as,6br,8ar,12ar,14as,14bs)-2-hydroxy-4,4a,6a,6b,8a,11,11,14a-octamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3C[C@@H](O)C(=O)[C@@H]1C DSEKYWAQQVUQTP-XEWMWGOFSA-N 0.000 description 1
- NAALWFYYHHJEFQ-ZASNTINBSA-N (2s,5r,6r)-6-[[(2r)-2-[[6-[4-[bis(2-hydroxyethyl)sulfamoyl]phenyl]-2-oxo-1h-pyridine-3-carbonyl]amino]-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC(O)=CC=1)C(=O)C(C(N1)=O)=CC=C1C1=CC=C(S(=O)(=O)N(CCO)CCO)C=C1 NAALWFYYHHJEFQ-ZASNTINBSA-N 0.000 description 1
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- FCUNPEPCEXJFID-UHFFFAOYSA-N (4-aminophenyl)-(6,7-dimethoxyquinazolin-4-yl)methanone hydrochloride Chemical compound Cl.NC1=CC=C(C=C1)C(=O)C1=NC=NC2=CC(=C(C=C12)OC)OC FCUNPEPCEXJFID-UHFFFAOYSA-N 0.000 description 1
- DUYGBIXYADAOBZ-UHFFFAOYSA-N (4-bromophenyl)-(6,7-dimethoxyquinazolin-4-yl)methanone Chemical compound BrC1=CC=C(C=C1)C(=O)C1=NC=NC2=CC(=C(C=C12)OC)OC DUYGBIXYADAOBZ-UHFFFAOYSA-N 0.000 description 1
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 1
- UCGKHZQIHHCPGN-LDADJPATSA-N (5E)-5-hydroxyimino-4-methyl-2-oxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxylic acid Chemical compound O\N=C/1\C=2C(=C(C(N(C=2CCC\1)C1=CC=CC=C1)=O)C(=O)O)C UCGKHZQIHHCPGN-LDADJPATSA-N 0.000 description 1
- ZSXWOARKRVGMOV-AUGOTPMTSA-N (5E)-N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-5-methoxyimino-2-oxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound COC=1C=C2C(=CC=NC2=CC=1OC)OC=1C=CC(=NC=1)NC(=O)C=1C(N(C=2CCC\C(\C=2C=1)=N/OC)C1=CC=CC=C1)=O ZSXWOARKRVGMOV-AUGOTPMTSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- MYZDPUZXMFCPMU-LRIWMWCYSA-N (6r,8s,9r,10s,11s,13s,14s,17r)-2-bromo-6,9-difluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one Chemical compound O=C1C(Br)=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3C[C@@H](F)C2=C1 MYZDPUZXMFCPMU-LRIWMWCYSA-N 0.000 description 1
- HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 description 1
- MWWSFMDVAYGXBV-FGBSZODSSA-N (7s,9s)-7-[(2r,4s,5r,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydron;chloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-FGBSZODSSA-N 0.000 description 1
- ZPHYPKKFSHAVOE-YZIXBPQXSA-N (7s,9s)-7-[(2r,4s,5s,6s)-4-amino-6-methyl-5-[(2r)-oxan-2-yl]oxyoxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound Cl.O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@@H]1CCCCO1 ZPHYPKKFSHAVOE-YZIXBPQXSA-N 0.000 description 1
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N 1,1'-Carbonyldiimidazole Substances C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- RUBQQRMAWLSCCJ-UHFFFAOYSA-N 1,2-difluoro-4-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C(F)=C1 RUBQQRMAWLSCCJ-UHFFFAOYSA-N 0.000 description 1
- OURMWAURVCHQRC-UHFFFAOYSA-N 1,2-oxazolidine Chemical compound C1CNOC1.C1CNOC1 OURMWAURVCHQRC-UHFFFAOYSA-N 0.000 description 1
- ARSMIBSHEYKMJT-UHFFFAOYSA-M 1,3-dimethylimidazolium iodide Chemical compound [I-].CN1C=C[N+](C)=C1 ARSMIBSHEYKMJT-UHFFFAOYSA-M 0.000 description 1
- HJTAZXHBEBIQQX-UHFFFAOYSA-N 1,5-bis(chloromethyl)naphthalene Chemical compound C1=CC=C2C(CCl)=CC=CC2=C1CCl HJTAZXHBEBIQQX-UHFFFAOYSA-N 0.000 description 1
- FNVCUVYWQBXYQZ-UHFFFAOYSA-N 1-(1-cyclopropyl-2-hydroxyethyl)-N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound C1(CC1)C(CO)N1C(C(=CC=2C(CCCC1=2)=O)C(=O)NC1=NC=C(C=C1)OC1=CC=NC2=CC(=C(C=C12)OC)OC)=O FNVCUVYWQBXYQZ-UHFFFAOYSA-N 0.000 description 1
- ABTILMMPVUDDQK-UHFFFAOYSA-N 1-(1-methylpyrazol-4-yl)-N-[5-[7-(3-morpholin-4-ylpropoxy)quinolin-4-yl]oxypyridin-2-yl]-2,5-dioxo-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound CN1N=CC(=C1)N1C(C(=CC=2C(CCCC1=2)=O)C(=O)NC1=NC=C(C=C1)OC1=CC=NC2=CC(=CC=C12)OCCCN1CCOCC1)=O ABTILMMPVUDDQK-UHFFFAOYSA-N 0.000 description 1
- OBEAQRYDUDPMNF-UHFFFAOYSA-N 1-(2,2-dimethylpropyl)-N-[5-(7-methoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound CC(CN1C(C(=CC=2C(CCCC1=2)=O)C(=O)NC1=NC=C(C=C1)OC1=CC=NC2=CC(=CC=C12)OC)=O)(C)C OBEAQRYDUDPMNF-UHFFFAOYSA-N 0.000 description 1
- XLVZJGSLQFMGJR-UHFFFAOYSA-N 1-(2,2-dimethylpropyl)-N-[5-[7-(3-morpholin-4-ylpropoxy)quinolin-4-yl]oxypyridin-2-yl]-2,5-dioxo-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound CC(CN1C(C(=CC=2C(CCCC1=2)=O)C(=O)NC1=NC=C(C=C1)OC1=CC=NC2=CC(=CC=C12)OCCCN1CCOCC1)=O)(C)C XLVZJGSLQFMGJR-UHFFFAOYSA-N 0.000 description 1
- MCBPAPMDTNNBLK-UHFFFAOYSA-N 1-(2,4-difluorophenyl)-N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound FC1=C(C=CC(=C1)F)N1C(C(=CC=2C(CCCC1=2)=O)C(=O)NC1=NC=C(C=C1)OC1=CC=NC2=CC(=C(C=C12)OC)OC)=O MCBPAPMDTNNBLK-UHFFFAOYSA-N 0.000 description 1
- FAAMKTKPKPCCNP-UHFFFAOYSA-N 1-(2,4-difluorophenyl)-N-[5-(6-methoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound FC1=C(C=CC(=C1)F)N1C(C(=CC=2C(CCCC1=2)=O)C(=O)NC1=NC=C(C=C1)OC1=CC=NC2=CC=C(C=C12)OC)=O FAAMKTKPKPCCNP-UHFFFAOYSA-N 0.000 description 1
- AXOSFVCKZJAZDE-UHFFFAOYSA-N 1-(2,4-difluorophenyl)-N-[5-(7-methoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound FC1=C(C=CC(=C1)F)N1C(C(=CC=2C(CCCC1=2)=O)C(=O)NC1=NC=C(C=C1)OC1=CC=NC2=CC(=CC=C12)OC)=O AXOSFVCKZJAZDE-UHFFFAOYSA-N 0.000 description 1
- RGSQJZQIEKKKRM-UHFFFAOYSA-N 1-(2-chlorophenyl)-N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound ClC1=C(C=CC=C1)N1C(C(=CC=2C(CCCC1=2)=O)C(=O)NC1=NC=C(C=C1)OC1=CC=NC2=CC(=C(C=C12)OC)OC)=O RGSQJZQIEKKKRM-UHFFFAOYSA-N 0.000 description 1
- XJMLRNSKPFCBCO-UHFFFAOYSA-N 1-(2-fluorophenyl)-N-[5-(6-methoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound FC1=C(C=CC=C1)N1C(C(=CC=2C(CCCC1=2)=O)C(=O)NC1=NC=C(C=C1)OC1=CC=NC2=CC=C(C=C12)OC)=O XJMLRNSKPFCBCO-UHFFFAOYSA-N 0.000 description 1
- UCBYBNPAVBJBCN-UHFFFAOYSA-N 1-(2-fluorophenyl)-N-[5-(7-methoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound FC1=C(C=CC=C1)N1C(C(=CC=2C(CCCC1=2)=O)C(=O)NC1=NC=C(C=C1)OC1=CC=NC2=CC(=CC=C12)OC)=O UCBYBNPAVBJBCN-UHFFFAOYSA-N 0.000 description 1
- XYGQGICOVBKKBX-UHFFFAOYSA-N 1-(3-chlorophenyl)-N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound ClC=1C=C(C=CC=1)N1C(C(=CC=2C(CCCC1=2)=O)C(=O)NC1=NC=C(C=C1)OC1=CC=NC2=CC(=C(C=C12)OC)OC)=O XYGQGICOVBKKBX-UHFFFAOYSA-N 0.000 description 1
- IHPFWIOCAXMKFM-UHFFFAOYSA-N 1-(3-fluorophenyl)-N-[5-(6-methoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound FC=1C=C(C=CC=1)N1C(C(=CC=2C(CCCC1=2)=O)C(=O)NC1=NC=C(C=C1)OC1=CC=NC2=CC=C(C=C12)OC)=O IHPFWIOCAXMKFM-UHFFFAOYSA-N 0.000 description 1
- BHUYPEAFMSKCPP-UHFFFAOYSA-N 1-(3-fluorophenyl)-N-[5-(7-methoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound FC=1C=C(C=CC=1)N1C(C(=CC=2C(CCCC1=2)=O)C(=O)NC1=NC=C(C=C1)OC1=CC=NC2=CC(=CC=C12)OC)=O BHUYPEAFMSKCPP-UHFFFAOYSA-N 0.000 description 1
- OVPMXLQIECJBAM-UHFFFAOYSA-N 1-(4,4-difluorocyclohexyl)-N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound FC1(CCC(CC1)N1C(C(=CC=2C(CCCC1=2)=O)C(=O)NC1=NC=C(C=C1)OC1=CC=NC2=CC(=C(C=C12)OC)OC)=O)F OVPMXLQIECJBAM-UHFFFAOYSA-N 0.000 description 1
- IZXOXGMSAGPPNE-UHFFFAOYSA-N 1-(4,4-difluorocyclohexyl)-N-[5-(7-methoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound FC1(CCC(CC1)N1C(C(=CC=2C(CCCC1=2)=O)C(=O)NC1=NC=C(C=C1)OC1=CC=NC2=CC(=CC=C12)OC)=O)F IZXOXGMSAGPPNE-UHFFFAOYSA-N 0.000 description 1
- QUMPPPOOXIDPLA-UHFFFAOYSA-N 1-(4-chlorophenyl)-N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound ClC1=CC=C(C=C1)N1C(C(=CC=2C(CCCC1=2)=O)C(=O)NC1=NC=C(C=C1)OC1=CC=NC2=CC(=C(C=C12)OC)OC)=O QUMPPPOOXIDPLA-UHFFFAOYSA-N 0.000 description 1
- UMGXQGZBAIWDHC-UHFFFAOYSA-N 1-(4-fluorophenyl)-N-[5-(6-methoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound FC1=CC=C(C=C1)N1C(C(=CC=2C(CCCC1=2)=O)C(=O)NC1=NC=C(C=C1)OC1=CC=NC2=CC=C(C=C12)OC)=O UMGXQGZBAIWDHC-UHFFFAOYSA-N 0.000 description 1
- CKNNGVUYXUCCHL-UHFFFAOYSA-N 1-(cyclopropylmethyl)-N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound C1(CC1)CN1C(C(=CC=2C(CCCC1=2)=O)C(=O)NC1=NC=C(C=C1)OC1=CC=NC2=CC(=C(C=C12)OC)OC)=O CKNNGVUYXUCCHL-UHFFFAOYSA-N 0.000 description 1
- QVWSGCXTFIEKAL-LJQANCHMSA-N 1-[(1R)-1-(4-fluorophenyl)ethyl]-N-[5-(7-methoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound FC1=CC=C(C=C1)[C@@H](C)N1C(C(=CC=2C(CCCC1=2)=O)C(=O)NC1=NC=C(C=C1)OC1=CC=NC2=CC(=CC=C12)OC)=O QVWSGCXTFIEKAL-LJQANCHMSA-N 0.000 description 1
- DUUSFHFFKXFVPE-RUZDIDTESA-N 1-[(1R)-1-(4-fluorophenyl)ethyl]-N-[5-[7-(3-morpholin-4-ylpropoxy)quinolin-4-yl]oxypyridin-2-yl]-2,5-dioxo-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound FC1=CC=C(C=C1)[C@@H](C)N1C(C(=CC=2C(CCCC1=2)=O)C(=O)NC1=NC=C(C=C1)OC1=CC=NC2=CC(=CC=C12)OCCCN1CCOCC1)=O DUUSFHFFKXFVPE-RUZDIDTESA-N 0.000 description 1
- IKXUDDUZXOARRN-QGZVFWFLSA-N 1-[(1R)-1-cyclopropylethyl]-N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound C1(CC1)[C@@H](C)N1C(C(=CC=2C(CCCC1=2)=O)C(=O)NC1=NC=C(C=C1)OC1=CC=NC2=CC(=C(C=C12)OC)OC)=O IKXUDDUZXOARRN-QGZVFWFLSA-N 0.000 description 1
- ZCODMVDMUXAVLR-QGZVFWFLSA-N 1-[(1R)-1-cyclopropylethyl]-N-[5-(7-methoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound C1(CC1)[C@@H](C)N1C(C(=CC=2C(CCCC1=2)=O)C(=O)NC1=NC=C(C=C1)OC1=CC=NC2=CC(=CC=C12)OC)=O ZCODMVDMUXAVLR-QGZVFWFLSA-N 0.000 description 1
- NLFLETHTLZNOSY-FQEVSTJZSA-N 1-[(1S)-1-cyclohexylethyl]-N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound C1(CCCCC1)[C@H](C)N1C(C(=CC=2C(CCCC1=2)=O)C(=O)NC1=NC=C(C=C1)OC1=CC=NC2=CC(=C(C=C12)OC)OC)=O NLFLETHTLZNOSY-FQEVSTJZSA-N 0.000 description 1
- IKXUDDUZXOARRN-KRWDZBQOSA-N 1-[(1S)-1-cyclopropylethyl]-N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound C1(CC1)[C@H](C)N1C(C(=CC=2C(CCCC1=2)=O)C(=O)NC1=NC=C(C=C1)OC1=CC=NC2=CC(=C(C=C12)OC)OC)=O IKXUDDUZXOARRN-KRWDZBQOSA-N 0.000 description 1
- PYVJRYLZKQEHKT-KRWDZBQOSA-N 1-[(1S)-1-cyclopropylethyl]-N-[5-(6-methoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound C1(CC1)[C@H](C)N1C(C(=CC=2C(CCCC1=2)=O)C(=O)NC1=NC=C(C=C1)OC1=CC=NC2=CC=C(C=C12)OC)=O PYVJRYLZKQEHKT-KRWDZBQOSA-N 0.000 description 1
- ZCODMVDMUXAVLR-KRWDZBQOSA-N 1-[(1S)-1-cyclopropylethyl]-N-[5-(7-methoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound C1(CC1)[C@H](C)N1C(C(=CC=2C(CCCC1=2)=O)C(=O)NC1=NC=C(C=C1)OC1=CC=NC2=CC(=CC=C12)OC)=O ZCODMVDMUXAVLR-KRWDZBQOSA-N 0.000 description 1
- VAHXDHKAQACDGW-MUUNZHRXSA-N 1-[(1S)-2-hydroxy-1-phenylethyl]-N-[5-(7-methoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound OC[C@H](C1=CC=CC=C1)N1C(C(=CC=2C(CCCC1=2)=O)C(=O)NC1=NC=C(C=C1)OC1=CC=NC2=CC(=CC=C12)OC)=O VAHXDHKAQACDGW-MUUNZHRXSA-N 0.000 description 1
- WWEUVTGGABFHMI-VWLOTQADSA-N 1-[(2R)-1-hydroxy-3-methylbutan-2-yl]-N-[5-(7-methoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound OC[C@@H](C(C)C)N1C(C(=CC=2C(CCCC1=2)=O)C(=O)NC1=NC=C(C=C1)OC1=CC=NC2=CC(=CC=C12)OC)=O WWEUVTGGABFHMI-VWLOTQADSA-N 0.000 description 1
- WWEUVTGGABFHMI-RUZDIDTESA-N 1-[(2S)-1-hydroxy-3-methylbutan-2-yl]-N-[5-(7-methoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound OC[C@H](C(C)C)N1C(C(=CC=2C(CCCC1=2)=O)C(=O)NC1=NC=C(C=C1)OC1=CC=NC2=CC(=CC=C12)OC)=O WWEUVTGGABFHMI-RUZDIDTESA-N 0.000 description 1
- PWDXULGSGANFRW-WJOKGBTCSA-N 1-[(2S)-1-hydroxy-3-methylbutan-2-yl]-N-[5-[7-(3-morpholin-4-ylpropoxy)quinolin-4-yl]oxypyridin-2-yl]-2,5-dioxo-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound OC[C@H](C(C)C)N1C(C(=CC=2C(CCCC1=2)=O)C(=O)NC1=NC=C(C=C1)OC1=CC=NC2=CC(=CC=C12)OCCCN1CCOCC1)=O PWDXULGSGANFRW-WJOKGBTCSA-N 0.000 description 1
- MTKXIMRKIDLOFP-UHFFFAOYSA-N 1-[1-(2-hydroxy-2-methylpropyl)pyrazol-4-yl]-N-[5-(7-methoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound OC(CN1N=CC(=C1)N1C(C(=CC=2C(CCCC1=2)=O)C(=O)NC1=NC=C(C=C1)OC1=CC=NC2=CC(=CC=C12)OC)=O)(C)C MTKXIMRKIDLOFP-UHFFFAOYSA-N 0.000 description 1
- BWPQSNMZHWGPJY-UHFFFAOYSA-N 1-[1-(2-hydroxy-2-methylpropyl)pyrazol-4-yl]-N-[5-[7-(3-morpholin-4-ylpropoxy)quinolin-4-yl]oxypyridin-2-yl]-2,5-dioxo-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound OC(CN1N=CC(=C1)N1C(C(=CC=2C(CCCC1=2)=O)C(=O)NC1=NC=C(C=C1)OC1=CC=NC2=CC(=CC=C12)OCCCN1CCOCC1)=O)(C)C BWPQSNMZHWGPJY-UHFFFAOYSA-N 0.000 description 1
- MOLPAVLSVAOSQO-UHFFFAOYSA-N 1-[1-(hydroxymethyl)cyclobutyl]-N-[5-(6-methoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound OCC1(CCC1)N1C(C(=CC=2C(CCCC1=2)=O)C(=O)NC1=NC=C(C=C1)OC1=CC=NC2=CC=C(C=C12)OC)=O MOLPAVLSVAOSQO-UHFFFAOYSA-N 0.000 description 1
- RJNNFRGLOYOPOM-UHFFFAOYSA-N 1-[1-(hydroxymethyl)cyclobutyl]-N-[5-(7-methoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound OCC1(CCC1)N1C(C(=CC=2C(CCCC1=2)=O)C(=O)NC1=NC=C(C=C1)OC1=CC=NC2=CC(=CC=C12)OC)=O RJNNFRGLOYOPOM-UHFFFAOYSA-N 0.000 description 1
- 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 1
- LOYZVRIHVZEDMW-UHFFFAOYSA-N 1-bromo-3-methylbut-2-ene Chemical compound CC(C)=CCBr LOYZVRIHVZEDMW-UHFFFAOYSA-N 0.000 description 1
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 1
- FKYXUNMRCOFHBI-UHFFFAOYSA-N 1-cyclobutyl-N-[5-(7-methoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound C1(CCC1)N1C(C(=CC=2C(CCCC1=2)=O)C(=O)NC1=NC=C(C=C1)OC1=CC=NC2=CC(=CC=C12)OC)=O FKYXUNMRCOFHBI-UHFFFAOYSA-N 0.000 description 1
- QHGARFGKIVWCIM-UHFFFAOYSA-N 1-cyclopropyl-N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound C1(CC1)N1C(C(=CC=2C(CCCC1=2)=O)C(=O)NC1=NC=C(C=C1)OC1=CC=NC2=CC(=C(C=C12)OC)OC)=O QHGARFGKIVWCIM-UHFFFAOYSA-N 0.000 description 1
- 125000004776 1-fluoroethyl group Chemical group [H]C([H])([H])C([H])(F)* 0.000 description 1
- HNEGJTWNOOWEMH-UHFFFAOYSA-N 1-fluoropropane Chemical group [CH2]CCF HNEGJTWNOOWEMH-UHFFFAOYSA-N 0.000 description 1
- LJCZNYWLQZZIOS-UHFFFAOYSA-N 2,2,2-trichlorethoxycarbonyl chloride Chemical group ClC(=O)OCC(Cl)(Cl)Cl LJCZNYWLQZZIOS-UHFFFAOYSA-N 0.000 description 1
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 1
- ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 1
- FJSNSFADDNXWFS-UHFFFAOYSA-N 2,5-dioxo-1-phenyl-7,8-dihydro-6h-quinoline-3-carboxylic acid Chemical compound O=C1C(C(=O)O)=CC=2C(=O)CCCC=2N1C1=CC=CC=C1 FJSNSFADDNXWFS-UHFFFAOYSA-N 0.000 description 1
- UFUAWXUPPHGAHW-UHFFFAOYSA-N 2,5-dioxo-1-phenyl-N-(4-quinolin-4-yloxyphenyl)-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound O=C1N(C=2CCCC(C=2C=C1C(=O)NC1=CC=C(C=C1)OC1=CC=NC2=CC=CC=C12)=O)C1=CC=CC=C1 UFUAWXUPPHGAHW-UHFFFAOYSA-N 0.000 description 1
- 125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- VXYDHPDQMSVQCU-UHFFFAOYSA-N 2-[4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)piperidin-1-yl]-n-hydroxyacetamide Chemical compound COC1=CC=C(C2(CCN(CC(=O)NO)CC2)C#N)C=C1OC1CCCC1 VXYDHPDQMSVQCU-UHFFFAOYSA-N 0.000 description 1
- ZNPNOVHKCAAQCG-UHFFFAOYSA-N 2-chloro-1-methylpyridin-1-ium Chemical compound C[N+]1=CC=CC=C1Cl ZNPNOVHKCAAQCG-UHFFFAOYSA-N 0.000 description 1
- KKZUMAMOMRDVKA-UHFFFAOYSA-N 2-chloropropane Chemical group [CH2]C(C)Cl KKZUMAMOMRDVKA-UHFFFAOYSA-N 0.000 description 1
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- MNYINUVGUKQTIK-UHFFFAOYSA-N 2-methoxy-1h-quinolin-4-one Chemical compound C1=CC=C2NC(OC)=CC(=O)C2=C1 MNYINUVGUKQTIK-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
- QCBZJQOUNVNUBH-UHFFFAOYSA-N 2-oxo-1-phenyl-6,7-dihydro-5H-cyclopenta[b]pyridine-3-carboxylic acid Chemical compound O=C1C(=CC2=C(N1C1=CC=CC=C1)CCC2)C(=O)O QCBZJQOUNVNUBH-UHFFFAOYSA-N 0.000 description 1
- WGTASENVNYJZBK-UHFFFAOYSA-N 3,4,5-trimethoxyamphetamine Chemical class COC1=CC(CC(C)N)=CC(OC)=C1OC WGTASENVNYJZBK-UHFFFAOYSA-N 0.000 description 1
- UZFPOOOQHWICKY-UHFFFAOYSA-N 3-[13-[1-[1-[8,12-bis(2-carboxyethyl)-17-(1-hydroxyethyl)-3,7,13,18-tetramethyl-21,24-dihydroporphyrin-2-yl]ethoxy]ethyl]-18-(2-carboxyethyl)-8-(1-hydroxyethyl)-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-2-yl]propanoic acid Chemical compound N1C(C=C2C(=C(CCC(O)=O)C(C=C3C(=C(C)C(C=C4N5)=N3)CCC(O)=O)=N2)C)=C(C)C(C(C)O)=C1C=C5C(C)=C4C(C)OC(C)C1=C(N2)C=C(N3)C(C)=C(C(O)C)C3=CC(C(C)=C3CCC(O)=O)=NC3=CC(C(CCC(O)=O)=C3C)=NC3=CC2=C1C UZFPOOOQHWICKY-UHFFFAOYSA-N 0.000 description 1
- KJDHWPSHIIFNAK-UHFFFAOYSA-N 3-[4-[3-(3,4,5-trimethoxybenzoyl)oxypropyl]-1,4-diazepan-1-yl]propyl 3,4,5-trimethoxybenzoate;hydrate;dihydrochloride Chemical compound O.Cl.Cl.COC1=C(OC)C(OC)=CC(C(=O)OCCCN2CCN(CCCOC(=O)C=3C=C(OC)C(OC)=C(OC)C=3)CCC2)=C1 KJDHWPSHIIFNAK-UHFFFAOYSA-N 0.000 description 1
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- RAVFDWMXMQATJC-UHFFFAOYSA-N 3-bromo-4-methyl-1-phenyl-7,8-dihydro-6H-quinoline-2,5-dione Chemical compound BrC=1C(N(C=2CCCC(C=2C=1C)=O)C1=CC=CC=C1)=O RAVFDWMXMQATJC-UHFFFAOYSA-N 0.000 description 1
- LBICJCUBTJBCMU-UHFFFAOYSA-N 3-bromo-4-methyl-7,8-dihydro-6H-chromene-2,5-dione Chemical compound BrC=1C(OC=2CCCC(C=2C=1C)=O)=O LBICJCUBTJBCMU-UHFFFAOYSA-N 0.000 description 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
- MVLNDUYPIKVWDO-UHFFFAOYSA-N 3-fluoro-4-[6-methoxy-7-(3-morpholin-4-ylpropoxy)quinolin-4-yl]oxyaniline Chemical compound C1=CN=C2C=C(OCCCN3CCOCC3)C(OC)=CC2=C1OC1=CC=C(N)C=C1F MVLNDUYPIKVWDO-UHFFFAOYSA-N 0.000 description 1
- IGPFOKFDBICQMC-UHFFFAOYSA-N 3-phenylmethoxyaniline Chemical compound NC1=CC=CC(OCC=2C=CC=CC=2)=C1 IGPFOKFDBICQMC-UHFFFAOYSA-N 0.000 description 1
- MHRMSZPCHBTAJN-UHFFFAOYSA-N 4-(2-fluoro-4-nitrophenoxy)-6,7-dimethoxyquinoline Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC1=CC=C([N+]([O-])=O)C=C1F MHRMSZPCHBTAJN-UHFFFAOYSA-N 0.000 description 1
- ZCQHXCZWPBJLKD-UHFFFAOYSA-N 4-(2-fluoro-4-nitrophenoxy)-6-methoxy-7-phenylmethoxyquinoline Chemical compound C1=CN=C2C=C(OCC=3C=CC=CC=3)C(OC)=CC2=C1OC1=CC=C([N+]([O-])=O)C=C1F ZCQHXCZWPBJLKD-UHFFFAOYSA-N 0.000 description 1
- MUTXSVYRSMBCRK-UHFFFAOYSA-N 4-(2-fluoro-4-nitrophenoxy)-6-methoxyquinolin-7-ol hydrobromide Chemical compound Br.COc1cc2c(Oc3ccc(cc3F)[N+]([O-])=O)ccnc2cc1O MUTXSVYRSMBCRK-UHFFFAOYSA-N 0.000 description 1
- KWGLRTYYVXUHDS-UHFFFAOYSA-N 4-(2-fluoro-4-nitrophenyl)-7-methoxyquinazoline Chemical compound FC1=C(C=CC(=C1)[N+](=O)[O-])C1=NC=NC2=CC(=CC=C12)OC KWGLRTYYVXUHDS-UHFFFAOYSA-N 0.000 description 1
- PIAZYBLGBSMNLX-UHFFFAOYSA-N 4-(3-chloropropyl)morpholine Chemical compound ClCCCN1CCOCC1 PIAZYBLGBSMNLX-UHFFFAOYSA-N 0.000 description 1
- SIDZXXQYQLBOHZ-UHFFFAOYSA-N 4-(6,7-dimethoxyquinolin-4-yl)oxy-3-fluoroaniline Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC1=CC=C(N)C=C1F SIDZXXQYQLBOHZ-UHFFFAOYSA-N 0.000 description 1
- FNIKBXUMRCVQCB-UHFFFAOYSA-N 4-(6-chloropyridin-3-yl)oxy-6,7-dimethoxyquinoline Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC1=CC=C(Cl)N=C1 FNIKBXUMRCVQCB-UHFFFAOYSA-N 0.000 description 1
- PCCOHQSTTYOONH-UHFFFAOYSA-N 4-(6-chloropyridin-3-yl)oxy-7-phenylmethoxy-1H-quinolin-2-one Chemical compound C(C1=CC=CC=C1)OC1=CC=C2C(=CC(NC2=C1)=O)OC=1C=NC(=CC=1)Cl PCCOHQSTTYOONH-UHFFFAOYSA-N 0.000 description 1
- IOLICGLKOXEGOP-UHFFFAOYSA-N 4-[3-[4-(2-fluoro-4-nitrophenoxy)-6-methoxyquinolin-7-yl]oxypropyl]morpholine Chemical compound C1=CN=C2C=C(OCCCN3CCOCC3)C(OC)=CC2=C1OC1=CC=C([N+]([O-])=O)C=C1F IOLICGLKOXEGOP-UHFFFAOYSA-N 0.000 description 1
- KCURWTAZOZXKSJ-JBMRGDGGSA-N 4-amino-1-[(2r,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one;hydron;chloride Chemical compound Cl.O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 KCURWTAZOZXKSJ-JBMRGDGGSA-N 0.000 description 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- ZRYZBQLXDKPBDU-UHFFFAOYSA-N 4-bromobenzaldehyde Chemical compound BrC1=CC=C(C=O)C=C1 ZRYZBQLXDKPBDU-UHFFFAOYSA-N 0.000 description 1
- GUQZHZBMDPEBQG-UHFFFAOYSA-N 4-chloro-7-methoxyquinazoline Chemical compound ClC1=NC=NC2=CC(OC)=CC=C21 GUQZHZBMDPEBQG-UHFFFAOYSA-N 0.000 description 1
- MUJZZTUVXQPDGY-UHFFFAOYSA-N 4-chloro-7-phenylmethoxy-1H-quinolin-2-one Chemical compound C(C1=CC=CC=C1)OC1=CC=C2C(=CC(NC2=C1)=O)Cl MUJZZTUVXQPDGY-UHFFFAOYSA-N 0.000 description 1
- GVRRXASZZAKBMN-UHFFFAOYSA-N 4-chloroquinazoline Chemical compound C1=CC=C2C(Cl)=NC=NC2=C1 GVRRXASZZAKBMN-UHFFFAOYSA-N 0.000 description 1
- OGVYUNXTNFYPRL-UHFFFAOYSA-N 4-methyl-7,8-dihydro-6h-chromene-2,5-dione Chemical compound C1CCC(=O)C2=C1OC(=O)C=C2C OGVYUNXTNFYPRL-UHFFFAOYSA-N 0.000 description 1
- QTQGHKVYLQBJLO-UHFFFAOYSA-N 4-methylbenzenesulfonate;(4-methyl-1-oxo-1-phenylmethoxypentan-2-yl)azanium Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1.CC(C)CC(N)C(=O)OCC1=CC=CC=C1 QTQGHKVYLQBJLO-UHFFFAOYSA-N 0.000 description 1
- WYNXSHZMAIXDSI-UHFFFAOYSA-N 4-quinazolin-4-yloxyaniline;hydrochloride Chemical compound Cl.C1=CC(N)=CC=C1OC1=NC=NC2=CC=CC=C12 WYNXSHZMAIXDSI-UHFFFAOYSA-N 0.000 description 1
- ORPHLVJBJOCHBR-UHFFFAOYSA-N 403-19-0 Chemical compound OC1=CC=C([N+]([O-])=O)C=C1F ORPHLVJBJOCHBR-UHFFFAOYSA-N 0.000 description 1
- PJACEUSXRKGZOC-UHFFFAOYSA-N 5-(6,7-dimethoxyquinazolin-4-yl)oxypyridin-2-amine hydrochloride Chemical compound Cl.COc1cc2ncnc(Oc3ccc(N)nc3)c2cc1OC PJACEUSXRKGZOC-UHFFFAOYSA-N 0.000 description 1
- NBFPSAKAPKBKNF-UHFFFAOYSA-N 5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-amine Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC1=CC=C(N)N=C1 NBFPSAKAPKBKNF-UHFFFAOYSA-N 0.000 description 1
- BOUWTAKOIVRZRA-UHFFFAOYSA-N 5-(6-methoxy-7-phenylmethoxyquinolin-4-yl)oxypyridin-2-amine Chemical compound C(C1=CC=CC=C1)OC1=C(C=C2C(=CC=NC2=C1)OC=1C=CC(=NC=1)N)OC BOUWTAKOIVRZRA-UHFFFAOYSA-N 0.000 description 1
- GQVUDYXXUUMOGU-UHFFFAOYSA-N 5-(7-phenylmethoxyquinolin-4-yl)oxypyridin-2-amine Chemical compound C1=NC(N)=CC=C1OC1=CC=NC2=CC(OCC=3C=CC=CC=3)=CC=C12 GQVUDYXXUUMOGU-UHFFFAOYSA-N 0.000 description 1
- CAGBQNICMSZCEL-UHFFFAOYSA-N 5-N-(6,7-dimethoxyquinazolin-4-yl)pyridine-2,5-diamine Chemical compound COC=1C=C2C(=NC=NC2=CC=1OC)NC=1C=CC(=NC=1)N CAGBQNICMSZCEL-UHFFFAOYSA-N 0.000 description 1
- XVYWFZUUIOJMJR-UHFFFAOYSA-N 5-[(3-hydroxy-4-methoxyanilino)methylidene]-2,2-dimethyl-1,3-dioxane-4,6-dione Chemical compound C1=C(O)C(OC)=CC=C1NC=C1C(=O)OC(C)(C)OC1=O XVYWFZUUIOJMJR-UHFFFAOYSA-N 0.000 description 1
- GYFKPTMIPZQKES-UHFFFAOYSA-N 5-[(4-methoxy-3-phenylmethoxyanilino)methylidene]-2,2-dimethyl-1,3-dioxane-4,6-dione Chemical compound C1=C(OCC=2C=CC=CC=2)C(OC)=CC=C1NC=C1C(=O)OC(C)(C)OC1=O GYFKPTMIPZQKES-UHFFFAOYSA-N 0.000 description 1
- BLQFHJKRTDIZLX-UHFFFAOYSA-N 5-amino-2-methoxyphenol Chemical compound COC1=CC=C(N)C=C1O BLQFHJKRTDIZLX-UHFFFAOYSA-N 0.000 description 1
- VZBPWGDMAFQWTI-UHFFFAOYSA-N 5-hydroxy-N-[5-(7-hydroxy-6-methoxyquinolin-4-yl)oxypyridin-2-yl]-2-oxo-1-phenyl-5,6,7,8-tetrahydroquinoline-3-carboxamide Chemical compound COC1=C(O)C=C2N=CC=C(OC3=CN=C(NC(=O)C4=CC5=C(CCCC5O)N(C5=CC=CC=C5)C4=O)C=C3)C2=C1 VZBPWGDMAFQWTI-UHFFFAOYSA-N 0.000 description 1
- 102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
- 125000003341 7 membered heterocyclic group Chemical group 0.000 description 1
- KABRXLINDSPGDF-UHFFFAOYSA-N 7-bromoisoquinoline Chemical compound C1=CN=CC2=CC(Br)=CC=C21 KABRXLINDSPGDF-UHFFFAOYSA-N 0.000 description 1
- KWQRHYWEGFFXKV-UHFFFAOYSA-N 7-phenylmethoxy-1h-quinolin-4-one Chemical compound C=1C=C2C(O)=CC=NC2=CC=1OCC1=CC=CC=C1 KWQRHYWEGFFXKV-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- NKGPJODWTZCHGF-UHFFFAOYSA-N 9-[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purine-6-thione Chemical compound OC1C(O)C(CO)OC1N1C(NC=NC2=S)=C2N=C1 NKGPJODWTZCHGF-UHFFFAOYSA-N 0.000 description 1
- MROJXXOCABQVEF-UHFFFAOYSA-N Actarit Chemical compound CC(=O)NC1=CC=C(CC(O)=O)C=C1 MROJXXOCABQVEF-UHFFFAOYSA-N 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- FHHHOYXPRDYHEZ-COXVUDFISA-N Alacepril Chemical compound CC(=O)SC[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 FHHHOYXPRDYHEZ-COXVUDFISA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
- 229940122815 Aromatase inhibitor Drugs 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- XHVAWZZCDCWGBK-WYRLRVFGSA-M Aurothioglucose Chemical compound OC[C@H]1O[C@H](S[Au])[C@H](O)[C@@H](O)[C@@H]1O XHVAWZZCDCWGBK-WYRLRVFGSA-M 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- VGGGPCQERPFHOB-MCIONIFRSA-N Bestatin Chemical compound CC(C)C[C@H](C(O)=O)NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1 VGGGPCQERPFHOB-MCIONIFRSA-N 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- PHNHOLRPKJCTQM-CIAFOILYSA-N C(C1=CC=CC=C1)OC=1C=C(C=CC=1)\N=C\C1C(OC(OC1=O)(C)C)=O Chemical compound C(C1=CC=CC=C1)OC=1C=C(C=CC=1)\N=C\C1C(OC(OC1=O)(C)C)=O PHNHOLRPKJCTQM-CIAFOILYSA-N 0.000 description 1
- 239000002083 C09CA01 - Losartan Substances 0.000 description 1
- 239000004072 C09CA03 - Valsartan Substances 0.000 description 1
- 239000002947 C09CA04 - Irbesartan Substances 0.000 description 1
- 239000002053 C09CA06 - Candesartan Substances 0.000 description 1
- 239000005537 C09CA07 - Telmisartan Substances 0.000 description 1
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 description 1
- QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 description 1
- MGZOGZHEFGAEFU-UHFFFAOYSA-N CN(CCCOC1=CC=C2C(=CC=NC2=C1)OC=1C=CC(=NC=1)NC(=O)C=1C(N(C=2CCCC(C=2C=1)=O)C1=CC=CC=C1)=O)C Chemical compound CN(CCCOC1=CC=C2C(=CC=NC2=C1)OC=1C=CC(=NC=1)NC(=O)C=1C(N(C=2CCCC(C=2C=1)=O)C1=CC=CC=C1)=O)C MGZOGZHEFGAEFU-UHFFFAOYSA-N 0.000 description 1
- LONOYUVWQQVYGR-UHFFFAOYSA-N COC1=CC=C2C(=CC=NC2=C1)OC=1C=CC(=NC=1)NC(=O)C=1C(N(C=2CC3(CC(C=2C=1)=O)CCC3)C1=CC=CC=C1)=O Chemical compound COC1=CC=C2C(=CC=NC2=C1)OC=1C=CC(=NC=1)NC(=O)C=1C(N(C=2CC3(CC(C=2C=1)=O)CCC3)C1=CC=CC=C1)=O LONOYUVWQQVYGR-UHFFFAOYSA-N 0.000 description 1
- VYVLRCBYFRISGX-UHFFFAOYSA-N COC=1C=C2C(=CC=NC2=CC=1OC)OC=1C=CC(=NC=1)NC(=O)C=1C(N(C=2CCCC(C=2C=1C)=O)C1=CC=CC=C1)=O Chemical compound COC=1C=C2C(=CC=NC2=CC=1OC)OC=1C=CC(=NC=1)NC(=O)C=1C(N(C=2CCCC(C=2C=1C)=O)C1=CC=CC=C1)=O VYVLRCBYFRISGX-UHFFFAOYSA-N 0.000 description 1
- BMLOMJKQMBPMJD-UHFFFAOYSA-N COC=1C=C2C(=NC=NC2=CC=1OC)NC=1C=CC(=NC=1)NC(=O)C=1C(N(C=2CCCC(C=2C=1)=O)C1=CC=CC=C1)=O Chemical compound COC=1C=C2C(=NC=NC2=CC=1OC)NC=1C=CC(=NC=1)NC(=O)C=1C(N(C=2CCCC(C=2C=1)=O)C1=CC=CC=C1)=O BMLOMJKQMBPMJD-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- AOCCBINRVIKJHY-UHFFFAOYSA-N Carmofur Chemical compound CCCCCCNC(=O)N1C=C(F)C(=O)NC1=O AOCCBINRVIKJHY-UHFFFAOYSA-N 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 241000283153 Cetacea Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- RURLVUZRUFHCJO-UHFFFAOYSA-N Chromomycin A3 Natural products COC(C1Cc2cc3cc(OC4CC(OC(=O)C)C(OC5CC(O)C(OC)C(C)O5)C(C)O4)c(C)c(O)c3c(O)c2C(=O)C1OC6CC(OC7CC(C)(O)C(OC(=O)C)C(C)O7)C(O)C(C)O6)C(=O)C(O)C(C)O RURLVUZRUFHCJO-UHFFFAOYSA-N 0.000 description 1
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- XIRJOMZGHXQROT-UHFFFAOYSA-N ClC1=NC=NC2=CC(=C(C=C12)OC)OC.ClC1=CC=C(C=N1)OC1=NC=NC2=CC(=C(C=C12)OC)OC Chemical compound ClC1=NC=NC2=CC(=C(C=C12)OC)OC.ClC1=CC=C(C=N1)OC1=NC=NC2=CC(=C(C=C12)OC)OC XIRJOMZGHXQROT-UHFFFAOYSA-N 0.000 description 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
- 101000862089 Clarkia lewisii Glucose-6-phosphate isomerase, cytosolic 1A Proteins 0.000 description 1
- ITRJWOMZKQRYTA-RFZYENFJSA-N Cortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O ITRJWOMZKQRYTA-RFZYENFJSA-N 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- VVNCNSJFMMFHPL-VKHMYHEASA-N D-penicillamine Chemical compound CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- FDJCVHVKXFIEPJ-JCNFZFLDSA-N Delapril hydrochloride Chemical compound Cl.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N(CC(O)=O)C1CC2=CC=CC=C2C1)CC1=CC=CC=C1 FDJCVHVKXFIEPJ-JCNFZFLDSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- WYQPLTPSGFELIB-JTQPXKBDSA-N Difluprednate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2CC[C@@](C(=O)COC(C)=O)(OC(=O)CCC)[C@@]2(C)C[C@@H]1O WYQPLTPSGFELIB-JTQPXKBDSA-N 0.000 description 1
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- OBMLHUPNRURLOK-XGRAFVIBSA-N Epitiostanol Chemical compound C1[C@@H]2S[C@@H]2C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 OBMLHUPNRURLOK-XGRAFVIBSA-N 0.000 description 1
- 102000009079 Epoprostenol Receptors Human genes 0.000 description 1
- 108010073099 Epoprostenol Receptors Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- AZLLRHYZGGZOSR-UHFFFAOYSA-N FC=1C=C(C=CC=1OC1=CC=NC2=CC(=C(C=C12)OC)OCCCN1CCOCC1)NC(=O)C=1C(N(C=2CCCC(C=2C=1)=O)C1=CC=CC=C1)=O Chemical compound FC=1C=C(C=CC=1OC1=CC=NC2=CC(=C(C=C12)OC)OCCCN1CCOCC1)NC(=O)C=1C(N(C=2CCCC(C=2C=1)=O)C1=CC=CC=C1)=O AZLLRHYZGGZOSR-UHFFFAOYSA-N 0.000 description 1
- 239000001293 FEMA 3089 Substances 0.000 description 1
- 108010029961 Filgrastim Proteins 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- WJOHZNCJWYWUJD-IUGZLZTKSA-N Fluocinonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O WJOHZNCJWYWUJD-IUGZLZTKSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- POPFMWWJOGLOIF-XWCQMRHXSA-N Flurandrenolide Chemical compound C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O POPFMWWJOGLOIF-XWCQMRHXSA-N 0.000 description 1
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- ZPLQIPFOCGIIHV-UHFFFAOYSA-N Gimeracil Chemical compound OC1=CC(=O)C(Cl)=CN1 ZPLQIPFOCGIIHV-UHFFFAOYSA-N 0.000 description 1
- VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 102100031487 Growth arrest-specific protein 6 Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 229940125497 HER2 kinase inhibitor Drugs 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000919358 Homo sapiens Cytochrome P450 2C8 Proteins 0.000 description 1
- 101000650322 Homo sapiens E3 ubiquitin-protein ligase Arkadia Proteins 0.000 description 1
- FOGXJPFPZOHSQS-AYVLZSQQSA-N Hydrocortisone butyrate propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)CC)(OC(=O)CCC)[C@@]1(C)C[C@@H]2O FOGXJPFPZOHSQS-AYVLZSQQSA-N 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 1
- 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 description 1
- 102000010781 Interleukin-6 Receptors Human genes 0.000 description 1
- 108010038501 Interleukin-6 Receptors Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 1
- 239000005536 L01XE08 - Nilotinib Substances 0.000 description 1
- 239000002118 L01XE12 - Vandetanib Substances 0.000 description 1
- 239000002146 L01XE16 - Crizotinib Substances 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 108010062867 Lenograstim Proteins 0.000 description 1
- 108010007859 Lisinopril Proteins 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 101150018665 MAPK3 gene Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 235000021360 Myristic acid Nutrition 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- UNLSGJXZFGXNGQ-UHFFFAOYSA-N N-[3-fluoro-4-(7-methoxyquinazolin-4-yl)oxyphenyl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound FC=1C=C(C=CC=1OC1=NC=NC2=CC(=CC=C12)OC)NC(=O)C=1C(N(C=2CCCC(C=2C=1)=O)C1=CC=CC=C1)=O UNLSGJXZFGXNGQ-UHFFFAOYSA-N 0.000 description 1
- TVCZSELSNUBCHU-UHFFFAOYSA-N N-[4-(6,7-dimethoxyquinazoline-4-carbonyl)phenyl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound COC=1C=C2C(=NC=NC2=CC=1OC)C(=O)C1=CC=C(C=C1)NC(=O)C=1C(N(C=2CCCC(C=2C=1)=O)C1=CC=CC=C1)=O TVCZSELSNUBCHU-UHFFFAOYSA-N 0.000 description 1
- GQBNIHJYEKWEHE-UHFFFAOYSA-N N-[4-(6,7-dimethoxyquinolin-4-yl)oxy-2,6-difluorophenyl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound COC=1C=C2C(=CC=NC2=CC=1OC)OC1=CC(=C(C(=C1)F)NC(=O)C=1C(N(C=2CCCC(C=2C=1)=O)C1=CC=CC=C1)=O)F GQBNIHJYEKWEHE-UHFFFAOYSA-N 0.000 description 1
- XWIFSPUXKOQAOC-UHFFFAOYSA-N N-[4-(6,7-dimethoxyquinolin-4-yl)oxy-2-methylphenyl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound COC=1C=C2C(=CC=NC2=CC=1OC)OC1=CC(=C(C=C1)NC(=O)C=1C(N(C=2CCCC(C=2C=1)=O)C1=CC=CC=C1)=O)C XWIFSPUXKOQAOC-UHFFFAOYSA-N 0.000 description 1
- FLNMTUMADPYIGA-UHFFFAOYSA-N N-[4-(6,7-dimethoxyquinolin-4-yl)oxy-3-fluorophenyl]-1-(2,2-dimethylpropyl)-2,5-dioxo-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound COC=1C=C2C(=CC=NC2=CC=1OC)OC1=C(C=C(C=C1)NC(=O)C=1C(N(C=2CCCC(C=2C=1)=O)CC(C)(C)C)=O)F FLNMTUMADPYIGA-UHFFFAOYSA-N 0.000 description 1
- WMIMUQXUIVHOGG-UHFFFAOYSA-N N-[4-(6,7-dimethoxyquinolin-4-yl)oxy-3-fluorophenyl]-2,5-dioxo-1-phenylspiro[6,8-dihydroquinoline-7,1'-cyclopropane]-3-carboxamide Chemical compound COC=1C=C2C(=CC=NC2=CC=1OC)OC1=C(C=C(C=C1)NC(=O)C=1C(N(C=2CC3(CC(C=2C=1)=O)CC3)C1=CC=CC=C1)=O)F WMIMUQXUIVHOGG-UHFFFAOYSA-N 0.000 description 1
- BJZKBNMFEYYCRS-UHFFFAOYSA-N N-[4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]-4-methyl-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound COC=1C=C2C(=CC=NC2=CC=1OC)OC1=CC=C(C=C1)NC(=O)C=1C(N(C=2CCCC(C=2C=1C)=O)C1=CC=CC=C1)=O BJZKBNMFEYYCRS-UHFFFAOYSA-N 0.000 description 1
- WEYSAXNVVXBMKT-UHFFFAOYSA-N N-[4-[(6,7-dimethoxyquinazolin-4-yl)amino]phenyl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound COC=1C=C2C(=NC=NC2=CC=1OC)NC1=CC=C(C=C1)NC(=O)C=1C(N(C=2CCCC(C=2C=1)=O)C1=CC=CC=C1)=O WEYSAXNVVXBMKT-UHFFFAOYSA-N 0.000 description 1
- LZGFSWXJWMTKGL-UHFFFAOYSA-N N-[4-[(6,7-dimethoxyquinolin-4-yl)amino]phenyl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound COC=1C=C2C(=CC=NC2=CC=1OC)NC1=CC=C(C=C1)NC(=O)C=1C(N(C=2CCCC(C=2C=1)=O)C1=CC=CC=C1)=O LZGFSWXJWMTKGL-UHFFFAOYSA-N 0.000 description 1
- QLFVCFBVDHJTKL-UHFFFAOYSA-N N-[5-(6,7-dimethoxyquinazolin-4-yl)oxypyridin-2-yl]-1-(2,2-dimethylpropyl)-2,5-dioxo-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound COC=1C=C2C(=NC=NC2=CC=1OC)OC=1C=CC(=NC=1)NC(=O)C=1C(N(C=2CCCC(C=2C=1)=O)CC(C)(C)C)=O QLFVCFBVDHJTKL-UHFFFAOYSA-N 0.000 description 1
- DBRRAYXUSXALOD-QHCPKHFHSA-N N-[5-(6,7-dimethoxyquinazolin-4-yl)oxypyridin-2-yl]-1-[(2R)-1-hydroxy-3-methylbutan-2-yl]-2,5-dioxo-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound COC=1C=C2C(=NC=NC2=CC=1OC)OC=1C=CC(=NC=1)NC(=O)C=1C(N(C=2CCCC(C=2C=1)=O)[C@@H](CO)C(C)C)=O DBRRAYXUSXALOD-QHCPKHFHSA-N 0.000 description 1
- DBRRAYXUSXALOD-HSZRJFAPSA-N N-[5-(6,7-dimethoxyquinazolin-4-yl)oxypyridin-2-yl]-1-[(2S)-1-hydroxy-3-methylbutan-2-yl]-2,5-dioxo-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound COC=1C=C2C(=NC=NC2=CC=1OC)OC=1C=CC(=NC=1)NC(=O)C=1C(N(C=2CCCC(C=2C=1)=O)[C@H](CO)C(C)C)=O DBRRAYXUSXALOD-HSZRJFAPSA-N 0.000 description 1
- YSYQKADPJSFBRQ-UHFFFAOYSA-N N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-1-(1-hydroxy-3-methylbutan-2-yl)-2,5-dioxo-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound COC=1C=C2C(=CC=NC2=CC=1OC)OC=1C=CC(=NC=1)NC(=O)C=1C(N(C=2CCCC(C=2C=1)=O)C(CO)C(C)C)=O YSYQKADPJSFBRQ-UHFFFAOYSA-N 0.000 description 1
- LUQJSLGBVOMBLZ-UHFFFAOYSA-N N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-1-(1-methylpyrazol-4-yl)-2,5-dioxo-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound COC=1C=C2C(=CC=NC2=CC=1OC)OC=1C=CC(=NC=1)NC(=O)C=1C(N(C=2CCCC(C=2C=1)=O)C=1C=NN(C=1)C)=O LUQJSLGBVOMBLZ-UHFFFAOYSA-N 0.000 description 1
- XBCWGUFJWAUDIO-UHFFFAOYSA-N N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-1-(2-hydroxy-2-methylpropyl)-2,5-dioxo-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound COC=1C=C2C(=CC=NC2=CC=1OC)OC=1C=CC(=NC=1)NC(=O)C=1C(N(C=2CCCC(C=2C=1)=O)CC(C)(C)O)=O XBCWGUFJWAUDIO-UHFFFAOYSA-N 0.000 description 1
- IPSKVHCWXZEZMA-UHFFFAOYSA-N N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-1-(2-methoxy-2-methylpropyl)-2,5-dioxo-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound COC=1C=C2C(=CC=NC2=CC=1OC)OC=1C=CC(=NC=1)NC(=O)C=1C(N(C=2CCCC(C=2C=1)=O)CC(C)(C)OC)=O IPSKVHCWXZEZMA-UHFFFAOYSA-N 0.000 description 1
- HMLRHSKIPHFVBX-UHFFFAOYSA-N N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-1-(2-methylphenyl)-2,5-dioxo-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound COC=1C=C2C(=CC=NC2=CC=1OC)OC=1C=CC(=NC=1)NC(=O)C=1C(N(C=2CCCC(C=2C=1)=O)C1=C(C=CC=C1)C)=O HMLRHSKIPHFVBX-UHFFFAOYSA-N 0.000 description 1
- NKYDTIGRIIRAJI-UHFFFAOYSA-N N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-1-(2-methylsulfonyl-1-phenylethyl)-2,5-dioxo-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound COC=1C=C2C(=CC=NC2=CC=1OC)OC=1C=CC(=NC=1)NC(=O)C=1C(N(C=2CCCC(C=2C=1)=O)C(CS(=O)(=O)C)C1=CC=CC=C1)=O NKYDTIGRIIRAJI-UHFFFAOYSA-N 0.000 description 1
- LCWDHRXUQNFZQD-UHFFFAOYSA-N N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-1-(3-hydroxy-3-methylbutan-2-yl)-2,5-dioxo-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound COC=1C=C2C(=CC=NC2=CC=1OC)OC=1C=CC(=NC=1)NC(=O)C=1C(N(C=2CCCC(C=2C=1)=O)C(C)C(C)(C)O)=O LCWDHRXUQNFZQD-UHFFFAOYSA-N 0.000 description 1
- KDMAPQZWJIYLQJ-UHFFFAOYSA-N N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-1-(3-methylbutan-2-yl)-2,5-dioxo-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound COC=1C=C2C(=CC=NC2=CC=1OC)OC=1C=CC(=NC=1)NC(=O)C=1C(N(C=2CCCC(C=2C=1)=O)C(C)C(C)C)=O KDMAPQZWJIYLQJ-UHFFFAOYSA-N 0.000 description 1
- QJCDHFHBQOOYHB-UHFFFAOYSA-N N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-1-(3-methylphenyl)-2,5-dioxo-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound COC=1C=C2C(=CC=NC2=CC=1OC)OC=1C=CC(=NC=1)NC(=O)C=1C(N(C=2CCCC(C=2C=1)=O)C1=CC(=CC=C1)C)=O QJCDHFHBQOOYHB-UHFFFAOYSA-N 0.000 description 1
- CTZGMYHRBITDIJ-UHFFFAOYSA-N N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-1-(4-methylphenyl)-2,5-dioxo-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound COC=1C=C2C(=CC=NC2=CC=1OC)OC=1C=CC(=NC=1)NC(=O)C=1C(N(C=2CCCC(C=2C=1)=O)C1=CC=C(C=C1)C)=O CTZGMYHRBITDIJ-UHFFFAOYSA-N 0.000 description 1
- ICCHMFKTVMRFQO-UHFFFAOYSA-N N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-1-(oxan-4-yl)-2,5-dioxo-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound COC=1C=C2C(=CC=NC2=CC=1OC)OC=1C=CC(=NC=1)NC(=O)C=1C(N(C=2CCCC(C=2C=1)=O)C1CCOCC1)=O ICCHMFKTVMRFQO-UHFFFAOYSA-N 0.000 description 1
- TVSHBIZAKFNBSD-UHFFFAOYSA-N N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-1-(oxetan-3-yl)-2,5-dioxo-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound COC=1C=C2C(=CC=NC2=CC=1OC)OC=1C=CC(=NC=1)NC(=O)C=1C(N(C=2CCCC(C=2C=1)=O)C1COC1)=O TVSHBIZAKFNBSD-UHFFFAOYSA-N 0.000 description 1
- QAWZIMUJXXAUKH-LJQANCHMSA-N N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-1-[(1R)-1-(4-fluorophenyl)ethyl]-2,5-dioxo-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound COC=1C=C2C(=CC=NC2=CC=1OC)OC=1C=CC(=NC=1)NC(=O)C=1C(N(C=2CCCC(C=2C=1)=O)[C@H](C)C1=CC=C(C=C1)F)=O QAWZIMUJXXAUKH-LJQANCHMSA-N 0.000 description 1
- HZZJBSHETVZMTD-MHZLTWQESA-N N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-1-[(1R)-2-hydroxy-1-phenylethyl]-2,5-dioxo-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound COC=1C=C2C(=CC=NC2=CC=1OC)OC=1C=CC(=NC=1)NC(=O)C=1C(N(C=2CCCC(C=2C=1)=O)[C@@H](CO)C1=CC=CC=C1)=O HZZJBSHETVZMTD-MHZLTWQESA-N 0.000 description 1
- QAWZIMUJXXAUKH-IBGZPJMESA-N N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-1-[(1S)-1-(4-fluorophenyl)ethyl]-2,5-dioxo-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound COC=1C=C2C(=CC=NC2=CC=1OC)OC=1C=CC(=NC=1)NC(=O)C=1C(N(C=2CCCC(C=2C=1)=O)[C@@H](C)C1=CC=C(C=C1)F)=O QAWZIMUJXXAUKH-IBGZPJMESA-N 0.000 description 1
- HZZJBSHETVZMTD-HHHXNRCGSA-N N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-1-[(1S)-2-hydroxy-1-phenylethyl]-2,5-dioxo-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound COC=1C=C2C(=CC=NC2=CC=1OC)OC=1C=CC(=NC=1)NC(=O)C=1C(N(C=2CCCC(C=2C=1)=O)[C@H](CO)C1=CC=CC=C1)=O HZZJBSHETVZMTD-HHHXNRCGSA-N 0.000 description 1
- YSYQKADPJSFBRQ-DEOSSOPVSA-N N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-1-[(2R)-1-hydroxy-3-methylbutan-2-yl]-2,5-dioxo-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound COC=1C=C2C(=CC=NC2=CC=1OC)OC=1C=CC(=NC=1)NC(=O)C=1C(N(C=2CCCC(C=2C=1)=O)[C@@H](CO)C(C)C)=O YSYQKADPJSFBRQ-DEOSSOPVSA-N 0.000 description 1
- KDMAPQZWJIYLQJ-GOSISDBHSA-N N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-1-[(2R)-3-methylbutan-2-yl]-2,5-dioxo-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound COC=1C=C2C(=CC=NC2=CC=1OC)OC=1C=CC(=NC=1)NC(=O)C=1C(N(C=2CCCC(C=2C=1)=O)[C@H](C)C(C)C)=O KDMAPQZWJIYLQJ-GOSISDBHSA-N 0.000 description 1
- KDMAPQZWJIYLQJ-SFHVURJKSA-N N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-1-[(2S)-3-methylbutan-2-yl]-2,5-dioxo-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound COC=1C=C2C(=CC=NC2=CC=1OC)OC=1C=CC(=NC=1)NC(=O)C=1C(N(C=2CCCC(C=2C=1)=O)[C@@H](C)C(C)C)=O KDMAPQZWJIYLQJ-SFHVURJKSA-N 0.000 description 1
- BVROTFIPUXVNAD-UHFFFAOYSA-N N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-1-[(4-fluorophenyl)methyl]-2,5-dioxo-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound COC=1C=C2C(=CC=NC2=CC=1OC)OC=1C=CC(=NC=1)NC(=O)C=1C(N(C=2CCCC(C=2C=1)=O)CC1=CC=C(C=C1)F)=O BVROTFIPUXVNAD-UHFFFAOYSA-N 0.000 description 1
- UAJZDNQKJWGVIU-UHFFFAOYSA-N N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-1-[1-(2-hydroxy-2-methylpropyl)pyrazol-4-yl]-2,5-dioxo-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound COC=1C=C2C(=CC=NC2=CC=1OC)OC=1C=CC(=NC=1)NC(=O)C=1C(N(C=2CCCC(C=2C=1)=O)C=1C=NN(C=1)CC(C)(C)O)=O UAJZDNQKJWGVIU-UHFFFAOYSA-N 0.000 description 1
- QAWZIMUJXXAUKH-UHFFFAOYSA-N N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-1-[1-(4-fluorophenyl)ethyl]-2,5-dioxo-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound COC=1C=C2C(=CC=NC2=CC=1OC)OC=1C=CC(=NC=1)NC(=O)C=1C(N(C=2CCCC(C=2C=1)=O)C(C)C1=CC=C(C=C1)F)=O QAWZIMUJXXAUKH-UHFFFAOYSA-N 0.000 description 1
- HJMQIAXBATVXPH-UHFFFAOYSA-N N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-1-[1-(hydroxymethyl)cyclobutyl]-2,5-dioxo-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound COC=1C=C2C(=CC=NC2=CC=1OC)OC=1C=CC(=NC=1)NC(=O)C=1C(N(C=2CCCC(C=2C=1)=O)C1(CCC1)CO)=O HJMQIAXBATVXPH-UHFFFAOYSA-N 0.000 description 1
- RWUHZRGSUYXNIH-UHFFFAOYSA-N N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-1-[2-(dimethylamino)ethyl]-2,5-dioxo-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound COC=1C=C2C(=CC=NC2=CC=1OC)OC=1C=CC(=NC=1)NC(=O)C=1C(N(C=2CCCC(C=2C=1)=O)CCN(C)C)=O RWUHZRGSUYXNIH-UHFFFAOYSA-N 0.000 description 1
- VJBBUGMAFSVXLA-UHFFFAOYSA-N N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-1-(3-phenylpropyl)-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound COC=1C=C2C(=CC=NC2=CC=1OC)OC=1C=CC(=NC=1)NC(=O)C=1C(N(C=2CCCC(C=2C=1)=O)CCCC1=CC=CC=C1)=O VJBBUGMAFSVXLA-UHFFFAOYSA-N 0.000 description 1
- WGMPYJXEPFWBII-HXUWFJFHSA-N N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-1-[(1R)-1-phenylethyl]-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound COC=1C=C2C(=CC=NC2=CC=1OC)OC=1C=CC(=NC=1)NC(=O)C=1C(N(C=2CCCC(C=2C=1)=O)[C@H](C)C1=CC=CC=C1)=O WGMPYJXEPFWBII-HXUWFJFHSA-N 0.000 description 1
- WGMPYJXEPFWBII-FQEVSTJZSA-N N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-1-[(1S)-1-phenylethyl]-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound COC=1C=C2C(=CC=NC2=CC=1OC)OC=1C=CC(=NC=1)NC(=O)C=1C(N(C=2CCCC(C=2C=1)=O)[C@@H](C)C1=CC=CC=C1)=O WGMPYJXEPFWBII-FQEVSTJZSA-N 0.000 description 1
- DBHNHFKATRCZBJ-UHFFFAOYSA-N N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-1-pentan-3-yl-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound COC=1C=C2C(=CC=NC2=CC=1OC)OC=1C=CC(=NC=1)NC(=O)C=1C(N(C=2CCCC(C=2C=1)=O)C(CC)CC)=O DBHNHFKATRCZBJ-UHFFFAOYSA-N 0.000 description 1
- MSZMVNPORJVXMT-UHFFFAOYSA-N N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-1-phenylspiro[6,8-dihydroquinoline-7,1'-cyclobutane]-3-carboxamide Chemical compound COC=1C=C2C(=CC=NC2=CC=1OC)OC=1C=CC(=NC=1)NC(=O)C=1C(N(C=2CC3(CC(C=2C=1)=O)CCC3)C1=CC=CC=C1)=O MSZMVNPORJVXMT-UHFFFAOYSA-N 0.000 description 1
- AZJARDNLQCXHGQ-UHFFFAOYSA-N N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-1-phenylspiro[6,8-dihydroquinoline-7,1'-cyclopropane]-3-carboxamide Chemical compound COC=1C=C2C(=CC=NC2=CC=1OC)OC=1C=CC(=NC=1)NC(=O)C=1C(N(C=2CC3(CC(C=2C=1)=O)CC3)C1=CC=CC=C1)=O AZJARDNLQCXHGQ-UHFFFAOYSA-N 0.000 description 1
- BINQWKKDWPLNSM-UHFFFAOYSA-N N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-1-pyridin-3-yl-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound COC=1C=C2C(=CC=NC2=CC=1OC)OC=1C=CC(=NC=1)NC(=O)C=1C(N(C=2CCCC(C=2C=1)=O)C=1C=NC=CC=1)=O BINQWKKDWPLNSM-UHFFFAOYSA-N 0.000 description 1
- OOUGEEKBJPKSCA-UHFFFAOYSA-N N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2-oxo-1-phenyl-5,6,7,8-tetrahydroquinoline-3-carboxamide Chemical compound COC=1C=C2C(=CC=NC2=CC=1OC)OC=1C=CC(=NC=1)NC(=O)C=1C(N(C=2CCCCC=2C=1)C1=CC=CC=C1)=O OOUGEEKBJPKSCA-UHFFFAOYSA-N 0.000 description 1
- HBZGXJAJRAXBJY-UHFFFAOYSA-N N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-8-hydroxy-2,5-dioxo-1-phenylspiro[6,8-dihydroquinoline-7,1'-cyclopropane]-3-carboxamide Chemical compound COC=1C=C2C(=CC=NC2=CC=1OC)OC=1C=CC(=NC=1)NC(=O)C=1C(N(C=2C(C3(CC(C=2C=1)=O)CC3)O)C1=CC=CC=C1)=O HBZGXJAJRAXBJY-UHFFFAOYSA-N 0.000 description 1
- FSXYYKNMVNWWOP-UHFFFAOYSA-N N-[5-(6-methoxyquinolin-4-yl)oxypyridin-2-yl]-1-(2-methylphenyl)-2,5-dioxo-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound COC=1C=C2C(=CC=NC2=CC=1)OC=1C=CC(=NC=1)NC(=O)C=1C(N(C=2CCCC(C=2C=1)=O)C1=C(C=CC=C1)C)=O FSXYYKNMVNWWOP-UHFFFAOYSA-N 0.000 description 1
- XMNQQNMUUIPFKU-UHFFFAOYSA-N N-[5-(6-methoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound COC=1C=C2C(=CC=NC2=CC=1)OC=1C=CC(=NC=1)NC(=O)C=1C(N(C=2CCCC(C=2C=1)=O)C1=CC=CC=C1)=O XMNQQNMUUIPFKU-UHFFFAOYSA-N 0.000 description 1
- KUXHPBSSHAPQQH-UHFFFAOYSA-N N-[5-(7-but-2-ynoxy-6-methoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound C(C#CC)OC1=C(C=C2C(=CC=NC2=C1)OC=1C=CC(=NC=1)NC(=O)C=1C(N(C=2CCCC(C=2C=1)=O)C1=CC=CC=C1)=O)OC KUXHPBSSHAPQQH-UHFFFAOYSA-N 0.000 description 1
- WKXXKLBBERHTBE-UHFFFAOYSA-N N-[5-(7-hydroxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound OC1=CC=C2C(=CC=NC2=C1)OC=1C=CC(=NC=1)NC(=O)C=1C(N(C=2CCCC(C=2C=1)=O)C1=CC=CC=C1)=O WKXXKLBBERHTBE-UHFFFAOYSA-N 0.000 description 1
- HRHDVXYSIYZBLW-UHFFFAOYSA-N N-[5-(7-methoxyquinazolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound COC1=CC=C2C(=NC=NC2=C1)OC=1C=CC(=NC=1)NC(=O)C=1C(N(C=2CCCC(C=2C=1)=O)C1=CC=CC=C1)=O HRHDVXYSIYZBLW-UHFFFAOYSA-N 0.000 description 1
- PBCIYTVNQULMOF-UHFFFAOYSA-N N-[5-(7-methoxyquinolin-4-yl)oxypyridin-2-yl]-1-(2-methylphenyl)-2,5-dioxo-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound COC1=CC=C2C(=CC=NC2=C1)OC=1C=CC(=NC=1)NC(=O)C=1C(N(C=2CCCC(C=2C=1)=O)C1=C(C=CC=C1)C)=O PBCIYTVNQULMOF-UHFFFAOYSA-N 0.000 description 1
- OXTIUNYXCXDDBB-UHFFFAOYSA-N N-[5-(7-methoxyquinolin-4-yl)oxypyridin-2-yl]-1-(2-methylpropyl)-2,5-dioxo-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound C(C(C)C)N1C(C(=CC=2C(CCCC1=2)=O)C(=O)NC1=NC=C(C=C1)OC1=CC=NC2=CC(=CC=C12)OC)=O OXTIUNYXCXDDBB-UHFFFAOYSA-N 0.000 description 1
- PNRVOODDWUOVLR-UHFFFAOYSA-N N-[5-(7-methoxyquinolin-4-yl)oxypyridin-2-yl]-1-(3-methylphenyl)-2,5-dioxo-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound COC1=CC=C2C(=CC=NC2=C1)OC=1C=CC(=NC=1)NC(=O)C=1C(N(C=2CCCC(C=2C=1)=O)C1=CC(=CC=C1)C)=O PNRVOODDWUOVLR-UHFFFAOYSA-N 0.000 description 1
- CTTJWEBWZKSPKD-UHFFFAOYSA-N N-[5-(7-methoxyquinolin-4-yl)oxypyridin-2-yl]-1-(4-methylphenyl)-2,5-dioxo-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound COC1=CC=C2C(=CC=NC2=C1)OC=1C=CC(=NC=1)NC(=O)C=1C(N(C=2CCCC(C=2C=1)=O)C1=CC=C(C=C1)C)=O CTTJWEBWZKSPKD-UHFFFAOYSA-N 0.000 description 1
- MPKLQCKXZLLVHA-GOSISDBHSA-N N-[5-(7-methoxyquinolin-4-yl)oxypyridin-2-yl]-1-[(2R)-3-methylbutan-2-yl]-2,5-dioxo-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound COC1=CC=C2C(=CC=NC2=C1)OC=1C=CC(=NC=1)NC(=O)C=1C(N(C=2CCCC(C=2C=1)=O)[C@H](C)C(C)C)=O MPKLQCKXZLLVHA-GOSISDBHSA-N 0.000 description 1
- MPKLQCKXZLLVHA-SFHVURJKSA-N N-[5-(7-methoxyquinolin-4-yl)oxypyridin-2-yl]-1-[(2S)-3-methylbutan-2-yl]-2,5-dioxo-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound COC1=CC=C2C(=CC=NC2=C1)OC=1C=CC(=NC=1)NC(=O)C=1C(N(C=2CCCC(C=2C=1)=O)[C@@H](C)C(C)C)=O MPKLQCKXZLLVHA-SFHVURJKSA-N 0.000 description 1
- PLELZBHFIVICDD-HXUWFJFHSA-N N-[5-(7-methoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-1-[(1R)-1-phenylethyl]-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound COC1=CC=C2C(=CC=NC2=C1)OC=1C=CC(=NC=1)NC(=O)C=1C(N(C=2CCCC(C=2C=1)=O)[C@H](C)C1=CC=CC=C1)=O PLELZBHFIVICDD-HXUWFJFHSA-N 0.000 description 1
- NDPXUEQWFPBNOT-UHFFFAOYSA-N N-[5-(7-methoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound COC1=CC=C2C(=CC=NC2=C1)OC=1C=CC(=NC=1)NC(=O)C=1C(N(C=2CCCC(C=2C=1)=O)C1=CC=CC=C1)=O NDPXUEQWFPBNOT-UHFFFAOYSA-N 0.000 description 1
- QAVYJCJAPABADQ-UHFFFAOYSA-N N-[5-(7-methoxyquinolin-4-yl)oxypyridin-2-yl]-6,6-dimethyl-2,5-dioxo-1-phenyl-7,8-dihydroquinoline-3-carboxamide Chemical compound COC1=CC=C2C(=CC=NC2=C1)OC=1C=CC(=NC=1)NC(=O)C=1C(N(C=2CCC(C(C=2C=1)=O)(C)C)C1=CC=CC=C1)=O QAVYJCJAPABADQ-UHFFFAOYSA-N 0.000 description 1
- PXOFSDNBDWNMGR-UHFFFAOYSA-N N-[5-[(7-methoxyquinolin-4-yl)amino]pyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound COC1=CC=C2C(=CC=NC2=C1)NC=1C=CC(=NC=1)NC(=O)C=1C(N(C=2CCCC(C=2C=1)=O)C1=CC=CC=C1)=O PXOFSDNBDWNMGR-UHFFFAOYSA-N 0.000 description 1
- LBDRGORVZQEWIF-UHFFFAOYSA-N N-[5-[6-methoxy-7-(3-methylsulfonylpropoxy)quinolin-4-yl]oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound COC=1C=C2C(=CC=NC2=CC=1OCCCS(=O)(=O)C)OC=1C=CC(=NC=1)NC(=O)C=1C(N(C=2CCCC(C=2C=1)=O)C1=CC=CC=C1)=O LBDRGORVZQEWIF-UHFFFAOYSA-N 0.000 description 1
- RPDVZYMVRZJOOV-UHFFFAOYSA-N N-[5-[6-methoxy-7-(3-piperazin-1-ylpropoxy)quinolin-4-yl]oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound COC=1C=C2C(=CC=NC2=CC=1OCCCN1CCNCC1)OC=1C=CC(=NC=1)NC(=O)C=1C(N(C=2CCCC(C=2C=1)=O)C1=CC=CC=C1)=O RPDVZYMVRZJOOV-UHFFFAOYSA-N 0.000 description 1
- RHIPXNPKYQIDMP-UHFFFAOYSA-N N-[5-[6-methoxy-7-(3-piperidin-1-ylpropoxy)quinolin-4-yl]oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound COC=1C=C2C(=CC=NC2=CC=1OCCCN1CCCCC1)OC=1C=CC(=NC=1)NC(=O)C=1C(N(C=2CCCC(C=2C=1)=O)C1=CC=CC=C1)=O RHIPXNPKYQIDMP-UHFFFAOYSA-N 0.000 description 1
- CCOOPZUIMJPOSE-UHFFFAOYSA-N N-[5-[6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinolin-4-yl]oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound COC=1C=C2C(=CC=NC2=CC=1OCCCN1CCN(CC1)C)OC=1C=CC(=NC=1)NC(=O)C=1C(N(C=2CCCC(C=2C=1)=O)C1=CC=CC=C1)=O CCOOPZUIMJPOSE-UHFFFAOYSA-N 0.000 description 1
- DJUWTJLIVDCTLF-UHFFFAOYSA-N N-[5-[7-(2-morpholin-4-ylethoxy)quinolin-4-yl]oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound N1(CCOCC1)CCOC1=CC=C2C(=CC=NC2=C1)OC=1C=CC(=NC=1)NC(=O)C=1C(N(C=2CCCC(C=2C=1)=O)C1=CC=CC=C1)=O DJUWTJLIVDCTLF-UHFFFAOYSA-N 0.000 description 1
- OWLGTXIFVWMXRV-UHFFFAOYSA-N N-[5-[7-(3-hydroxy-3-methylbutoxy)quinolin-4-yl]oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound OC(CCOC1=CC=C2C(=CC=NC2=C1)OC=1C=CC(=NC=1)NC(=O)C=1C(N(C=2CCCC(C=2C=1)=O)C1=CC=CC=C1)=O)(C)C OWLGTXIFVWMXRV-UHFFFAOYSA-N 0.000 description 1
- UHFDBJSBNBCMEP-UHFFFAOYSA-N N-[5-[7-(3-methylbut-2-enoxy)quinolin-4-yl]oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound CC(=CCOC1=CC=C2C(=CC=NC2=C1)OC=1C=CC(=NC=1)NC(=O)C=1C(N(C=2CCCC(C=2C=1)=O)C1=CC=CC=C1)=O)C UHFDBJSBNBCMEP-UHFFFAOYSA-N 0.000 description 1
- SXDKKCKJOSVVKA-SSEXGKCCSA-N N-[5-[7-[(2R)-2,3-dihydroxy-3-methylbutoxy]-6-methoxyquinolin-4-yl]oxypyridin-2-yl]-1-(2,2-dimethylpropyl)-2,5-dioxo-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound O[C@H](COC1=C(C=C2C(=CC=NC2=C1)OC=1C=CC(=NC=1)NC(=O)C=1C(N(C=2CCCC(C=2C=1)=O)CC(C)(C)C)=O)OC)C(C)(C)O SXDKKCKJOSVVKA-SSEXGKCCSA-N 0.000 description 1
- PBIWQCSFRLWDGE-JGCGQSQUSA-N N-[5-[7-[(2R)-2,3-dihydroxy-3-methylbutoxy]-6-methoxyquinolin-4-yl]oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound O[C@H](COC1=C(C=C2C(=CC=NC2=C1)OC=1C=CC(=NC=1)NC(=O)C=1C(N(C=2CCCC(C=2C=1)=O)C1=CC=CC=C1)=O)OC)C(C)(C)O PBIWQCSFRLWDGE-JGCGQSQUSA-N 0.000 description 1
- YERDYTIVZZTHKG-LJQANCHMSA-N N-[5-[7-[(2R)-2,3-dihydroxypropoxy]-6-methoxyquinolin-4-yl]oxypyridin-2-yl]-1-(2,2-dimethylpropyl)-2,5-dioxo-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound O[C@@H](COC1=C(C=C2C(=CC=NC2=C1)OC=1C=CC(=NC=1)NC(=O)C=1C(N(C=2CCCC(C=2C=1)=O)CC(C)(C)C)=O)OC)CO YERDYTIVZZTHKG-LJQANCHMSA-N 0.000 description 1
- ZBGCRQPEYHSUAU-OAQYLSRUSA-N N-[5-[7-[(2R)-2,3-dihydroxypropoxy]-6-methoxyquinolin-4-yl]oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound O[C@@H](COC1=C(C=C2C(=CC=NC2=C1)OC=1C=CC(=NC=1)NC(=O)C=1C(N(C=2CCCC(C=2C=1)=O)C1=CC=CC=C1)=O)OC)CO ZBGCRQPEYHSUAU-OAQYLSRUSA-N 0.000 description 1
- SXDKKCKJOSVVKA-PMERELPUSA-N N-[5-[7-[(2S)-2,3-dihydroxy-3-methylbutoxy]-6-methoxyquinolin-4-yl]oxypyridin-2-yl]-1-(2,2-dimethylpropyl)-2,5-dioxo-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound O[C@@H](COC1=C(C=C2C(=CC=NC2=C1)OC=1C=CC(=NC=1)NC(=O)C=1C(N(C=2CCCC(C=2C=1)=O)CC(C)(C)C)=O)OC)C(C)(C)O SXDKKCKJOSVVKA-PMERELPUSA-N 0.000 description 1
- FZQIAAAHHPCCDL-YTTGMZPUSA-N N-[5-[7-[(2S)-2,3-dihydroxy-3-methylbutoxy]-6-methoxyquinolin-4-yl]oxypyridin-2-yl]-1-(3-fluorophenyl)-2,5-dioxo-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound O[C@@H](COC1=C(C=C2C(=CC=NC2=C1)OC=1C=CC(=NC=1)NC(=O)C=1C(N(C=2CCCC(C=2C=1)=O)C1=CC(=CC=C1)F)=O)OC)C(C)(C)O FZQIAAAHHPCCDL-YTTGMZPUSA-N 0.000 description 1
- PBIWQCSFRLWDGE-YTTGMZPUSA-N N-[5-[7-[(2S)-2,3-dihydroxy-3-methylbutoxy]-6-methoxyquinolin-4-yl]oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound O[C@@H](COC1=C(C=C2C(=CC=NC2=C1)OC=1C=CC(=NC=1)NC(=O)C=1C(N(C=2CCCC(C=2C=1)=O)C1=CC=CC=C1)=O)OC)C(C)(C)O PBIWQCSFRLWDGE-YTTGMZPUSA-N 0.000 description 1
- YERDYTIVZZTHKG-IBGZPJMESA-N N-[5-[7-[(2S)-2,3-dihydroxypropoxy]-6-methoxyquinolin-4-yl]oxypyridin-2-yl]-1-(2,2-dimethylpropyl)-2,5-dioxo-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound O[C@H](COC1=C(C=C2C(=CC=NC2=C1)OC=1C=CC(=NC=1)NC(=O)C=1C(N(C=2CCCC(C=2C=1)=O)CC(C)(C)C)=O)OC)CO YERDYTIVZZTHKG-IBGZPJMESA-N 0.000 description 1
- ZBGCRQPEYHSUAU-NRFANRHFSA-N N-[5-[7-[(2S)-2,3-dihydroxypropoxy]-6-methoxyquinolin-4-yl]oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound O[C@H](COC1=C(C=C2C(=CC=NC2=C1)OC=1C=CC(=NC=1)NC(=O)C=1C(N(C=2CCCC(C=2C=1)=O)C1=CC=CC=C1)=O)OC)CO ZBGCRQPEYHSUAU-NRFANRHFSA-N 0.000 description 1
- FTXNALPIJQTXGV-PSXMRANNSA-N N-[5-[7-[(3R)-3,4-dihydroxy-3-methylbutoxy]-6-methoxyquinolin-4-yl]oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound O[C@](CCOC1=C(C=C2C(=CC=NC2=C1)OC=1C=CC(=NC=1)NC(=O)C=1C(N(C=2CCCC(C=2C=1)=O)C1=CC=CC=C1)=O)OC)(CO)C FTXNALPIJQTXGV-PSXMRANNSA-N 0.000 description 1
- FTXNALPIJQTXGV-BHVANESWSA-N N-[5-[7-[(3S)-3,4-dihydroxy-3-methylbutoxy]-6-methoxyquinolin-4-yl]oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound O[C@@](CCOC1=C(C=C2C(=CC=NC2=C1)OC=1C=CC(=NC=1)NC(=O)C=1C(N(C=2CCCC(C=2C=1)=O)C1=CC=CC=C1)=O)OC)(CO)C FTXNALPIJQTXGV-BHVANESWSA-N 0.000 description 1
- POXCPVAMGRVNRW-DEOSSOPVSA-N N-[5-[7-[[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]methoxy]-6-methoxyquinolin-4-yl]oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide Chemical compound CC1(OC[C@@H](O1)COC1=C(C=C2C(=CC=NC2=C1)OC=1C=CC(=NC=1)NC(=O)C=1C(N(C=2CCCC(C=2C=1)=O)C1=CC=CC=C1)=O)OC)C POXCPVAMGRVNRW-DEOSSOPVSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- IAGYZUVTUDMJLV-UHFFFAOYSA-N NC1=CC=C(C=C1)O.COC=1C=C2C(=CC=NC2=CC1OC)OC1=CC=C(C=C1)N Chemical compound NC1=CC=C(C=C1)O.COC=1C=C2C(=CC=NC2=CC1OC)OC1=CC=C(C=C1)N IAGYZUVTUDMJLV-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- 229910021586 Nickel(II) chloride Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- AFLXUQUGROGEFA-UHFFFAOYSA-N Nitrogen mustard N-oxide Chemical compound ClCC[N+]([O-])(C)CCCl AFLXUQUGROGEFA-UHFFFAOYSA-N 0.000 description 1
- JBLVAMNSJDDGGK-WJOKGBTCSA-N O[C@H](COC1=CC=C2C(=CC=NC2=C1)OC=1C=CC(=NC=1)NC(=O)C=1C(N(C=2CCCC(C=2C=1)=O)C1=CC=CC=C1)=O)C(C)(C)O Chemical compound O[C@H](COC1=CC=C2C(=CC=NC2=C1)OC=1C=CC(=NC=1)NC(=O)C=1C(N(C=2CCCC(C=2C=1)=O)C1=CC=CC=C1)=O)C(C)(C)O JBLVAMNSJDDGGK-WJOKGBTCSA-N 0.000 description 1
- 108010016076 Octreotide Proteins 0.000 description 1
- 239000005480 Olmesartan Substances 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 102000038030 PI3Ks Human genes 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- TVQZAMVBTVNYLA-UHFFFAOYSA-N Pranoprofen Chemical compound C1=CC=C2CC3=CC(C(C(O)=O)C)=CC=C3OC2=N1 TVQZAMVBTVNYLA-UHFFFAOYSA-N 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- HUMXXHTVHHLNRO-KAJVQRHHSA-N Prednisolone tebutate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)CC(C)(C)C)(O)[C@@]1(C)C[C@@H]2O HUMXXHTVHHLNRO-KAJVQRHHSA-N 0.000 description 1
- 102000008866 Prostaglandin E receptors Human genes 0.000 description 1
- 108010088540 Prostaglandin E receptors Proteins 0.000 description 1
- 102000000471 Prostaglandin F receptors Human genes 0.000 description 1
- 108050008995 Prostaglandin F receptors Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010037596 Pyelonephritis Diseases 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- AHHFEZNOXOZZQA-ZEBDFXRSSA-N Ranimustine Chemical compound CO[C@H]1O[C@H](CNC(=O)N(CCCl)N=O)[C@@H](O)[C@H](O)[C@H]1O AHHFEZNOXOZZQA-ZEBDFXRSSA-N 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- SKZKKFZAGNVIMN-UHFFFAOYSA-N Salicilamide Chemical compound NC(=O)C1=CC=CC=C1O SKZKKFZAGNVIMN-UHFFFAOYSA-N 0.000 description 1
- 229910052772 Samarium Inorganic materials 0.000 description 1
- 229920002536 Scavenger resin Polymers 0.000 description 1
- OCOKWVBYZHBHLU-UHFFFAOYSA-N Sobuzoxane Chemical compound C1C(=O)N(COC(=O)OCC(C)C)C(=O)CN1CCN1CC(=O)N(COC(=O)OCC(C)C)C(=O)C1 OCOKWVBYZHBHLU-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108091077436 Tam family Proteins 0.000 description 1
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 description 1
- WFWLQNSHRPWKFK-UHFFFAOYSA-N Tegafur Chemical compound O=C1NC(=O)C(F)=CN1C1OCCC1 WFWLQNSHRPWKFK-UHFFFAOYSA-N 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- IWEQQRMGNVVKQW-OQKDUQJOSA-N Toremifene citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 IWEQQRMGNVVKQW-OQKDUQJOSA-N 0.000 description 1
- VXFJYXUZANRPDJ-WTNASJBWSA-N Trandopril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-WTNASJBWSA-N 0.000 description 1
- RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 description 1
- 101150098329 Tyro3 gene Proteins 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- MUXFZBHBYYYLTH-UHFFFAOYSA-N Zaltoprofen Chemical compound O=C1CC2=CC(C(C(O)=O)C)=CC=C2SC2=CC=CC=C21 MUXFZBHBYYYLTH-UHFFFAOYSA-N 0.000 description 1
- LXRZVMYMQHNYJB-UNXOBOICSA-N [(1R,2S,4R)-4-[[5-[4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate Chemical compound CC1=C(C=C(S1)C(=O)C1=C(N[C@H]2C[C@H](O)[C@@H](COS(N)(=O)=O)C2)N=CN=C1)[C@@H]1NCCC2=C1C=C(Cl)C=C2 LXRZVMYMQHNYJB-UNXOBOICSA-N 0.000 description 1
- FPVRUILUEYSIMD-RPRRAYFGSA-N [(8s,9r,10s,11s,13s,14s,16r,17r)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(OC(C)=O)[C@@]1(C)C[C@@H]2O FPVRUILUEYSIMD-RPRRAYFGSA-N 0.000 description 1
- FBRAWBYQGRLCEK-UHFFFAOYSA-N [17-(2-chloroacetyl)-9-fluoro-10,13,16-trimethyl-3,11-dioxo-7,8,12,14,15,16-hexahydro-6h-cyclopenta[a]phenanthren-17-yl] butanoate Chemical compound C1CC2=CC(=O)C=CC2(C)C2(F)C1C1CC(C)C(C(=O)CCl)(OC(=O)CCC)C1(C)CC2=O FBRAWBYQGRLCEK-UHFFFAOYSA-N 0.000 description 1
- RYVJQEZJUFRANT-UHFFFAOYSA-N [3-[4-(3-ethoxy-2-hydroxypropoxy)anilino]-3-oxopropyl]-dimethylsulfanium;4-methylbenzenesulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1.CCOCC(O)COC1=CC=C(NC(=O)CC[S+](C)C)C=C1 RYVJQEZJUFRANT-UHFFFAOYSA-N 0.000 description 1
- RBNWMSXZPICYAL-ISLYRVAYSA-N [4-[(e)-4-(4-hydroxyphenyl)hex-3-en-3-yl]phenyl] dihydrogen phosphate Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(OP(O)(O)=O)C=C1 RBNWMSXZPICYAL-ISLYRVAYSA-N 0.000 description 1
- DSVGQVZAZSZEEX-UHFFFAOYSA-N [C].[Pt] Chemical compound [C].[Pt] DSVGQVZAZSZEEX-UHFFFAOYSA-N 0.000 description 1
- JLCHNBRGUPQWKF-UHFFFAOYSA-J [OH-].[C+4].[OH-].[OH-].[OH-] Chemical compound [OH-].[C+4].[OH-].[OH-].[OH-] JLCHNBRGUPQWKF-UHFFFAOYSA-J 0.000 description 1
- CJINHRUMOFBPQP-UHFFFAOYSA-N [Rh+].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 Chemical compound [Rh+].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 CJINHRUMOFBPQP-UHFFFAOYSA-N 0.000 description 1
- ZVQOOHYFBIDMTQ-UHFFFAOYSA-N [methyl(oxido){1-[6-(trifluoromethyl)pyridin-3-yl]ethyl}-lambda(6)-sulfanylidene]cyanamide Chemical compound N#CN=S(C)(=O)C(C)C1=CC=C(C(F)(F)F)N=C1 ZVQOOHYFBIDMTQ-UHFFFAOYSA-N 0.000 description 1
- MGVGMXLGOKTYKP-ZFOBEOMCSA-N acetic acid;(6s,8s,9s,10r,11s,13s,14s,17r)-11,17-dihydroxy-17-(2-hydroxyacetyl)-6,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-3-one Chemical compound CC(O)=O.C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 MGVGMXLGOKTYKP-ZFOBEOMCSA-N 0.000 description 1
- MNZMECMQTYGSOI-UHFFFAOYSA-N acetic acid;hydron;bromide Chemical compound Br.CC(O)=O MNZMECMQTYGSOI-UHFFFAOYSA-N 0.000 description 1
- XBJFCYDKBDVADW-UHFFFAOYSA-N acetonitrile;formic acid Chemical compound CC#N.OC=O XBJFCYDKBDVADW-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 description 1
- 229960004176 aclarubicin Drugs 0.000 description 1
- 229950003218 actarit Drugs 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- YKIOKAURTKXMSB-UHFFFAOYSA-N adams's catalyst Chemical compound O=[Pt]=O YKIOKAURTKXMSB-UHFFFAOYSA-N 0.000 description 1
- 229950007884 alacepril Drugs 0.000 description 1
- 239000005456 alcohol based solvent Substances 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 235000010210 aluminium Nutrition 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229960003099 amcinonide Drugs 0.000 description 1
- ILKJAFIWWBXGDU-MOGDOJJUSA-N amcinonide Chemical compound O([C@@]1([C@H](O2)C[C@@H]3[C@@]1(C[C@H](O)[C@]1(F)[C@@]4(C)C=CC(=O)C=C4CC[C@H]13)C)C(=O)COC(=O)C)C12CCCC1 ILKJAFIWWBXGDU-MOGDOJJUSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
- 229960003437 aminoglutethimide Drugs 0.000 description 1
- 229960004909 aminosalicylic acid Drugs 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 229960004238 anakinra Drugs 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000003092 anti-cytokine Effects 0.000 description 1
- 229940045985 antineoplastic platinum compound Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 229940046844 aromatase inhibitors Drugs 0.000 description 1
- GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 description 1
- ZDQSOHOQTUFQEM-PKUCKEGBSA-N ascomycin Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C\C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](O)[C@H](OC)C1 ZDQSOHOQTUFQEM-PKUCKEGBSA-N 0.000 description 1
- ZDQSOHOQTUFQEM-XCXYXIJFSA-N ascomycin Natural products CC[C@H]1C=C(C)C[C@@H](C)C[C@@H](OC)[C@H]2O[C@@](O)([C@@H](C)C[C@H]2OC)C(=O)C(=O)N3CCCC[C@@H]3C(=O)O[C@H]([C@H](C)[C@@H](O)CC1=O)C(=C[C@@H]4CC[C@@H](O)[C@H](C4)OC)C ZDQSOHOQTUFQEM-XCXYXIJFSA-N 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- 229960001799 aurothioglucose Drugs 0.000 description 1
- KLNFSAOEKUDMFA-UHFFFAOYSA-N azanide;2-hydroxyacetic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OCC(O)=O KLNFSAOEKUDMFA-UHFFFAOYSA-N 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 1
- 229910001863 barium hydroxide Inorganic materials 0.000 description 1
- 229940092705 beclomethasone Drugs 0.000 description 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- VPSRQEHTHIMDQM-FKLPMGAJSA-N benazepril hydrochloride Chemical compound Cl.C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 VPSRQEHTHIMDQM-FKLPMGAJSA-N 0.000 description 1
- 229960003619 benazepril hydrochloride Drugs 0.000 description 1
- 229960002707 bendamustine Drugs 0.000 description 1
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- MMIMIFULGMZVPO-UHFFFAOYSA-N benzyl 3-bromo-2,6-dinitro-5-phenylmethoxybenzoate Chemical compound [O-][N+](=O)C1=C(C(=O)OCC=2C=CC=CC=2)C([N+](=O)[O-])=C(Br)C=C1OCC1=CC=CC=C1 MMIMIFULGMZVPO-UHFFFAOYSA-N 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 229960002890 beraprost Drugs 0.000 description 1
- YTCZZXIRLARSET-VJRSQJMHSA-M beraprost sodium Chemical compound [Na+].O([C@H]1C[C@@H](O)[C@@H]([C@@H]21)/C=C/[C@@H](O)C(C)CC#CC)C1=C2C=CC=C1CCCC([O-])=O YTCZZXIRLARSET-VJRSQJMHSA-M 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 229960002938 bexarotene Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 125000005997 bromomethyl group Chemical group 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- KVUAALJSMIVURS-ZEDZUCNESA-L calcium folinate Chemical compound [Ca+2].C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 KVUAALJSMIVURS-ZEDZUCNESA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 229960000932 candesartan Drugs 0.000 description 1
- SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- UHKPOGGUWJGGID-UHFFFAOYSA-N carbonic acid;cesium Chemical compound [Cs].OC(O)=O UHKPOGGUWJGGID-UHFFFAOYSA-N 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 229960003261 carmofur Drugs 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- IVUMCTKHWDRRMH-UHFFFAOYSA-N carprofen Chemical compound C1=CC(Cl)=C[C]2C3=CC=C(C(C(O)=O)C)C=C3N=C21 IVUMCTKHWDRRMH-UHFFFAOYSA-N 0.000 description 1
- 229960003184 carprofen Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 238000012054 celltiter-glo Methods 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 125000002603 chloroethyl group Chemical group [H]C([*])([H])C([H])([H])Cl 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- ZYVSOIYQKUDENJ-WKSBCEQHSA-N chromomycin A3 Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@@H]1OC(C)=O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](O[C@@H]3O[C@@H](C)[C@H](OC(C)=O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@@H]1C[C@@H](O)[C@@H](OC)[C@@H](C)O1 ZYVSOIYQKUDENJ-WKSBCEQHSA-N 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 229960003728 ciclesonide Drugs 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- YZFWTZACSRHJQD-UHFFFAOYSA-N ciglitazone Chemical compound C=1C=C(CC2C(NC(=O)S2)=O)C=CC=1OCC1(C)CCCCC1 YZFWTZACSRHJQD-UHFFFAOYSA-N 0.000 description 1
- 229950009226 ciglitazone Drugs 0.000 description 1
- GPUVGQIASQNZET-CCEZHUSRSA-N cinnoxicam Chemical compound C=1C=CC=CC=1/C=C/C(=O)OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 GPUVGQIASQNZET-CCEZHUSRSA-N 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 description 1
- 229960004703 clobetasol propionate Drugs 0.000 description 1
- 229960005465 clobetasone butyrate Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 1
- BMCQMVFGOVHVNG-TUFAYURCSA-N cortisol 17-butyrate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)CO)(OC(=O)CCC)[C@@]1(C)C[C@@H]2O BMCQMVFGOVHVNG-TUFAYURCSA-N 0.000 description 1
- BGSOJVFOEQLVMH-VWUMJDOOSA-N cortisol phosphate Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COP(O)(O)=O)[C@@H]4[C@@H]3CCC2=C1 BGSOJVFOEQLVMH-VWUMJDOOSA-N 0.000 description 1
- 229960003290 cortisone acetate Drugs 0.000 description 1
- 229960005061 crizotinib Drugs 0.000 description 1
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- HWEQKSVYKBUIIK-UHFFFAOYSA-N cyclobuta-1,3-diene Chemical compound C1=CC=C1 HWEQKSVYKBUIIK-UHFFFAOYSA-N 0.000 description 1
- CFBGXYDUODCMNS-UHFFFAOYSA-N cyclobutene Chemical compound C1CC=C1 CFBGXYDUODCMNS-UHFFFAOYSA-N 0.000 description 1
- SNRCKKQHDUIRIY-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloromethane;dichloropalladium;iron(2+) Chemical compound [Fe+2].ClCCl.Cl[Pd]Cl.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 SNRCKKQHDUIRIY-UHFFFAOYSA-L 0.000 description 1
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 1
- NISGSNTVMOOSJQ-UHFFFAOYSA-N cyclopentanamine Chemical class NC1CCCC1 NISGSNTVMOOSJQ-UHFFFAOYSA-N 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 229960002448 dasatinib Drugs 0.000 description 1
- 229960003109 daunorubicin hydrochloride Drugs 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 229960002923 denileukin diftitox Drugs 0.000 description 1
- 108010017271 denileukin diftitox Proteins 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 229960003657 dexamethasone acetate Drugs 0.000 description 1
- PLCQGRYPOISRTQ-FCJDYXGNSA-L dexamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-FCJDYXGNSA-L 0.000 description 1
- 229960002344 dexamethasone sodium phosphate Drugs 0.000 description 1
- 229950006825 dexamethasone valerate Drugs 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- MIOUTPXNKVBIFR-UHFFFAOYSA-J dicalcium 2-hydroxyacetate Chemical compound C(CO)(=O)[O-].[Ca+2].[Ca+2].C(CO)(=O)[O-].C(CO)(=O)[O-].C(CO)(=O)[O-] MIOUTPXNKVBIFR-UHFFFAOYSA-J 0.000 description 1
- ZFTFAPZRGNKQPU-UHFFFAOYSA-N dicarbonic acid Chemical compound OC(=O)OC(O)=O ZFTFAPZRGNKQPU-UHFFFAOYSA-N 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- PWHROYKAGRUWDQ-UHFFFAOYSA-N difenpiramide Chemical compound C=1C=CC=NC=1NC(=O)CC(C=C1)=CC=C1C1=CC=CC=C1 PWHROYKAGRUWDQ-UHFFFAOYSA-N 0.000 description 1
- 229960001536 difenpiramide Drugs 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 229960004875 difluprednate Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- BADXJIPKFRBFOT-UHFFFAOYSA-N dimedone Chemical compound CC1(C)CC(=O)CC(=O)C1 BADXJIPKFRBFOT-UHFFFAOYSA-N 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 125000006222 dimethylaminomethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])* 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 229960002768 dipyridamole Drugs 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- MSJMDZAOKORVFC-UAIGNFCESA-L disodium maleate Chemical compound [Na+].[Na+].[O-]C(=O)\C=C/C([O-])=O MSJMDZAOKORVFC-UAIGNFCESA-L 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- GUVUOGQBMYCBQP-UHFFFAOYSA-N dmpu Chemical compound CN1CCCN(C)C1=O GUVUOGQBMYCBQP-UHFFFAOYSA-N 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 229960002918 doxorubicin hydrochloride Drugs 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 229940047652 ear drops Drugs 0.000 description 1
- 229940121647 egfr inhibitor Drugs 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 239000012156 elution solvent Substances 0.000 description 1
- OYFJQPXVCSSHAI-QFPUQLAESA-N enalapril maleate Chemical compound OC(=O)\C=C/C(O)=O.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 OYFJQPXVCSSHAI-QFPUQLAESA-N 0.000 description 1
- 229960000309 enalapril maleate Drugs 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229960003265 epirubicin hydrochloride Drugs 0.000 description 1
- 229950002973 epitiostanol Drugs 0.000 description 1
- QAMYWGZHLCQOOJ-PWIVHLLHSA-N eribulin mesylate Chemical compound CS(O)(=O)=O.C([C@H]1CC[C@@H]2O[C@@H]3[C@H]4O[C@H]5C[C@](O[C@H]4[C@H]2O1)(O[C@@H]53)CC[C@@H]1O[C@H](C(C1)=C)CC1)C(=O)C[C@@H]2[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]2C[C@@H]2C(=C)[C@H](C)C[C@H]1O2 QAMYWGZHLCQOOJ-PWIVHLLHSA-N 0.000 description 1
- 229960000439 eribulin mesylate Drugs 0.000 description 1
- GTTBEUCJPZQMDZ-UHFFFAOYSA-N erlotinib hydrochloride Chemical compound [H+].[Cl-].C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 GTTBEUCJPZQMDZ-UHFFFAOYSA-N 0.000 description 1
- 229960005073 erlotinib hydrochloride Drugs 0.000 description 1
- 229960001766 estramustine phosphate sodium Drugs 0.000 description 1
- IIUMCNJTGSMNRO-VVSKJQCTSA-L estramustine sodium phosphate Chemical compound [Na+].[Na+].ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)OP([O-])([O-])=O)[C@@H]4[C@@H]3CCC2=C1 IIUMCNJTGSMNRO-VVSKJQCTSA-L 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- NUIWRMGOBPOIOY-UHFFFAOYSA-N ethanesulfonic acid;methanesulfonic acid Chemical compound CS(O)(=O)=O.CCS(O)(=O)=O NUIWRMGOBPOIOY-UHFFFAOYSA-N 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- KTMGNAIGXYODKQ-VOTSOKGWSA-N ethyl (e)-2-cyano-3-ethoxyprop-2-enoate Chemical compound CCO\C=C(/C#N)C(=O)OCC KTMGNAIGXYODKQ-VOTSOKGWSA-N 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 125000005290 ethynyloxy group Chemical group C(#C)O* 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229960005167 everolimus Drugs 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 229960000255 exemestane Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229960004177 filgrastim Drugs 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- SYWHXTATXSMDSB-GSLJADNHSA-N fludrocortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O SYWHXTATXSMDSB-GSLJADNHSA-N 0.000 description 1
- 229960004511 fludroxycortide Drugs 0.000 description 1
- 229940042902 flumethasone pivalate Drugs 0.000 description 1
- JWRMHDSINXPDHB-OJAGFMMFSA-N flumethasone pivalate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)COC(=O)C(C)(C)C)(O)[C@@]2(C)C[C@@H]1O JWRMHDSINXPDHB-OJAGFMMFSA-N 0.000 description 1
- 229960000676 flunisolide Drugs 0.000 description 1
- ARPYQKTVRGFPIS-VIFPVBQESA-N flunoxaprofen Chemical compound N=1C2=CC([C@@H](C(O)=O)C)=CC=C2OC=1C1=CC=C(F)C=C1 ARPYQKTVRGFPIS-VIFPVBQESA-N 0.000 description 1
- 229960001321 flunoxaprofen Drugs 0.000 description 1
- 229960001347 fluocinolone acetonide Drugs 0.000 description 1
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 1
- 229960000785 fluocinonide Drugs 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229960003336 fluorocortisol acetate Drugs 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- 229960002714 fluticasone Drugs 0.000 description 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 1
- 229960003765 fluvastatin Drugs 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 229960002258 fulvestrant Drugs 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005144 gemcitabine hydrochloride Drugs 0.000 description 1
- 229950009822 gimeracil Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 229960003690 goserelin acetate Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 108010004351 growth arrest-specific protein 6 Proteins 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229940125697 hormonal agent Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 102000048370 human CYP2C8 Human genes 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229960001524 hydrocortisone butyrate Drugs 0.000 description 1
- 229960004204 hydrocortisone sodium phosphate Drugs 0.000 description 1
- 229960001401 hydrocortisone sodium succinate Drugs 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 229960004171 hydroxychloroquine Drugs 0.000 description 1
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 229960001176 idarubicin hydrochloride Drugs 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- KLZWOWYOHUKJIG-BPUTZDHNSA-N imidapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1C(N(C)C[C@H]1C(O)=O)=O)CC1=CC=CC=C1 KLZWOWYOHUKJIG-BPUTZDHNSA-N 0.000 description 1
- 229960003409 imidapril hydrochloride Drugs 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 201000006334 interstitial nephritis Diseases 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229960002198 irbesartan Drugs 0.000 description 1
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- 229960000779 irinotecan hydrochloride Drugs 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- FBAFATDZDUQKNH-UHFFFAOYSA-M iron chloride Chemical compound [Cl-].[Fe] FBAFATDZDUQKNH-UHFFFAOYSA-M 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 229960004891 lapatinib Drugs 0.000 description 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 1
- 229960004942 lenalidomide Drugs 0.000 description 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 1
- 229960002618 lenograstim Drugs 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229960002394 lisinopril Drugs 0.000 description 1
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- OXROWJKCGCOJDO-JLHYYAGUSA-N lornoxicam Chemical compound O=C1C=2SC(Cl)=CC=2S(=O)(=O)N(C)\C1=C(\O)NC1=CC=CC=N1 OXROWJKCGCOJDO-JLHYYAGUSA-N 0.000 description 1
- 229960002202 lornoxicam Drugs 0.000 description 1
- 229960004773 losartan Drugs 0.000 description 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 229960002373 loxoprofen Drugs 0.000 description 1
- BAZQYVYVKYOAGO-UHFFFAOYSA-M loxoprofen sodium hydrate Chemical compound O.O.[Na+].C1=CC(C(C([O-])=O)C)=CC=C1CC1C(=O)CCC1 BAZQYVYVKYOAGO-UHFFFAOYSA-M 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 229960002985 medroxyprogesterone acetate Drugs 0.000 description 1
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 1
- GXHFUVWIGNLZSC-UHFFFAOYSA-N meldrum's acid Chemical compound CC1(C)OC(=O)CC(=O)O1 GXHFUVWIGNLZSC-UHFFFAOYSA-N 0.000 description 1
- 229960001929 meloxicam Drugs 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 1
- 229960004963 mesalazine Drugs 0.000 description 1
- 239000003475 metalloproteinase inhibitor Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- BUXFOYXGVBMKTM-UHFFFAOYSA-N methyl 2-oxo-1,5,6,7-tetrahydrocyclopenta[b]pyridine-3-carboxylate Chemical compound N1C(=O)C(C(=O)OC)=CC2=C1CCC2 BUXFOYXGVBMKTM-UHFFFAOYSA-N 0.000 description 1
- MCUQERXCGTXSMW-UHFFFAOYSA-N methyl 2-oxo-1-phenyl-6,7-dihydro-5H-cyclopenta[b]pyridine-3-carboxylate Chemical compound O=C1C(=CC2=C(N1C1=CC=CC=C1)CCC2)C(=O)OC MCUQERXCGTXSMW-UHFFFAOYSA-N 0.000 description 1
- 229960001293 methylprednisolone acetate Drugs 0.000 description 1
- 229960000334 methylprednisolone sodium succinate Drugs 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 229960002744 mometasone furoate Drugs 0.000 description 1
- WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 description 1
- NPGREARFJMFTDF-UHFFFAOYSA-N n-(3,5-dichloro-1-hydroxypyridin-4-ylidene)-8-methoxy-2-(trifluoromethyl)quinoline-5-carboxamide Chemical compound C12=CC=C(C(F)(F)F)N=C2C(OC)=CC=C1C(=O)N=C1C(Cl)=CN(O)C=C1Cl NPGREARFJMFTDF-UHFFFAOYSA-N 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- BLCLNMBMMGCOAS-UHFFFAOYSA-N n-[1-[[1-[[1-[[1-[[1-[[1-[[1-[2-[(carbamoylamino)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amin Chemical compound C1CCC(C(=O)NNC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 BLCLNMBMMGCOAS-UHFFFAOYSA-N 0.000 description 1
- XUJHJSMXOAAPRS-UHFFFAOYSA-N n-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-1-(4-fluorophenyl)-2,5-dioxo-7,8-dihydro-6h-quinoline-3-carboxamide Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=N1)=CC=C1NC(=O)C(C1=O)=CC=2C(=O)CCCC=2N1C1=CC=C(F)C=C1 XUJHJSMXOAAPRS-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- XBXCNNQPRYLIDE-UHFFFAOYSA-M n-tert-butylcarbamate Chemical compound CC(C)(C)NC([O-])=O XBXCNNQPRYLIDE-UHFFFAOYSA-M 0.000 description 1
- 229950007221 nedaplatin Drugs 0.000 description 1
- IXOXBSCIXZEQEQ-UHTZMRCNSA-N nelarabine Chemical compound C1=NC=2C(OC)=NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O IXOXBSCIXZEQEQ-UHTZMRCNSA-N 0.000 description 1
- 229960000801 nelarabine Drugs 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960001346 nilotinib Drugs 0.000 description 1
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 description 1
- 229960001420 nimustine Drugs 0.000 description 1
- VFEDRRNHLBGPNN-UHFFFAOYSA-N nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229960003301 nivolumab Drugs 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 229950005751 ocrelizumab Drugs 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
- 229960001494 octreotide acetate Drugs 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005069 octynyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C#C* 0.000 description 1
- 229940060184 oil ingredients Drugs 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- VTRAEEWXHOVJFV-UHFFFAOYSA-N olmesartan Chemical compound CCCC1=NC(C(C)(C)O)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 VTRAEEWXHOVJFV-UHFFFAOYSA-N 0.000 description 1
- 229960005117 olmesartan Drugs 0.000 description 1
- QQBDLJCYGRGAKP-FOCLMDBBSA-N olsalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=C(C(O)=CC=2)C(O)=O)=C1 QQBDLJCYGRGAKP-FOCLMDBBSA-N 0.000 description 1
- 229960004110 olsalazine Drugs 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 1
- 229960002739 oxaprozin Drugs 0.000 description 1
- AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 description 1
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229950007318 ozogamicin Drugs 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- MUJIDPITZJWBSW-UHFFFAOYSA-N palladium(2+) Chemical compound [Pd+2] MUJIDPITZJWBSW-UHFFFAOYSA-N 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- DXHYQIJBUNRPJT-UHFFFAOYSA-N parsalmide Chemical compound CCCCNC(=O)C1=CC(N)=CC=C1OCC#C DXHYQIJBUNRPJT-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- HQQSBEDKMRHYME-UHFFFAOYSA-N pefloxacin mesylate Chemical compound [H+].CS([O-])(=O)=O.C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCN(C)CC1 HQQSBEDKMRHYME-UHFFFAOYSA-N 0.000 description 1
- 108010044644 pegfilgrastim Proteins 0.000 description 1
- 229960001373 pegfilgrastim Drugs 0.000 description 1
- 229960002621 pembrolizumab Drugs 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 229960002340 pentostatin Drugs 0.000 description 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- IYNMDWMQHSMDDE-MHXJNQAMSA-N perindopril erbumine Chemical compound CC(C)(C)N.C1CCC[C@@H]2N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H](C(O)=O)C[C@@H]21 IYNMDWMQHSMDDE-MHXJNQAMSA-N 0.000 description 1
- 229960003929 perindopril erbumine Drugs 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000005633 phthalidyl group Chemical group 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229960005095 pioglitazone Drugs 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 229960001369 piroxicam cinnamate Drugs 0.000 description 1
- 229960002797 pitavastatin Drugs 0.000 description 1
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 description 1
- 229910003446 platinum oxide Inorganic materials 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 108010001062 polysaccharide-K Proteins 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229960004293 porfimer sodium Drugs 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- ZUFQCVZBBNZMKD-UHFFFAOYSA-M potassium 2-ethylhexanoate Chemical compound [K+].CCCCC(CC)C([O-])=O ZUFQCVZBBNZMKD-UHFFFAOYSA-M 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229960003101 pranoprofen Drugs 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- JDOZJEUDSLGTLU-VWUMJDOOSA-N prednisolone phosphate Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COP(O)(O)=O)[C@@H]4[C@@H]3CCC2=C1 JDOZJEUDSLGTLU-VWUMJDOOSA-N 0.000 description 1
- 229960002943 prednisolone sodium phosphate Drugs 0.000 description 1
- 229960002176 prednisolone sodium succinate Drugs 0.000 description 1
- FKKAEMQFOIDZNY-CODXZCKSSA-M prednisolone sodium succinate Chemical compound [Na+].O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COC(=O)CCC([O-])=O)[C@@H]4[C@@H]3CCC2=C1 FKKAEMQFOIDZNY-CODXZCKSSA-M 0.000 description 1
- 229960004259 prednisolone tebutate Drugs 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 229960001586 procarbazine hydrochloride Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- NSETWVJZUWGCKE-UHFFFAOYSA-N propylphosphonic acid Chemical compound CCCP(O)(O)=O NSETWVJZUWGCKE-UHFFFAOYSA-N 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- KAQKFAOMNZTLHT-OZUDYXHBSA-N prostaglandin I2 Chemical compound O1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-OZUDYXHBSA-N 0.000 description 1
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 1
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 229960003042 quinapril hydrochloride Drugs 0.000 description 1
- IBBLRJGOOANPTQ-JKVLGAQCSA-N quinapril hydrochloride Chemical compound Cl.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 IBBLRJGOOANPTQ-JKVLGAQCSA-N 0.000 description 1
- 150000003246 quinazolines Chemical class 0.000 description 1
- 229910052705 radium Inorganic materials 0.000 description 1
- HCWPIIXVSYCSAN-UHFFFAOYSA-N radium atom Chemical compound [Ra] HCWPIIXVSYCSAN-UHFFFAOYSA-N 0.000 description 1
- 229960002185 ranimustine Drugs 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- MNDBXUUTURYVHR-UHFFFAOYSA-N roflumilast Chemical compound FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CC1 MNDBXUUTURYVHR-UHFFFAOYSA-N 0.000 description 1
- 229960002586 roflumilast Drugs 0.000 description 1
- HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 description 1
- 229950005741 rolipram Drugs 0.000 description 1
- 229960004586 rosiglitazone Drugs 0.000 description 1
- 229960000672 rosuvastatin Drugs 0.000 description 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 1
- YBCAZPLXEGKKFM-UHFFFAOYSA-K ruthenium(iii) chloride Chemical compound [Cl-].[Cl-].[Cl-].[Ru+3] YBCAZPLXEGKKFM-UHFFFAOYSA-K 0.000 description 1
- HNMATTJJEPZZMM-BPKVFSPJSA-N s-[(2r,3s,4s,6s)-6-[[(2r,3s,4s,5r,6r)-5-[(2s,4s,5s)-5-[acetyl(ethyl)amino]-4-methoxyoxan-2-yl]oxy-6-[[(2s,5z,9r,13e)-13-[2-[[4-[(2e)-2-[1-[4-(4-amino-4-oxobutoxy)phenyl]ethylidene]hydrazinyl]-2-methyl-4-oxobutan-2-yl]disulfanyl]ethylidene]-9-hydroxy-12-(m Chemical compound C1[C@H](OC)[C@@H](N(CC)C(C)=O)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@@](C/3=C/CSSC(C)(C)CC(=O)N\N=C(/C)C=3C=CC(OCCCC(N)=O)=CC=3)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HNMATTJJEPZZMM-BPKVFSPJSA-N 0.000 description 1
- KZUNJOHGWZRPMI-UHFFFAOYSA-N samarium atom Chemical compound [Sm] KZUNJOHGWZRPMI-UHFFFAOYSA-N 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 229950010372 sobuzoxane Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- KDWCFTLLFHIQHU-UHFFFAOYSA-M sodium;4-methoxy-4-oxobutanoate Chemical compound [Na+].COC(=O)CCC([O-])=O KDWCFTLLFHIQHU-UHFFFAOYSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 229940012831 stearyl alcohol Drugs 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 229960001796 sunitinib Drugs 0.000 description 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000003447 supported reagent Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- MUTNCGKQJGXKEM-UHFFFAOYSA-N tamibarotene Chemical compound C=1C=C2C(C)(C)CCC(C)(C)C2=CC=1NC(=O)C1=CC=C(C(O)=O)C=C1 MUTNCGKQJGXKEM-UHFFFAOYSA-N 0.000 description 1
- 229950010130 tamibarotene Drugs 0.000 description 1
- FQZYTYWMLGAPFJ-OQKDUQJOSA-N tamoxifen citrate Chemical compound [H+].[H+].[H+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 FQZYTYWMLGAPFJ-OQKDUQJOSA-N 0.000 description 1
- 229960003454 tamoxifen citrate Drugs 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229960005187 telmisartan Drugs 0.000 description 1
- 229960004084 temocapril Drugs 0.000 description 1
- FIQOFIRCTOWDOW-BJLQDIEVSA-N temocapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C[C@H](SC1)C=1SC=CC=1)=O)CC1=CC=CC=C1 FIQOFIRCTOWDOW-BJLQDIEVSA-N 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- CMARJZRIECEQDX-UHFFFAOYSA-N tert-butyl (2-methylpropan-2-yl)oxycarbonyl carbonate;carboxy hydrogen carbonate Chemical compound OC(=O)OC(O)=O.CC(C)(C)OC(=O)OC(=O)OC(C)(C)C CMARJZRIECEQDX-UHFFFAOYSA-N 0.000 description 1
- ZOACWEFWKDHNNY-UHFFFAOYSA-N tert-butyl N-[5-[(6,7-dimethoxyquinazolin-4-yl)amino]pyridin-2-yl]carbamate Chemical compound COC=1C=C2C(=NC=NC2=CC=1OC)NC=1C=CC(=NC=1)NC(OC(C)(C)C)=O ZOACWEFWKDHNNY-UHFFFAOYSA-N 0.000 description 1
- YRQMBQUMJFVZLF-UHFFFAOYSA-N tert-butyl n-(4-hydroxyphenyl)carbamate Chemical compound CC(C)(C)OC(=O)NC1=CC=C(O)C=C1 YRQMBQUMJFVZLF-UHFFFAOYSA-N 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- RWXZKKKYLRFREK-UHFFFAOYSA-N thiadiazepane Chemical compound C1CCSNNC1 RWXZKKKYLRFREK-UHFFFAOYSA-N 0.000 description 1
- BXVYJQULAWJPSR-UHFFFAOYSA-N thiadiazepine Chemical group S1C=CC=CN=N1 BXVYJQULAWJPSR-UHFFFAOYSA-N 0.000 description 1
- XSROQCDVUIHRSI-UHFFFAOYSA-N thietane Chemical compound C1CSC1 XSROQCDVUIHRSI-UHFFFAOYSA-N 0.000 description 1
- 229960001196 thiotepa Drugs 0.000 description 1
- MIMJSJSRRDZIPW-UHFFFAOYSA-N tilmacoxib Chemical compound C=1C=C(S(N)(=O)=O)C(F)=CC=1C=1OC(C)=NC=1C1CCCCC1 MIMJSJSRRDZIPW-UHFFFAOYSA-N 0.000 description 1
- 229910052718 tin Inorganic materials 0.000 description 1
- 239000011135 tin Substances 0.000 description 1
- HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 description 1
- 229960003989 tocilizumab Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- 229960004167 toremifene citrate Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229960002051 trandolapril Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- 229940126307 triamcinolone acetate Drugs 0.000 description 1
- 229960002117 triamcinolone acetonide Drugs 0.000 description 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
- DBGVGMSCBYYSLD-UHFFFAOYSA-N tributylstannane Chemical compound CCCC[SnH](CCCC)CCCC DBGVGMSCBYYSLD-UHFFFAOYSA-N 0.000 description 1
- GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 1
- 229960001641 troglitazone Drugs 0.000 description 1
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 229950009811 ubenimex Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 229960004699 valsartan Drugs 0.000 description 1
- ACWBQPMHZXGDFX-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=NN1 ACWBQPMHZXGDFX-QFIPXVFZSA-N 0.000 description 1
- 229960000241 vandetanib Drugs 0.000 description 1
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 description 1
- 229940124676 vascular endothelial growth factor receptor Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- KDQAABAKXDWYSZ-PNYVAJAMSA-N vinblastine sulfate Chemical compound OS(O)(=O)=O.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 KDQAABAKXDWYSZ-PNYVAJAMSA-N 0.000 description 1
- 229960004982 vinblastine sulfate Drugs 0.000 description 1
- AQTQHPDCURKLKT-JKDPCDLQSA-N vincristine sulfate Chemical compound OS(O)(=O)=O.C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 AQTQHPDCURKLKT-JKDPCDLQSA-N 0.000 description 1
- 229960002110 vincristine sulfate Drugs 0.000 description 1
- 229960005212 vindesine sulfate Drugs 0.000 description 1
- 229960002166 vinorelbine tartrate Drugs 0.000 description 1
- GBABOYUKABKIAF-IWWDSPBFSA-N vinorelbinetartrate Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC(C23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IWWDSPBFSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 229950004227 zaltoprofen Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
Abstract
Description
[1] 一般式(I)
ここで、R1で表されるC1~8アルキル基が分枝鎖アルキル基の場合、同一の炭素原子から分枝したC1~3アルキル基は結合する炭素原子と一緒になってC3~7の飽和炭素環を形成してもよく、
R2は(1)C1~4アルキル基、(2)ハロゲン原子、(3)C1~4ハロアルキル基、(4)オキソ基、(5)-OR21基、または(6)=NR22基を表し、
R3は(1)C1~4アルキル基、(2)ハロゲン原子、または(3)C1~4ハロアルキル基を表し、
R4は(1)C1~4アルコキシ基、(2)C1~4ハロアルキル基、(3)-OR41基、(4)C1~4アルキル基、(5)C2~4アルケニルオキシ基、または(6)C2~4アルキニルオキシ基を表し、
R5は(1)水素原子、(2)C1~4アルキル基、(3)ハロゲン原子、(4)C1~4ハロアルキル基、または(5)-OR21基を表し、
R11は(1)-OR101基、(2)SO2R102基、(3)NR103R104基、または(4)1~3個のハロゲン原子で置換されていてもよいC3~7の炭素環を表し、
R12は(1)水酸基で置換されていてもよいC1~8アルキル基、または(2)ハロゲン原子を表し、
R13は(1)水酸基で置換されていてもよいC1~8アルキル基、または(2)ハロゲン原子を表し、
R21は(1)水素原子、または(2)C1~4アルキル基を表し、
R22は(1)水酸基、または(2)C1~4アルコキシ基を表し、
R41は、
(1)水素原子、
(2)(a)(i)C1~4アルキル基、(ii)C1~4ハロアルキル基、および(iii)ハロゲン原子からなる群から選択される1~2個の置換基で置換されていてもよい5~7員の環状基、(b)NR401R402、(c)水酸基、および(d)SO2R403基からなる群から選択される1~2個の置換基で置換されたC1~8アルキル基、
(3)(a)(i)C1~4アルキル基、(ii)C1~4ハロアルキル基、および(iii)ハロゲン原子からなる群から選択される1~2個の置換基で置換されていてもよい5~7員の環状基、(b)NR401R402、(c)水酸基、および(d)SO2R403基からなる群から選択される1~2個の置換基で置換されたC2~8アルケニル基、
または
(4)(a)(i)C1~4アルキル基、(ii)C1~4ハロアルキル基、および(iii)ハロゲン原子からなる群から選択される1~2個の置換基で置換されていてもよい5~7員の環状基、(b)NR401R402、(c)水酸基、および(d)SO2R403基からなる群から選択される1~2個の置換基で置換されたC2~8アルキニル基を表し、
R101は(1)水素原子、または(2)C1~4アルキル基を表し、
R102は(1)水素原子、または(2)C1~4アルキル基を表し、
R103およびR104はそれぞれ独立して、(1)水素原子、または(2)C1~4アルキル基を表し、
R401およびR402はそれぞれ独立して、(1)水素原子、または(2)C1~4アルキル基を表し、
R403は(1)水素原子、または(2)C1~4アルキル基を表し、
Aは(1)CH、または(2)窒素原子を表し、
Lは(1)-O-、(2)-NH-、(3)-C(O)-、(4)-CR6R7-、(5)-S-、(6)-S(O)-、または(7)-S(O)2-を表し、
R6およびR7はそれぞれ独立して、(1)水素原子、(2)ハロゲン原子、(3)C1~4アルキル基、(4)水酸基、または(5)NH2を表し、
ring1は5~7員の環状基を表し、
mは0~5の整数を表し、
nは0~5の整数を表し、
pは0~2の整数を表し、
qは0~4の整数を表し、
mが2以上のとき、複数のR2は同じでも異なっていてもよく、ここで、2個のR2がC1~3アルキル基を表し、かつ同一の炭素原子上にあるとき、当該R2と結合する炭素原子が一緒になってC3~7の飽和炭素環を形成してもよく、
nが2以上のとき、複数のR3は同じでも異なっていてもよく、
qが2以上のとき、複数のR4は同じでも異なっていてもよい。]で示される化合物、その塩、その溶媒和物、そのN-オキシド体、またはそれらのプロドラッグ、
[2] mが1以上であり、かつR2の1つが必ずオキソ基である前記[1]記載の化合物、
[3] ring1がベンゼン、またはピリジンである前記[1]または[2]に記載の化合物、
[4] Lが(1)-O-、(2)-NH-、または(3)-C(O)-である前記[1]~[3]のいずれかに記載の化合物、
[5] 一般式(I-1)
m-1は0~4の整数を表し、
L1は(1)-O-、(2)-NH-、または(3)-C(O)-を表し、
ring1-1はベンゼン、またはピリジンを表し、
m-1が2以上のとき、複数のR2-1は同じでも異なっていてもよく、
ここで、2個のR2-1がC1~3アルキル基を表し、かつ同一の炭素原子上にあるとき、当該R2-1と結合する炭素原子が一緒になってC3~7の飽和炭素環を形成してもよく、
その他の記号は前記[1]記載と同じ意味を表す。]で示される前記[1]記載の化合物、
[6] (1)N-{5-[(6,7-ジメトキシ-4-キノリニル)オキシ]-2-ピリジニル}-2,5-ジオキソ-1-フェニル-1,2,5,6,7,8-ヘキサヒドロ-3-キノリンカルボキサミド、(2)N-{5-[(6,7-ジメトキシ-4-キノリニル)オキシ]-2-ピリジニル}-7,7-ジメチル-2,5-ジオキソ-1-フェニル-1,2,5,6,7,8-ヘキサヒドロ-3-キノリンカルボキサミド、(3)N-{5-[(6,7-ジメトキシ-4-キノリニル)オキシ]-2-ピリジニル}-1-(2,2-ジメチルプロピル)-2,5-ジオキソ-1,2,5,6,7,8-ヘキサヒドロ-3-キノリンカルボキサミド、(4)N-[5-({7-[3-(4-モルホリニル)プロポキシ]-4-キノリニル}オキシ)-2-ピリジニル]2,5-ジオキソ-1-フェニル-1,2,5,6,7,8-ヘキサヒドロ-3-キノリンカルボキサミド、(5)N-{4-[(6,7-ジメトキシ-4-キノリニル)オキシ]-3-フルオロフェニル}-2,5-ジオキソ-1-フェニル-1,2,5,6,7,8-ヘキサヒドロ-3-キノリンカルボキサミド、(6)N-{4-[(6,7-ジメトキシ-4-キノリニル)オキシ]フェニル}-2,5-ジオキソ-1-フェニル-1,2,5,6,7,8-ヘキサヒドロ-3-キノリンカルボキサミド、(7)N-{5-[(6,7-ジメトキシ-4-キノリニル)オキシ]-2-ピリジニル}-1-(4-フルオロフェニル)-2,5-ジオキソ-1,2,5,6,7,8-ヘキサヒドロ-3-キノリンカルボキサミド、(8)N-{5-[(6,7-ジメトキシ-4-キノリニル)オキシ]-2-ピリジニル}-1-(3-フルオロフェニル)-2,5-ジオキソ-1,2,5,6,7,8-ヘキサヒドロ-3-キノリンカルボキサミド、(9)N-{5-[(6,7-ジメトキシ-4-キノリニル)オキシ]-2-ピリジニル}-1-(2-フルオロフェニル)-2,5-ジオキソ-1,2,5,6,7,8-ヘキサヒドロ-3-キノリンカルボキサミド、(10)N-{5-[(6,7-ジメトキシ-4-キナゾリニル)オキシ]-2-ピリジニル}-2,5-ジオキソ-1-フェニル-1,2,5,6,7,8-ヘキサヒドロ-3-キノリンカルボキサミド、(11)N-{5-[(6,7-ジメトキシ-4-キナゾリニル)オキシ]-2-ピリジニル}-1-(4-フルオロフェニル)-2,5-ジオキソ-1,2,5,6,7,8-ヘキサヒドロ-3-キノリンカルボキサミド、(12)N-{5-[(6,7-ジメトキシ-4-キノリニル)オキシ]-2-ピリジニル}-1-[(2S)-1-ヒドロキシ-3-メチル-2-ブタニル]-2,5-ジオキソ-1,2,5,6,7,8-ヘキサヒドロ-3-キノリンカルボキサミド、(13)N-{4-[(6,7-ジメトキシ-4-キノリニル)オキシ]-3-フルオロフェニル}-1-(3-フルオロフェニル)-2,5-ジオキソ-1,2,5,6,7,8-ヘキサヒドロ-3-キノリンカルボキサミド、(14)N-{5-[(6,7-ジメトキシ-4-キノリニル)オキシ]-2-ピリジニル}-6,6-ジメチル-2,5-ジオキソ-1-フェニル-1,2,5,6,7,8-ヘキサヒドロ-3-キノリンカルボキサミド、(15)N-[5-({6-メトキシ-7-[3-(4-モルホリニル)プロポキシ]-4-キノリニル}オキシ)-2-ピリジニル]-2,5-ジオキソ-1-フェニル-1,2,5,6,7,8-ヘキサヒドロ-3-キノリンカルボキサミド、(16)N-(5-{[7-(3-ヒドロキシ-3-メチルブトキシ)-6-メトキシ-4-キノリニリル]オキシ}-2-ピリジニル)-2,5-ジオキソ-1-フェニル-1,2,5,6,7,8-ヘキサヒドロ-3-キノリンカルボキサミド、または(17)N-[5-({6-メトキシ-7-[3-(1-ピロリジニル)プロポキシ]-4-キノリニル}オキシ)-2-ピリジニル]-2,5-ジオキソ-1-フェニル-1,2,5,6,7,8-ヘキサヒドロ-3-キノリンカルボキサミドである前記[1]~[5]のいずれかに記載の化合物。
[7] 前記[1]記載の一般式(I)で示される化合物、その塩、その溶媒和物、そのN-オキシド体、またはそれらのプロドラッグを含有してなる医薬組成物、
[8] Axl阻害剤である前記[7]記載の医薬組成物、
[9] Axl関連疾患の予防および/または治療剤である前記[7]記載の医薬組成物、
[10] Axl関連疾患が、癌、腎臓疾患、免疫系疾患、または循環器系疾患である前記[9]記載の医薬組成物、
[11] 癌が、急性骨髄性白血病、慢性骨髄性白血病、急性リンパ性白血病、メラノーマ、乳癌、膵臓癌、神経膠腫、食道腺癌、大腸癌、腎細胞癌、甲状腺癌、非小細胞肺癌、前立腺癌、胃癌、肝癌、ブドウ膜悪性黒色腫、卵巣癌、子宮内膜癌、リンパ腫、頭頸部癌、または肉腫である前記[10]記載の医薬組成物、
[12] 癌細胞の転移抑制剤である前記[7]記載の医薬組成物、
[13] 前記[1]記載の一般式(I)で示される化合物、その塩、その溶媒和物、そのN-オキシド、またはそれらのプロドラッグの有効量を哺乳動物に投与することを特徴とする、Axl関連疾患の予防および/または治療方法、
[14] Axl関連疾患の予防および/または治療のための前記[1]記載の一般式(I)で示される化合物、その塩、その溶媒和物、そのN-オキシド、またはそれらのプロドラッグ、および
[15] Axl関連疾患の予防および/または治療剤を製造するための請求項1記載の一般式(I)で示される化合物、その塩、その溶媒和物、そのN-オキシド、またはそれらのプロドラッグの使用等に関する。
本発明において、ハロゲン原子とは、フッ素、塩素、臭素、ヨウ素を意味する。
本発明においては、特に指示しない限り異性体はこれをすべて包含する。例えば、アルキル基には直鎖のものおよび分枝鎖のものが含まれる。さらに、二重結合、環、縮合環における幾何異性体(E体、Z体、シス体、トランス体)、不斉炭素原子の存在等による光学異性体(R、S体、α、β配置、エナンチオマー、ジアステレオマー)、旋光性を有する光学活性体(D、L、d、l体)、クロマトグラフ分離による極性体(高極性体、低極性体)、平衡化合物、回転異性体、これらの任意の割合の混合物、ラセミ混合物は、すべて本発明に含まれる。また、本発明においては、互変異性体による異性体をもすべて包含する。
本発明化合物は、公知の方法、例えば、Comprehensive Organic Transformations : A Guide to Functional Group Preparations, 2nd Edition (Richard C. Larock, John Wiley & Sons Inc, 1999)に記載された方法、または実施例に示す方法等を適宜改良し、組み合わせて用いることで製造することができる。
(1)酸ハライドを用いる方法、
(2)混合酸無水物を用いる方法、
(3)縮合剤を用いる方法等が挙げられる。
(1)酸ハライドを用いる方法は、例えば、カルボン酸を有機溶媒(クロロホルム、ジクロロメタン、ジエチルエーテル、テトラヒドロフラン等)中または無溶媒で、酸ハライド化剤(オキザリルクロライド、チオニルクロライド等)と-20℃~還流温度で反応させ、得られた酸ハライドを塩基(ピリジン、トリエチルアミン、ジメチルアニリン、ジメチルアミノピリジン、ジイソプロピルエチルアミン等)の存在下、アミンと有機溶媒(クロロホルム、ジクロロメタン、ジエチルエーテル、テトラヒドロフラン等)中、0~40℃の温度で反応させることにより行なわれる。また、得られた酸ハライドを有機溶媒(ジオキサン、テトラヒドロフラン等)中、アルカリ水溶液(重曹水または水酸化ナトリウム溶液等)を用いて、アミンと0~40℃で反応させることにより行なうこともできる。
(1)アルカリ加水分解による脱保護反応は、例えば有機溶媒(例えば、メタノール、テトラヒドロフラン、ジオキサン等)中、アルカリ金属の水酸化物(例えば、水酸化ナトリウム、水酸化カリウム、水酸化リチウム等)、アルカリ土類金属の水酸化物(例えば、水酸化バリウム、水酸化カルシウム等)または炭酸塩(例えば、炭酸ナトリウム、炭酸カリウム等)あるいはその水溶液もしくはこれらの混合物を用いて、0~40℃で行なわれる。
本発明化合物の毒性は十分に低いものであり、医薬品として安全に使用することができる。
本発明化合物は、Axl阻害活性を有するので、哺乳動物、特にヒトにおいて、Axl関連疾患の予防および/または治療剤として使用することができる。
1)その化合物の予防および/または治療効果の補完および/または増強、
2)その化合物の動態・吸収改善、投与量の低減、および/または
3)その化合物の副作用の軽減のために他の薬物と組み合わせて、併用薬として投与してもよい。
クロマトグラフィーによる分離の箇所およびTLCに示されている括弧内の溶媒は、使用した溶出溶媒または展開溶媒を示し、割合は体積比を表す。また、NHシリカの記載は、富士シリシア製CHROMATOREX NH TLC PLATE(カタログ番号;3800003)を使用した旨を表し、DNHシリカの記載は、富士シリシア製CHROMATOREX NH TLC PLATE(カタログ番号;3800403)を使用した旨を表す。
LC-MS/ELSDは、下記条件:
{カラム:Waters ACQUITY C18(粒子径:1.7 x 10-6 m;カラム長:30 x 2.1 mm I.D.);流速:1.0mL/min;カラム温度:40℃;移動相(A):0.1%ギ酸水溶液;移動相(B):0.1%ギ酸-アセトニトリル溶液;グラジエント(移動相(A):移動相(B)の比率を記載):[0分]95:5;[0.1分]95:5;[1.2分]5:95;[1.4分]5:95;[1.41分]95:5;[1.5分]95:5;検出器:UV(PDA)、ELSD、MS}で行った。
NMRの箇所に示されているカッコ内は測定に使用した溶媒を示す。
本明細書中に用いた化合物名は、一般的にIUPACの規則に準じて命名を行なうコンピュータプログラム、Advanced Chemistry Development社のACD/Name(登録商標)を用いるか、または、IUPAC命名法に準じて命名したものである。
窒素気流下、100mLの4つ口フラスコに、4-クロロ-6,7-ジメトキシキノリン(1.00g)(CAS登録番号:35654-56-9)のクロロベンゼン(9mL)溶液、6-クロロピリジン-3-オール(0.65g)、トリエチルアミン(11.3mL)を加え、バス温(140℃)で5日間撹拌した。室温まで放冷した後、水、酢酸エチルを加えて分液した。水層を酢酸エチルで再度抽出し、合わせた有機層を飽和食塩水で洗浄後、無水硫酸ナトリウムで乾燥させた。溶媒を減圧留去し、得られた残渣をシリカゲルカラムクロマトグラフィー(ヘキサン:酢酸エチル=1:8)で精製し、下記物性値を有する標題化合物(1.16g)を得た。
TLC:Rf 0.22 (ヘキサン:酢酸エチル=1:3);
1H-NMR (DMSO-d6):δ 8.52, 8.48, 7.87 - 7.85, 7.66, 7.49, 7.43, 6.65, 3.95, 3.93。
窒素気流下、200mLの4つ口フラスコに、実施例1で製造した化合物(1.15g)のテトラヒドロフラン(THF)(18mL)溶液、1.0mol/Lのリチウムビス(トリメチルシリル)アミド(LHDMS)(5.45mL)、トリス(ジベンジリデンアセトン)ジパラジウム(0)クロロホルム錯体(0.19g)、2-ジシクロヘキシルホスフィノ-2’,6’-ジメトキシビフェニル(0.15g)を加え、バス温(80℃)で16.5時間撹拌した。さらに6mol/Lの塩酸(10mL)を加え、バス温(80℃)で2時間撹拌した。室温まで放冷後、飽和重炭酸水素ナトリウム水溶液、酢酸エチルを加えて分液した。水層を酢酸エチルで再度抽出し、合わせた有機層を飽和食塩水で洗浄後、無水硫酸ナトリウムで乾燥させた。溶媒を減圧留去し、得られた残渣をシリカゲルカラムクロマトグラフィー(酢酸エチル→酢酸エチル:メタノール=9:1)で精製し、下記物性値を有する標題化合物(0.80g)を得た。
TLC:Rf 0.51 (酢酸エチル:メタノール=4:1);
1H-NMR (DMSO-d6):δ 8.45, 7.89, 7.51, 7.38 - 7.36, 6.56, 6.42, 6.05, 3.94。
室温において1,3-シクロヘキサンジオン(CAS登録番号:504-02-9)(13.25g)をN,N-ジメチルホルムアミド(DMF)(200mL)に溶解し、tert-ブトキシカリウム(13.26g)、エチル (E)-2-シアノ-3-エトキシ-2-プロペノエート(CAS登録番号:94-05-3)(20.00g)を加え、21時間撹拌した。反応溶液を酢酸エチルで希釈し、2mol/Lの塩酸水溶液を加え撹拌した。さらに酢酸エチル、水を加え有機層を抽出した。飽和食塩水で洗浄後、無水硫酸ナトリウムで乾燥し、溶媒を減圧留去し、下記物性値を有する標題化合物(23.62g)を得た。
TLC:Rf 0.35 (ヘキサン:酢酸エチル=1:1);
1H-NMR (CDCl3):δ 1.37, 2.19, 2.61, 2.92, 4.36, 8.63。
室温において実施例3で製造した化合物(10.00g)をエタノール(200mL)に溶解し、アニリン(3.94g)を加え、6時間撹拌した。反応液中から析出した固体を桐山ロートでろ取、エタノールで洗浄し、得られた残渣を60℃で減圧乾燥した。下記物性値を有する標題化合物(4.01g)を得た。
TLC:Rf 0.37 (ジクロロメタン:メタノール=9:1);
1H-NMR (CDCl3):δ 2.11, 2.60, 7.25, 7.63, 9.21。
TLC:Rf 0.76 (酢酸エチル:メタノール=5:1);
1H-NMR (CDCl3):δ 2.13, 2.60, 4.05, 6.44, 7.25, 7.42, 7.53, 7.63, 8.22, 8.48, 8.51, 9.32, 11.93。
実施例2で製造した化合物、および実施例4で製造した化合物の代わりに相当するカルボン酸誘導体を用いて、実施例5と同様の目的の操作に付すことにより、以下の実施例化合物を得た。
1H-NMR (CDCl3):δ 1.06, 2.43, 2.48, 4.05, 6.45, 7.25, 7.43, 7.54, 7.55-7.65, 8.22, 8.48, 8.51, 9.32, 11.92。
TLC:Rf 0.69 (酢酸エチル:メタノール=5:1);
1H-NMR (CDCl3):δ 0.39, 0.54, 2.41, 2.48, 4.05, 6.45, 7.22, 7.43, 7.53, 7.55-7.62, 8.22, 8.49, 8.51, 9.36, 11.92。
(副生成物)N-{5-[(6,7-ジメトキシ-4-キノリニル)オキシ]-2-ピリジニル}-8’-ヒドロキシ-2’,5’-ジオキソ-1’-フェニル-2’,5’,6’,8’-テトラヒドロ-1’H-スピロ[シクロプロパン-1,7’-キノリン]-3’-カルボキサミド
TLC:Rf 0.68 (酢酸エチル:メタノール=5:1);
1H-NMR (CDCl3):δ 0.44, 0.61, 1.89, 3.39, 3.45, 4.10, 4.14, 6.76, 7.19, 7.47, 7.58-7.65, 7.86, 8.25, 8.63, 9.27, 12.05。
(LC-MS/ELSD):(保持時間:0.70分);
1H-NMR (CDCl3):δ 1.41-1.46, 2.25-2.29, 2.62-2.65, 3.07-3.11, 4.06, 4.26-4.30, 6.45-6.47, 7.43, 7.55, 7.55-7.60, 8.29-8.31,8.50-8.53, 9.21, 12.23。
(LC-MS/ELSD):(保持時間:0.80分);
1H-NMR (CDCl3):δ 2.14-2.20, 2.58-2.63, 2.96-3.01, 4.06, 5.50, 6.45-6.47, 6.89-7.10, 7.26-7.37, 7.43, 7.55, 7.57-7.61, 8.29-8.30, 8.50-8.54, 9.29, 12.10。
(LC-MS/ELSD):(保持時間:0.67分);
1H-NMR (CDCl3):δ 2.20-2.30, 2.60-2.64, 3.00-3.30, 3.45-3.55, 4.06, 4.15-4.20, 4.40-4.60, 6.45-6.47, 7.44, 7.55-7.61, 8.30-8.31, 8.49-8.52, 9.20, 12.17。
1H-NMR (CDCl3):δ 0.99, 2.09, 2.56, 3.19, 3.94, 4.25, 6.54, 7.40, 7.53, 7.86, 8.39, 8.48, 8.89, 12.19。
1H-NMR (CDCl3):δ 2.13, 2.60, 4.05, 6.44, 7.24 - 7.35, 7.43, 7.54, 7.57, 8.23, 8.50, 9.32, 11.88。
1H-NMR (CDCl3):δ 1.13, 1.80-1.90, 2.40-2.60, 3.92, 3.94, 6.53-6.55, 7.40, 7.50-7.53, 7.57-7.66, 7.84-7.88, 8.34-8.36, 8.40-8.43, 8.47-8.49, 8.99, 11.98。
TLC:Rf 0.50 (酢酸エチル:メタノール=19:1);
1H-NMR (DMSO-d6):δ 0.94, 2.05-2.25, 2.49-2.65, 3.15-3.24, 3.93, 4.13, 6.54, 7.04, 7.53, 7.86, 8.38-8.45, 8.48, 8.89, 12.24。
TLC:Rf 0.20 (酢酸エチル、NHシリカ);
1H-NMR (CDCl3):δ 0.70, 1.11, 2.13, 2.41, 2.87-2.99, 3.35, 4.02, 4.07, 4.19, 4.88, 6.17, 7.19, 7.53, 7.86, 8.17, 8.37, 8.58, 8.61, 12.18。
1H-NMR (CDCl3):δ 0.70, 1.11, 2.13, 2.41, 2.87-2.99, 3.35, 4.02, 4.07, 4.19, 4.88, 6.17, 7.19, 7.53, 7.86, 8.17, 8.37, 8.58, 8.61, 12.18。
1H-NMR (CDCl3):δ 2.13, 2.60, 4.05, 6.44, 7.07, 7.32, 7.43, 7.54, 7.59, 8.23, 8.49, 9.32, 11.85。
TLC:Rf 0.15 (酢酸エチル、NHシリカ);
1H-NMR (CDCl3):δ 1.81-1.95, 2.16-2.29, 2.40-2.75, 2.83-3.01, 3.45, 4.05, 4.06, 4.18, 4.48, 6.41, 7.39, 7.55, 7.61, 8.28, 8.46, 8.54, 9.08, 11.99。
TLC:Rf 0.51 (酢酸エチル);
1H-NMR (CDCl3):δ 2.00-2.20, 2.45-3.07, 4.05, 4.06, 6.45, 7.03-7.12, 7.18-7.23, 7.43, 7.55, 7.58, 8.28, 8.50, 8.51, 9.23, 12.07。
TLC:Rf 0.50 (酢酸エチル、NHシリカ);
1H-NMR (CDCl3):δ 2.00-2.20, 2.45-3.07, 4.05, 4.06, 6.45, 7.03-7.12, 7.18-7.23, 7.43, 7.55, 7.58, 8.28, 8.50, 8.51, 9.23, 12.07。
1H-NMR (CDCl3):δ 2.15, 2.63, 4.05, 6.44, 7.26 - 7.61, 8.22, 8.49, 9.33, 11.85。
TLC:Rf 0.71 (酢酸エチル:メタノール=5:1);
1H-NMR (CDCl3):δ 1.78-1.93, 2.64, 2.73, 2.93, 3.02, 4.05, 6.45, 7.24, 7.42, 7.53-7.67, 8.22, 8.49, 9.29, 11.92。
TLC:Rf 0.69 (酢酸エチル:メタノール=5:1);
1H-NMR (CDCl3):δ 2.01, 2.55, 2.95, 4.05, 4.06, 6.44, 7.19, 7.29-7.43, 7.55, 7.57, 8.28, 8.49-8.53, 9.25, 12.13。
(LC-MS/ELSD):(保持時間:0.69分);
MASS(ESI,Pos.):527(M+H)+。
(LC-MS/ELSD):(保持時間:0.71分);
MASS(ESI,Pos.):571(M+H)+。
TLC:Rf 0.67 (酢酸エチル:メタノール=5:1);
1H-NMR (CDCl3):δ 2.20-2.80, 3.14, 3.92, 3.93, 4.61, 6.29, 6.49, 7.33, 7.39, 7.50, 7.83, 8.34, 8.45, 8.92, 11.80。
(LC-MS/ELSD):(保持時間:0.80分);
MASS(ESI,Pos.):557(M+H)+。
(LC-MS/ELSD):(保持時間:0.66分);
MASS(ESI,Pos.):559(M+H)+。
(LC-MS/ELSD):(保持時間:0.71分);
MASS(ESI,Pos.):573(M+H)+。
(LC-MS/ELSD):(保持時間:0.74分);
MASS(ESI,Pos.):541(M+H)+。
(LC-MS/ELSD):(保持時間:0.80分);
MASS(ESI,Pos.):609(M+H)+。
(LC-MS/ELSD):(保持時間:0.63分);
MASS(ESI,Pos.):564(M+H)+。
(LC-MS/ELSD):(保持時間:0.51分);
MASS(ESI,Pos.):558(M+H)+。
TLC:Rf 0.65 (ジクロロメタン:メタノール=9:1);
1H-NMR (CDCl3):δ 1.19-1.35, 2.18, 2.62, 2.81, 3.16, 3.83, 4.06, 4.07, 4.99, 6.45, 7.27, 7.44, 7.56, 7.59, 8.31, 8.51, 8.54, 9.23, 12.24。
(LC-MS/ELSD):(保持時間:0.70分);
MASS(ESI,Pos.):573(M+H)+。
(LC-MS/ELSD):(保持時間:0.68分);
MASS(ESI,Pos.):543(M+H)+。
(LC-MS/ELSD):(保持時間:0.80分);
MASS(ESI,Pos.):605(M+H)+。
(LC-MS/ELSD):(保持時間:0.63分);
MASS(ESI,Pos.):567(M+H)+。
(LC-MS/ELSD):(保持時間:0.75分);
MASS(ESI,Pos.):541(M+H)+。
(LC-MS/ELSD):(保持時間:0.82分);
MASS(ESI,Pos.):557(M+H)+。
(LC-MS/ELSD):(保持時間:0.88分);
MASS(ESI,Pos.):571(M+H)+。
(LC-MS/ELSD):(保持時間:0.92分);
MASS(ESI,Pos.):597(M+H)+。
(LC-MS/ELSD):(保持時間:0.85分);
MASS(ESI,Pos.):605(M+H)+。
(LC-MS/ELSD):(保持時間:0.79分);
MASS(ESI,Pos.):555(M+H)+。
(LC-MS/ELSD):(保持時間:0.80分);
MASS(ESI,Pos.):555(M+H)+。
TLC:Rf 0.66 (酢酸エチル:メタノール=9:1);
1H-NMR (CDCl3):δ 2.10, 2.48, 2.60, 4.05, 6.44, 7.13, 7.42, 7.53, 7.56, 8.21, 8.49, 8.50, 9.31, 11.94。
TLC:Rf 0.60 (酢酸エチル:メタノール=9:1);
1H-NMR (CDCl3):δ 2.13, 2.60, 4.05, 6.45, 7.22, 7.42, 7.53, 7.57, 7.61, 8.23, 8.48, 8.50, 9.31, 11.85。
TLC:Rf 0.33 (酢酸エチル);
1H-NMR (CDCl3):δ 2.17, 2.62, 4.06, 6.44, 7.14, 7.31, 7.43, 7.54, 7.57, 8.24, 8.50, 9.33, 11.79。
TLC:Rf 0.29 (酢酸エチル);
1H-NMR (CDCl3):δ 2.14, 2.54, 2.64, 4.05, 6.44, 7.34, 7.43, 7.55, 7.57, 7.69, 8.23, 8.49, 8.51, 9.35, 11.85。
TLC:Rf 0.36 (酢酸エチル);
1H-NMR (CDCl3):δ 2.08-2.15, 2.36, 2.58-2.65, 4.05, 6.44, 7.15, 7.43-7.59, 8.23, 8.48-8.52, 9.35, 11.97。
TLC:Rf 0.15 (酢酸エチル、NHシリカ);
1H-NMR (CDCl3):δ 2.14, 2.48, 3.04, 3.30, 4.04, 4.05, 4.51, 5.11, 6.22, 7.19 - 7.42, 7.53, 7.73, 8.16, 8.40, 8.51, 8.86, 11.89。
TLC:Rf 0.51 (酢酸エチル:メタノール=10:1);
1H-NMR (CDCl3):δ 2.08-2.25, 2.30-2.70, 2.97-3.16, 3.16-3.40, 4.05, 4.06, 4.45-4.60, 4.88-5.19, 5.67-6.15, 6.26, 7.16-7.42, 7.53, 7.72, 8.18, 8.43, 8.52, 8.94, 11.90。
TLC:Rf 0.51 (酢酸エチル);
1H-NMR (CDCl3):δ 1.99-2.10, 2.40-2.70, 2.91, 4.06, 6.45, 7.21, 7.30-7.43, 7.55, 7.58, 8.29, 8.52, 9.26, 12.14。
TLC:Rf 0.51 (酢酸エチル:メタノール=10:1)
1H-NMR (CDCl3):δ 0.74, 1.07, 1.70, 2.10-2.40, 2.48-2.73, 2.95-3.15, 3.96, 4.06, 4.07, 6.45, 7.43, 7.52-7.64, 8.31, 8.47-8.56, 9.21, 12.27。
TLC:Rf 0.72 (酢酸エチル:メタノール=19:1);
1H-NMR (DMSO-d6):δ 1.98-2.07, 2.48-2.60, 3.93, 6.54, 7.40, 7.45-7.51, 7.67-7.69, 7.90, 8.36, 8.41, 8.48, 8.97, 11.89。
TLC:Rf 0.38 (酢酸エチル:メタノール=19:1);
1H-NMR (DMSO-d6):δ 1.89-2.04, 2.36-2.62, 3.92-3.94, 6.54, 7.10-7.56, 7.86, 8.35, 8.42, 8.47-8.49, 8.97, 11.97。
TLC:Rf 0.48 (酢酸エチル:メタノール=10:1);
1H-NMR (CDCl3):δ 0.74, 1.07, 1.70, 2.10-2.38, 2.49-2.75, 2.93-3.15, 3.88-4.02, 4.06, 4.07, 6.45, 7.43, 7.52-7.63, 8.31, 8.46-8.58, 9.21, 12.27。
TLC:Rf 0.15 (酢酸エチル,NHシリカ);
1H-NMR (CDCl3):δ 1.27, 2.14, 2.59, 2.73, 3.20, 4.05, 4.18, 6.44, 7.43, 7.53, 7.54, 7.70, 8.24, 8.49, 8.51, 9.28, 11.88。
TLC:Rf 0.32 (酢酸エチル);
1H-NMR (CDCl3):δ 1.80, 1.91, 2.71, 2.77, 4.05, 6.45, 7.25, 7.43, 7.53-7.66, 8.21, 8.48, 8.50, 9.11, 11.99。
TLC:Rf 0.73 (酢酸エチル:メタノール=19:1);
1H-NMR (CDCl3):δ 1.92-2.09, 2.40-2.70, 3.93, 6.54, 7.29, 7.41-7.60, 7.87, 8.21, 8.36, 8.41, 8.61, 8.97, 11.94。
4-クロロ-7-メトキシキノリンまたはその代わりに相当するキノリン誘導体、および実施例4で製造した化合物またはその代わりに相当するカルボン酸誘導体を用いて、実施例6と同様の目的の操作に付すことにより、以下の実施例化合物を得た。
TLC:Rf 0.30 (酢酸エチル、NHシリカ);
1H-NMR (DMSO-d6):δ 1.98, 2.45-2.57, 3.92, 6.52, 7.28, 7.40, 7.44, 7.46, 7.57-7.67, 7.85, 8.20, 8.35, 8.40, 8.60, 8.97, 11.95。
(LC-MS/ELSD):(保持時間:0.77分);
1H-NMR (CDCl3):δ 2.05-2.20, 2.51-2.68, 3.97, 6.52, 7.25-7.26, 7.27-7.29, 7.41, 7.54-7.67, 8.00, 8.22, 8.50, 8.55, 9.33, 11.93。
TLC:Rf 0.71 (酢酸エチル:メタノール=5:1);
1H-NMR (CDCl3):δ 0.72, 1.12, 2.18, 2.48, 2.92-3.02, 3.31, 3.95, 4.04, 4.17, 4.77, 5.23, 6.23, 7.21, 7.78, 8.21, 8.24, 8.51, 8.55, 8.77, 12.16。
TLC:Rf 0.71 (酢酸エチル:メタノール=5:1);
1H-NMR (CDCl3):δ 0.72, 1.12, 2.18, 2.48, 2.92-3.02, 3.31, 3.95, 4.04, 4.17, 4.77, 5.23, 6.23, 7.21, 7.78, 8.21, 8.24, 8.51, 8.55, 8.77, 12.16。
TLC:Rf 0.43 (酢酸エチル:メタノール=19:1);
1H-NMR (CDCl3):δ 1.93-2.08, 2.40-2.65, 3.93, 6.54, 7.27-7.55, 7.65-7.76, 7.87, 8.21, 8.34-8.47, 8.62, 8.98, 11.91。
(LC-MS/ELSD):(保持時間:1.06分);
1H-NMR (DMSO-d6):δ 2.00, 2.52-2.55, 6.88, 7.46-7.48, 7.58-7.66, 7.93-7.96, 8.40-8.44, 8.46, 8.57, 8.85, 8.99, 11.99。
TLC:Rf 0.69 (酢酸エチル:メタノール=19:1);
1H-NMR (DMSO-d6):δ 1.70-1.90, 1.95-2.10, 2.35-2.60, 2.73-2.89, 3.04-3.15, 3.94, 4.89-5.03, 6.55, 7.30, 7.42, 7.88, 8.22, 8.40, 8.42, 8.62, 8.83, 12.16。
TLC:Rf 0.65 (酢酸エチル:メタノール=19:1);
1H-NMR (DMSO-d6):δ 0.99, 2.00-2.16, 2.48-2.65, 3.15-3.22, 3.94, 4.12-4.38, 6.55, 7.30, 7.42, 7.88, 8.22, 8.39, 8.42, 8.62, 8.90, 12.20。
TLC:Rf 0.55 (酢酸エチル:メタノール=19:1);
1H-NMR (DMSO-d6):δ 1.13, 1.80-1.90, 2.34-2.56, 3.92, 6.54, 7.29, 7.41, 7.48-7.68, 7.87, 8.20, 8.35, 8.41, 8.61, 8.99, 11.98。
TLC:Rf 0.52 (酢酸エチル:メタノール=19:1);
1H-NMR (DMSO-d6):δ 1.91-2.04, 2.37-2.60, 3.93, 6.54, 7.29, 7.41, 7.52, 7.72, 7.88, 8.20, 8.34, 8.41, 8.61, 8.97, 11.91。
TLC:Rf 0.41 (酢酸エチル:メタノール=19:1);
1H-NMR (DMSO-d6):δ 1.91-2.03, 2.42, 2.40-2.60, 3.93, 6.54, 7.26-7.46, 7.87, 8.20, 8.36, 8.41, 8.61, 8.96, 11.97。
TLC:Rf 0.50 (酢酸エチル、NHシリカ);
1H-NMR (CDCl3):δ 1.81, 2.25, 2.31, 2.62, 3.08, 3.30, 3.98, 4.10, 6.43, 7.25, 7.42, 7.57, 8.24, 8.30, 8.51, 8.61, 9.19, 12.08。
TLC:Rf 0.55 (酢酸エチル、NHシリカ);
1H-NMR (CDCl3):δ 0.62, 1.15, 2.26, 2.64, 3.15, 3.98, 4.20, 6.43, 7.23, 7.42, 7.57, 8.23, 8.29, 8.51, 8.61, 9.22, 12.23。
TLC:Rf 0.55 (酢酸エチル、NHシリカ);
1H-NMR (CDCl3):δ 0.06, 0.30, 0.56, 0.77, 1.80, 2.24, 2.60, 2.89, 3.43, 3.98, 6.44, 7.22, 7.43, 7.56, 8.23, 8.30, 8.51, 8.61, 9.20, 12.29。
TLC:Rf 0.55 (酢酸エチル、NHシリカ);
1H-NMR (CDCl3):δ 0.06, 0.30, 0.56, 0.77, 1.80, 2.24, 2.60, 2.89, 3.43, 3.98, 6.44, 7.22, 7.43, 7.56, 8.23, 8.30, 8.51, 8.61, 9.20, 12.29。
TLC:Rf 0.69 (酢酸エチル:メタノール=5:1);
1H-NMR (CDCl3):δ 2.13, 2.60, 3.97, 6.52, 7.29-7.35, 7.41, 7.55-7.60, 8.00, 8.23, 8.49, 8.54, 9.32, 11.88。
TLC:Rf 0.34 (酢酸エチル:メタノール=19:1);
1H-NMR (DMSO-d6):δ 0.94, 2.08-2.20, 2.40-2.60, 3.12-3.26, 3.94, 4.12, 6.55, 7.30, 7.42, 7.88, 8.22, 8.39, 8.41, 8.62, 8.90, 12.24。
TLC:Rf 0.56 (酢酸エチル:メタノール=19:1);
1H-NMR (DMSO-d6):δ 1.65-1.91, 2.63-2.74, 3.93, 7.29, 7.45, 7.46-7.53, 7.58-7.71, 7.87, 8.20, 8.36, 8.41, 8.61, 8.94, 11.94。
TLC:Rf 0.51 (酢酸エチル);
1H-NMR (CDCl3):δ 2.16, 2.62, 3.97, 6.42, 7.10-7.33, 7.42, 7.56, 8.21-8.24, 8.49, 8.60, 9.33, 11.79。
TLC:Rf 0.40 (酢酸エチル);
1H-NMR (CDCl3):δ 2.14, 2.55, 2.63, 3.97, 6.41, 7.23, 7.35, 7.42, 7.53-7.58, 7.68, 8.21, 8.23, 8.49, 8.60, 9.34, 11.84。
TLC:Rf 0.44 (酢酸エチル);
1H-NMR (CDCl3):δ 2.15-2.20, 2.35, 2.58-2.67, 3.97, 6.41, 7.15, 7.24, 7.41-7.49, 7.56, 8.21, 8.23, 8.49, 8.60, 9.34, 11.96。
TLC:Rf 0.15 (酢酸エチル、NHシリカ);
1H-NMR (CDCl3):δ 1.87, 2.18, 2.40, 2.62, 2.94, 3.44, 3.98, 4.10, 4.18, 4.50, 6.46, 7.38, 7.58, 7.62, 7.92, 8.28, 8.49, 8.57, 9.02, 12.02。
TLC:Rf 0.15 (酢酸エチル、NHシリカ);
1H-NMR (CDCl3):δ 1.95, 2.21, 2.38-2.69, 2.95, 3.42, 3.68, 3.97, 4.15, 4.46, 6.40, 7.23, 7.39, 7.61, 8.24, 8.28, 8.53, 8.58, 9.10,11.99。
TLC:Rf 0.25 (酢酸エチル、NHシリカ);
1H-NMR (CDCl3):δ 2.12, 2.26, 2.60, 3.97, 6.51, 7.15, 7.40-7.49, 7.58, 8.00, 8.23, 8.49, 8.55, 9.34, 11.98。
TLC:Rf 0.25 (酢酸エチル、NHシリカ);
1H-NMR (CDCl3):δ 2.15, 2.57, 2.63, 3.97, 6.51, 7.35-7.61, 7.68, 8.00, 8.23, 8.50, 8.55, 9.34, 11.86。
TLC:Rf 0.25 (酢酸エチル、NHシリカ);
1H-NMR (CDCl3):δ 2.18, 2.62, 3.97, 6.51, 7.18, 7.21-7.40, 7.41, 7.57, 8.01, 8.24, 8.50, 8.55, 9.32, 11.79。
TLC:Rf 0.60 (酢酸エチル:メタノール=10:1);
1H-NMR (CDCl3):δ 0.03-0.13, 0.20-0.40, 0.49-0.67, 0.69-0.89, 1.81, 2.09-2.42, 2.47-2.72, 2.89, 3.31-3.52, 3.98, 6.53, 7.42, 7.55-7.64, 8.00, 8.31, 8.53, 8.56, 9.21, 12.30。
TLC:Rf 0.54 (酢酸エチル:メタノール=10:1);
1H-NMR (CDCl3):δ 2.07-2.29, 2.36-2.68, 2.97-3.16, 3.17-3.43, 3.96, 4.45-4.62, 4.95-5.23, 5.68-6.05, 6.22, 7.12-7.43, 7.72, 8.17, 8.23, 8.47-8.56, 8.86, 11.90。
TLC:Rf 0.58 (酢酸エチル);
1H-NMR (CDCl3):δ 2.00, 2.05, 2.40-2.80, 2.96, 3.98, 6.43, 7.08, 7.18-7.29, 7.42, 7.58, 8.24, 8.28, 8.51, 8.61, 9.25, 12.07。
TLC:Rf 0.58 (酢酸エチル);
1H-NMR (CDCl3):δ 1.99-2.10, 2.40-2.70, 2.90, 3.98, 6.43, 7.22, 7.27-7.43, 7.59, 8.24, 8.28, 8.52, 8.61, 9.26, 12.13。
TLC:Rf 0.60 (酢酸エチル:メタノール=10:1);
1H-NMR (CDCl3):δ 2.06-2.25, 2.63, 3.97, 6.52, 7.42, 7.51-7.67, 7.99, 8.23, 8.50, 8.55, 9.33, 11.85。
TLC:Rf 0.66 (酢酸エチル:メタノール=10:1);
1H-NMR (CDCl3):δ 2.04-2.26, 2.53-2.70, 3.97, 6.52, 6.99-7.14, 7.27-7.36, 7.37-7.44, 7.52-7.68, 7.99, 8.23, 8.49, 8.55, 9.32, 11.85。
TLC:Rf 0.57 (酢酸エチル:メタノール=10:1);
1H-NMR (CDCl3):δ 0.74, 1.07, 1.70, 2.10-2.34, 2.45-2.76, 2.94-3.14, 3.86-3.96, 3.98, 6.42, 7.21-7.25, 7.43, 7.58, 8.24, 8.30, 8.52, 8.61, 9.21, 12.27。
TLC:Rf 0.35 (酢酸エチル:メタノール=19:1);
1H-NMR (DMSO-d6):δ 1.96-2.18, 2.30-2.60, 3.93, 6.54, 7.29, 7.41, 7.44-7.72, 7.88, 8.21, 8.36, 8.41, 8.61, 9.00, 11.81。
TLC:Rf 0.50 (酢酸エチル:メタノール=19:1);
1H-NMR (DMSO-d6):δ 1.94-2.05, 2.40, 2.45-2.60, 3.93, 6.54, 7.22-7.55, 7.87, 8.21, 8.36, 8.42, 8.62, 8.97, 11.97。
TLC:Rf 0.74 (酢酸エチル:メタノール=19:1);
1H-NMR (DMSO-d6):δ 1.98-2.07, 2.45-2.60, 3.93, 6.54, 7.29, 7.41, 7.46-7.51, 7.66-7.69, 7.87, 8.20, 8.36, 8.41, 8.61, 8.97, 11.89。
TLC:Rf 0.55 (酢酸エチル:メタノール=10:1);
1H-NMR (CDCl3):δ 0.74, 1.07, 1.70, 2.12-2.38, 2.47-2.74, 2.95-3.20, 3.90-3.95, 3.98, 6.43, 7.20-7.25, 7.43, 7.58, 8.24, 8.30, 8.52, 8.61, 9.21, 12.26。
TLC:Rf 0.15 (酢酸エチル、NHシリカ);
1H-NMR (CDCl3):δ 1.28, 2.14, 2.62, 2.75, 3.10, 3.97, 4.18, 6.41, 7.22, 7.42, 7.52-7.60, 7.70, 8.21, 8.23, 8.48, 8.60, 9.27, 11.87。
室温において4-クロロ-6,7-ジメトキシキナゾリン(CAS登録番号:13790-39-1)(450mg)、tert-ブチル (5-アミノピリジン-2-イル)カルバマート(420mg)をN,N-ジメチルアセトアミド(DMA)(20mL)に溶解した。これに、50℃において、4mol/Lの塩酸-ジオキサン(0.5mL)を加え撹拌した。その後80℃に加熱し、3時間撹拌した。室温まで放冷し、反応溶液にメチルtert-ブチルエーテル(MTBE)を加え、析出した固体を桐山ロートでろ取、MTBEで洗浄し、得られた残渣を60℃で減圧乾燥した。下記物性値を有する標題化合物(821mg)を得た。
TLC:Rf 0.45 (酢酸エチル:メタノール=5:1);
1H-NMR (DMSO-d6):δ 1.49, 4.00, 7.34, 7.88, 8.05, 8.32, 8.56, 8.84, 10.02, 11.54。
室温において実施例7で製造した化合物(800mg)をジクロロメタン(10mL)に溶解し、トリフルオロ酢酸(0.3mL)を加え、室温で6時間撹拌した。反応溶液を酢酸エチルで希釈し、飽和重曹水を加え撹拌した。さらに酢酸エチル、水を加え有機層を抽出した。水層にTHF、水を加え有機層を抽出した。有機層を集め、飽和食塩水で洗浄後、無水硫酸ナトリウムで乾燥し、溶媒を減圧留去した。得られた残渣に酢酸エチル、ヘキサンを加え、室温で撹拌し固体をスラリー洗浄した。桐山ロートでろ取し、得られた残渣を60℃で減圧乾燥し、下記物性値を有する標題化合物(598mg)を得た。
TLC:Rf 0.16 (酢酸エチル:メタノール=5:1);
1H-NMR (DMSO-d6):δ 3.91, 5.83, 6.49, 7.12, 7.65, 7.82, 8.09, 8.30, 9.36。
TLC:Rf 0.59 (酢酸エチル:メタノール=5:1);
1H-NMR (CDCl3):δ 2.10, 2.58, 4.04, 7.04, 7.13, 7.25, 7.59, 8.20, 8.41, 8.50, 8.64, 9.30, 11.82。
4-クロロ-6,7-ジメトキシキナゾリン、またはその代わりに相当するキノリン誘導体、tert-ブチル (5-アミノピリジン-2-イル)カルバマート、またはその代わりに相当するアミン誘導体、および実施例4で製造した化合物を用いて、実施例7→実施例8→実施例9と同様の目的の操作に付すことにより、以下の実施例化合物を得た。
TLC:Rf 0.21 (ジクロロメタン:メタノール=10:1);
1H-NMR (DMSO-d6):δ 1.86-2.14, 2.49-2.62, 3.98, 4.02, 6.75, 7.35-7.40, 7.41-7.52, 7.53-7.73, 7.94-8.07, 8.36-8.56, 8.99, 10.42, 12.03, 14.00。
(LC-MS/ELSD):(保持時間:0.75分);
1H-NMR (CD3OD):δ 2.04-2.13, 2.56-2.64, 4.01, 4.02, 6.82, 7.24, 7.35-7.42, 7.59-7.67, 7.69, 7.75-7.79, 8.19, 9.17。
TLC:Rf 0.63 (酢酸エチル:メタノール:アンモニア水=9:1:0.5);
1H-NMR (DMSO-d6):δ 1.90-2.05, 2.40-2.60, 3.89, 6.70, 7.18, 7.25, 7.42-7.50, 7.54-7.68, 7.86, 8.22-8.40, 8.97, 8.99, 11.85。
(LC-MS/ELSD):(保持時間:0.79分);
1H-NMR (CD3OD):δ 1.94-2.07, 2.50-2.58, 3.94, 3.96, 7.18, 7.43-7.51, 7.57-7.68, 7.75, 7.87, 8.50, 8.95, 9.69, 11.48。
200mLのナスフラスコに3-ベンジルオキシアニリン(25g)、メルドラム酸(22g)、オルトギ酸エチル(22g)、エタノール(25mL)を加えた。80分間加熱還流した後、室温まで放冷し、析出した粉末をろ取した。粉末をエタノール(50mL)で洗浄した後、乾燥することで下記物性値を有する標題化合物(43g)を得た。
TLC:Rf 0.48 (ヘキサン:酢酸エチル=2:1);
1H-NMR (DMSO-d6):δ 1.66, 5.15, 6.88, 7.11, 7.30 - 7.45, 8.60, 11.2。
1Lのナスフラスコに実施例10で製造した化合物(42g)と1,2-ジクロロベンゼン(420mL)を加えた。5.5時間加熱還流した後、室温まで放冷し、析出した粉末をろ取した。粉末をメタノール(84mL)で洗浄した後、乾燥することで下記物性値を有する標題化合物(18g)を得た。
TLC:Rf 0.60 (酢酸エチル:メタノール=9:1);
1H-NMR (DMSO-d6):δ 5.19, 5.92, 6.98, 7.32 - 7.43, 7.77, 7.97。
アルゴン雰囲気下、300mLのナスフラスコに実施例11で製造した化合物(17g)、トルエン(34mL)、オキシ塩化リン(10g)を加えた。2.5時間加熱還流した後、70℃まで放冷し、酢酸エチル(135mL)で希釈した。その後室温まで放冷し、2mol/L水酸化ナトリウム水溶液で中和した。酢酸エチルで抽出した後、飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥させ、溶媒を減圧留去することで下記物性値を有する標題化合物(18g)を得た。
TLC:Rf 0.60 (ヘキサン:酢酸エチル=2:1);
1H-NMR (CDCl3):δ 5.22, 7.34 - 7.51, 8.13, 8.86。
300mLのナスフラスコに実施例12で製造した化合物(15g)、6-クロロピリジン3-オール(8.3g)、4-ジメチルアミノピリジン(7.5g)、トルエン(75mL)を加えた。6.5時間110℃で加熱した後、室温まで放冷し、水、酢酸エチルを加えて分液を行った。抽出液を飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥させ、溶媒を減圧留去させた。得られた残渣を少量の酢酸エチルに溶解させた後、メタノールを加えることで結晶化させ、沈殿物をろ過することで下記物性値を有する標題化合物(15g)を得た。
TLC:Rf 0.37 (ヘキサン:酢酸エチル=1:1);
1H-NMR (CDCl3):δ 5.24, 6.46, 7.31 - 7.52, 8.19, 8.34, 8.65。
アルゴン雰囲気下、200mLの4径ナスフラスコに実施例13で製造した化合物(5g)のTHF(25mL)溶液、1.0mol/LのLHMDS(3.5mL)、トリス(ジベンジリデンアセトン)ジパラジウム(0)クロロホルム錯体(0.63g)、2-ジシクロヘキシルホスフィノ-2’,6’-ジメトキシビフェニル(0.73g)を加え、70℃で撹拌した。原料消失を確認した後、室温まで放冷し、水、酢酸エチルを加えて分液を行った。酢酸エチルで抽出した後、飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥、溶媒を減圧留去させた。得られた残渣をアセトニトリル(100mL)に懸濁し、2.0mol/L塩酸(10mL)を加えて室温で2.5時間撹拌した。1.0mol/L水酸化ナトリウム水溶液、飽和重炭酸水素ナトリウム水溶液、酢酸エチルを加えて分液を行った。抽出液を飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥させ、溶媒を減圧留去させた。残渣をシリカゲルカラムクロマトグラフィー(ヘキサン:酢酸エチル=1:1→0:1)で精製し、下記物性値を有する標題化合物(2.9g)を得た。
TLC:Rf 0.33 (ジクロロメタン:酢酸エチル:メタノール=8:4:1);
1H-NMR (DMSO-d6):δ 5.29, 6.06, 6.41, 6.55, 7.31 - 7.52, 7.88, 8.20, 8.56。
TLC:Rf 0.74 (酢酸エチル:メタノール=9:1);
1H-NMR (CDCl3):δ 2.11, 2.59, 5.23, 6.42, 7.25 - 7.63, 8.20, 8.24, 8.49, 8.59, 9.32, 11.92。
TLC:Rf 0.63 (酢酸エチル:メタノール=9:1);
1H-NMR (DMSO-d6):δ 2.00, 2.50, 6.44, 7.19, 7.25, 7.46, 7.60, 7.85, 8.15, 8.34, 8.41, 8.53, 8.97, 10.28, 11.95。
TLC:Rf 0.75 (酢酸エチル:メタノール=5:1、NHシリカ);
1H-NMR (CDCl3):δ 2.11, 2.34, 2.59, 4.19, 6.40, 7.25, 7.40, 7.54, 7.62, 8.20, 8.23, 8.49, 8.59, 9.33, 11.92。
実施例16で製造した化合物、および3-(ジメチルアミノ)-1-プロパノールの代わりに相当するアルコール誘導体を用いて、実施例16→実施例17と同様の目的の操作に付すことにより、以下の実施例化合物を得た。
TLC:Rf 0.78(酢酸エチル:メタノール=5:1、NHシリカ);
1H-NMR (CDCl3):δ 1.35, 2.09, 2.60, 4.36, 6.41, 7.21, 7.44, 7.55, 7.58-7.65, 8.21, 8.22, 8.49, 8.60, 9.32, 11.92。
TLC:Rf 0.33(酢酸エチル、DNHシリカ);
1H-NMR (CDCl3):δ 2.00-2.20, 2.45-2.52, 2.53-2.65, 3.72-3.75, 4.18-4.22, 6.40-6.42, 7.20-7.30, 7.40-7.41, 7.53-7.70, 8.19-8.22, 8.47-8.50, 8.58-8.60, 9.32, 11.92。
TLC:Rf 0.80 (酢酸エチル:メタノール=5:1、NHシリカ);
1H-NMR (CDCl3):δ 2.10, 2.56-2.64, 2.90, 3.76, 4.29, 6.42, 7.22-7.28, 7.40, 7.53-7.65, 8.20, 8.22, 8.49, 8.60, 9.33, 11.92。
TLC:Rf 0.18 (酢酸エチル、DNHシリカ);
1H-NMR (CDCl3):δ 0.73, 1.13, 1.98-2.11, 2.12-2.26, 2.38-2.63, 2.82-3.08, 3.18-3.41, 3.70-3.79, 3.99-4.08, 4.09-4.27, 4.56-4.79, 6.26, 7.21, 7.26-7.29, 7.74, 8.18-8.27, 8.48-8.59, 8.86, 12.15。
TLC:Rf 0.41 (酢酸エチル、DNHシリカ);
1H-NMR (CDCl3):δ 1.06, 2.01-2.13, 2.14-2.30, 2.44-2.52, 2.53-2.69, 3.01-3.16, 3.67-3.79, 4.21, 6.42, 7.23, 7.42, 7.57, 8.23, 8.29, 8.53, 8.60, 9.22, 12.18。
TLC:Rf 0.50 (酢酸エチル:メタノール=10:1、NHシリカ);
1H-NMR (CDCl3):δ 2.01-2.21, 2.46-2.52, 2.54-2.66, 2.76, 3.69-3.77, 4.03, 4.20, 6.42, 7.22, 7.41, 7.52, 7.53-7.60, 8.17-8.26, 8.48, 8.59, 9.28, 11.90。
TLC:Rf 0.50 (酢酸エチル:メタノール=10:1、NHシリカ);
1H-NMR (CDCl3):δ 1.28, 2.01-2.22, 2.45-2.53, 2.54-2.66, 2.69-2.80, 3.20, 3.68-3.78, 4.16-4.25, 6.41, 7.19-7.25, 7.41, 7.52-7.60, 7.69, 8.16-8.26, 8.49, 8.59, 9.28, 11.87。
TLC:Rf 0.62 (酢酸エチル:メタノール=10:1、NHシリカ);
1H-NMR (CDCl3):δ 1.93-2.17,2.41-2.64, 2.81-3.13, 3.74, 4.21, 6.42, 7.02-7.13, 7.18-7.26, 7.42, 7.57, 8.23, 8.28, 8.51, 8.60, 9.25, 11.99-12.11。
室温において50mLナスフラスコに、4-クロロ-6,7-ジメトキシキナゾリン(224mg)、4-ブロモベンズアルデヒド(221mg)、および1,3-ジメチルイミダゾリウムヨーダイド(74mg)を加え、1,4-ジオキサン(3mL)に懸濁した。室温において60%水素化ナトリウム(52mg)を加え撹拌した。その後100℃に加熱し、1時間撹拌した。室温まで放冷し、反応溶液を酢酸エチル(10mL)で希釈し、水(10mL)を加え、析出した結晶をろ取し、下記物性値を有する標題化合物(196mg)を得た。
TLC:Rf 0.31 (ヘキサン:酢酸エチル=1:1);
1H-NMR (CDCl3):δ 3.99, 4.10, 7.42, 7.43, 7.64-7.68, 7.84-7.88 , 9.23。
アルゴン雰囲気下、50mLのナスフラスコに、実施例18で製造した化合物(149mg)、tert-ブチルカルバマート(51mg)、トリス(ジベンジリデンアセトン)ジパラジウム-クロロホルム付加物(21mg)、4、5-ビス(ジフェニルホスフィノ)-9,9-ジメチルキサンテン(35mg)、および炭酸セシウム(182mg)を加え、1,4-ジオキサン(4mL)に懸濁した。その後100℃に加熱し、12時間撹拌した。室温まで放冷し、これに水を加え、酢酸エチルで抽出した。抽出液を水、飽和食塩水で洗浄後、無水硫酸ナトリウムで乾燥した。その後、溶媒を減圧留去した。シリカゲルカラムクロマトグラフィー(ヘキサン:酢酸エチル=1:1)によって精製し、下記物性値を有する標題化合物(145mg)を得た。
TLC:Rf 0.17 (ヘキサン:酢酸エチル=1:1);
1H-NMR (CDCl3):δ 1.53, 3.96, 4.09, 6.73, 7.33, 7.40, 7.47-7.51, 7.92-7.96, 9.22。
室温において、50mLナスフラスコに実施例19で製造した化合物(41mg)を加えメタノール(0.5mL)に懸濁した。4mol/Lの塩化水素/酢酸エチル溶液(1mL)を加え、反応混合物を室温で1時間撹拌後、濃縮して、下記物性値を有する標題化合物(35mg)を得た。
TLC:Rf 0.48 (ジクロロメタン:メタノール=9:1);
1H-NMR (DMSO-d6):δ 3.79, 4.01, 6.57 - 6.60, 7.06, 7.46, 7.54 - 7.57 , 9.14。
TLC:Rf 0.55 (ジクロロメタン:メタノール=9:1);
1H-NMR (CDCl3):δ 2.06-2.14, 2.54-2.63, 3.95, 4.11, 7.26-7.29, 7.33, 7.41, 7.61-7.70, 7.82-7.86, 7.94-7.97, 9.23, 9.32, 11.70。
室温において4-アミノフェノール(500mg)をジメチルスルホキシド(DMSO)(5mL)に溶解し、55%水素化ナトリウム(98mg)を加えた。その後、4-クロロ-6,7-ジメトキシキノリン(244mg)を加え、100℃で3時間撹拌した.反応溶液を酢酸エチルで希釈し、飽和重曹水を加え撹拌した。さらに酢酸エチル、水を加え有機層を抽出した。有機層を飽和食塩水で洗浄後、無水硫酸ナトリウムで乾燥し、溶媒を減圧留去した。得られた残渣をメタノールで洗浄し、下記物性値を有する標題化合物(442mg)を得た。
TLC:Rf 0.57 (酢酸エチル);
1H-NMR (CDCl3):δ 3.71, 4.04, 6.41, 6.76, 6.98, 7.39, 7.57, 8.44。
TLC:Rf 0.72 (酢酸エチル:メタノール=5:1);
1H-NMR (CDCl3):δ 2.11, 2.60, 4.05, 6.49, 7.14, 7.28,7.43, 7.56, 7.61-7.70, 7.80, 8.47, 9.34, 11.46。
4-クロロ-6,7-ジメトキシキノリンまたはその代わりに相当するキノリン誘導体、4-アミノフェノールまたはその代わりに相当するフェノール誘導体、および実施例4で製造した化合物を用いて、実施例22→実施例23と同様の目的の操作に付すことにより、以下の実施例化合物を得た。
(LC-MS/ELSD):(保持時間:0.79分);
1H-NMR (CDCl3):δ 2.05-2.18, 2.53-2.69, 6.56, 7.12-7.20, 7.26-7.34, 7.54-7.85, 8.08, 8.36, 8.66, 9.34, 11.45。
TLC:Rf 0.50 (ジクロロメタン:メタノール=9:1);
1H-NMR (CDCl3):δ 2.05-2.15, 2.32, 2.53-2.63, 4.04, 4.05, 6.50, 7.00, 7.06, 7.26-7.30, 7.42, 7.55-7.68, 8.30, 8.48, 9.35, 11.23。
TLC:Rf 0.28 (酢酸エチル);
1H-NMR (CDCl3):δ 2.06-2.14, 2.55-2.63, 4.03, 4.05, 6.69, 6.78-6.83, 7.26-7.30, 7.41, 7.45, 7.56-7.68, 8.58, 9.32, 10.77。
DMF(20mL)に、6,7-ジメトキシ-キノリン-4-オール(5.0g)、炭酸セシウム(1.3g)と1,2-ジフルオロ-4-ニトロベンゼン(3.5mL)を加えて室温で6時間撹拌した。反応液を酢酸エチルで希釈後、水で有機層を洗浄した。水層を酢酸エチルで2回抽出し、合わせた有機層を飽和食塩水で洗浄後、無水硫酸ナトリウムで乾燥した。有機層を濃縮し、得られた残渣をシリカゲルカラムクロマトグラフィー(ヘキサン:酢酸エチル=1:1→0:100)によって精製し、下記物性値を有する標題化合物(2.3g)を得た。
TLC:Rf 0.62(ヘキサン:酢酸エチル=1:9);
1H-NMR (CDCl3):δ 4.04, 4.07, 6.55, 7.31-7.38, 7.45, 7.47, 8.11-8.26, 8.19,8.58。
実施例24で製造した化合物(2.1g)をDMF:水=3:1(45mL)に溶解し、亜鉛(3.9g)及び塩化アンモニウム(1.9mg)を加えて室温で1時間撹拌後、反応液をセライトでろ過した。ろ液に飽和炭酸水素ナトリウム水溶液を加えて、析出した固体を再度セライトろ過で除去した。酢酸エチルを加えた後、水層を酢酸エチルで抽出し、合わせた有機層を飽和食塩水で洗浄後、無水硫酸ナトリウムで乾燥した。有機層を濃縮し、下記物性値を有する標題化合物(1.9g)を得た。
TLC:Rf 0.35(ヘキサン:酢酸エチル=1:9);
1H-NMR (DMSO-d6):δ 3.93, 5.48, 6.38, 6.42-6.48, 6.54, 7.06, 7.37, 7.49, 8.44。
TLC:Rf 0.17 (ヘキサン:酢酸エチル=1:9);
1H-NMR (CDCl3):δ 2.06-2.20, 2.54-2.68, 4.06, 6.43, 7.15-7.47, 7.57-7.74, 7.94, 8.48, 9.32, 11.55。
実施例4で製造した化合物の代わりに相当するカルボン酸誘導体を用いて、実施例26と同様の目的の操作に付すことにより、以下の実施例化合物を得た。
TLC:Rf 0.36 (酢酸エチル);
1H-NMR (DMSO-d6):δ 0.99, 2.00-2.16, 2.54-2.60, 3.11-3.24, 3.94, 4.28, 6.47, 7.40-7.57, 8.05, 8.47, 8.84, 11.81。
1H-NMR (CDCl3):δ 2.07-2.21, 2.51-2.71, 4.05, 4.06, 6.39-6.45, 7.01-7.13, 7.15-7.23, 7.29-7.40, 7.42, 7.57, 7.60-7.74, 7.85-8.00, 8.48, 9.33, 11.38-11.49。
TLC:Rf 0.33 (酢酸エチル);
1H-NMR (CDCl3):δ 0.32-0.44, 0.50-0.61, 2.40, 2.48, 4.05, 4.06, 6.42, 7.14-7.25, 7.34-7.40, 7.42, 7.58, 7.59-7.70, 7.93, 8.49, 9.37, 11.54。
アルゴン雰囲気下、4-クロロ-6,7ジメトキシキナゾリン(8.0g)、6-クロロピリジン-3-オール(4.6g)のDMSO懸濁液(20mL)にDMAP(4.4g)を加えてバス温(80℃)にて2時間加熱撹拌した。室温まで放冷後、酢酸エチルで反応液を希釈し、水、飽和炭酸水素ナトリウム水溶液で洗浄した。有機層を無水硫酸ナトリウムで乾燥後、濃縮し、得られた残渣をヘキサン-酢酸エチル(3:1)で洗浄し、下記物性値を有する標題化合物(9.1g)を得た。
TLC:Rf 0.16 (ヘキサン:酢酸エチル=1:1);
1H-NMR (DMSO-d6):δ 3.97, 3.99, 7.41, 7.58, 7.69, 7.97, 8.50, 8.57。
アルゴン雰囲気下、実施例27で製造した化合物(1.0g)のTHF溶液(15mL)に1.0mol/LのLHMDS(4.7mL)、トリス(ジベンジリデンアセトン)ジパラジウム(0)クロロホルム錯体(140mg)、2-ジシクロヘキシルホスフィノ-2’,6’-ジメトキシビフェニル(170mg)を加え、バス温(70℃)で4時間撹拌した。反応液を室温まで放冷後、氷水にあけ、酢酸エチルで抽出した。有機層を水で洗浄後、無水硫酸ナトリウムで乾燥し、濃縮した。得られた残渣をアセトニトリル(30mL)に懸濁し、2.0mol/Lの塩酸(10mL)を加えて室温で30分撹拌した。反応液中に生じた析出物をろ取し、下記物性値を有する標題化合物(591mg)を得た。
TLC:Rf 0.16 (酢酸エチル:メタノール=10:1);
1H-NMR (DMSO-d6):δ 3.96, 3.99, 4.24, 7.10, 7.42, 7.53, 8.00-8.20, 8.07, 8.20, 8.61。
TLC:Rf 0.75 (酢酸エチル:メタノール=5:1);
1H-NMR (CDCl3):δ 2.11, 2.59, 4.07, 7.26, 7.33, 7.54, 7.58-7.69, 8.27, 8.52, 8.61, 9.33, 11.91。
4-クロロ-6,7-ジメトキシキナゾリンの代わりに相当するキナゾリン誘導体、6-クロロピリジン-3-オール、および実施例4で製造した化合物またはその代わりに相当するカルボン酸誘導体を用いて、実施例27→実施例28→実施例29と同様の目的の操作に付すことにより、以下の実施例化合物を得た。
(LC-MS/ELSD):(保持時間:0.99分);
1H-NMR (CDCl3):δ 2.02-2.21, 2.57, 3.99, 7.24-7.25, 7.27-7.29, 7.30-7.33, 7.55-7.69, 8.23, 8.26, 8.51, 8.67, 9.33, 11.89。
TLC:Rf 0.47 (酢酸エチル:メタノール=10:1);
1H-NMR (CDCl3):δ 1.75-1.95, 1.96-2.10, 2.11-2.25, 2.40-2.54, 2.55-2.65, 2.92-3.16, 4.08, 4.09, 4.74-4.93, 7.34, 7.56, 7.68, 8.36, 8.56, 8.62, 9.16, 12.13。
TLC:Rf 0.44 (酢酸エチル:メタノール=10:1);
1H-NMR (CDCl3):δ 1.06, 2.18-2.27, 2.63, 3.02-3.18, 4.08, 4.09, 7.34, 7.56, 7.69, 8.36, 8.56, 8.61, 9.22, 12.17。
TLC:Rf 0.38 (酢酸エチル:メタノール=10:1);
1H-NMR (CDCl3):δ 0.74, 1.13, 2.09-2.34, 2.41-2.72, 2.77-3.39,3.90-4.20, 4.07, 4.09, 4.44-4.69, 7.32, 7.55, 7.70, 8.32, 8.53, 8.60, 9.15, 12.07。
1H-NMR (CDCl3):δ 2.12, 2.56-2.63, 4.07, 4.07, 7.23-7.35, 7.53, 7.66, 8.26, 8.50, 8.60, 9.30, 11.84。
TLC:Rf 0.20 (酢酸エチル、NHシリカ);
1H-NMR (CDCl3):δ 0.72, 1.11, 2.22, 2.52, 2.94, 3.34, 4.07, 4.08, 4.16, 4.40, 4.72, 7.27, 7.54, 7.72, 8.24, 8.45, 8.56, 8.86, 91.5, 12.14。
ジフェニルエーテル(10mL)に、4-クロロ-7-メトキシ-キナゾリン(50mg)と2-フルオロ-4-ニトロフェノール(60mg)を加えて、マイクロウェーブを用いて、150℃で2時間撹拌した。反応液を冷却し水を加えた後、水層を酢酸エチルで抽出し、合わせた有機層を飽和食塩水で洗浄後濃縮し、得られた残渣をシリカゲルカラムクロマトグラフィー(ヘキサン:酢酸エチル=100:0→0:100)によって精製し、下記物性値を有する標題化合物(60mg)を得た。
MASS(ESI,Pos.):286(M+H)+。
実施例30で製造した化合物を用いて、実施例25と同様の目的の操作に付すことにより、下記物性値を有する標題化合物を得た。
1H-NMR (CDCl3):δ 3.70, 3.98, 6.49-6.57, 7.06, 7.24-7.30, 8.25, 9.47。
(LC-MS/ELSD):(保持時間:1.02分);
1H-NMR (CDCl3):δ 2.06-2.20, 2.53-2.68, 3.98, 7.19-7.44, 7.58-7.73, 7.93, 8.25, 8.67, 9.32, 11.51。
アセトニトリル(10mL)に、4-クロロ-キナゾリン(0.95g)、炭酸カルシウム(3.5g)と(4-ヒドロキシ-フェニル)-カルバミン酸 tert-ブチルエステル(0.90g)を加えて、100℃で3時間撹拌した。反応液に水を加えて、水層を酢酸エチルで抽出し、合わせた有機層を飽和食塩水で洗浄後濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー(ヘキサン:酢酸エチル=100:0→0:100)によって精製し、下記物性値を有する標題化合物(1.3g)を得た。
1H-NMR (CDCl3):δ 1.53, 6.63, 7.18-7.20, 7.47, 7.64-7.68, 7.89-7.93, 8.00, 8.37, 8.76。
実施例33で製造した化合物(100mg)のTHF溶液(5mL)に4mol/L塩酸-1,4-ジオキサン溶液(5mL)を加えて室温で3時間撹拌した。反応液を濃縮し、下記物性値を有する標題化合物(81mg)を得た。
MASS(ESI,Pos.):238(M+H)+。
(LC-MS/ELSD):(保持時間:0.98分);
1H-NMR (CDCl3):δ 2.08-2.13, 2.54-2.63, 7.21-7.29, 7.60-7.68, 7.82-7.84, 7.91-7.93, 8.00, 8.37, 8.76, 9.34, 11.43。
アルゴン雰囲気下、メルドラム酸(8.0g)のオルトギ酸メチル(50mL)溶液を100℃にて5分間加熱した後に、3-ヒドロキシ-4-メトキシアニリン(7.0g)を加えて105℃にて25分間加熱攪拌した。加熱を止めて水冷し、析出した粉末をろ取した。オルトギ酸メチルおよびMTBEで洗浄し、減圧下で乾燥することにより、下記物性値を有する標題化合物(12.3g)を得た。
TLC:Rf 0.25 (ヘキサン:酢酸エチル=1:1);
1H-NMR (CDCl3):δ 1.75, 3.92, 5.82, 6.73, 6.84-6.88, 8.53, 11.2。
アルゴン雰囲気下、実施例36で製造した化合物(12.0g)を50℃にてDMA(80mL)に溶解させた。室温に戻して炭酸カリウム(7.35g)および臭化ベンジル(8.75g)を加えてから60℃にて2時間加熱攪拌した。室温まで放冷し、溶媒を濃縮した後、酢酸エチルおよび水を加えて振とうした。沈殿が析出したのでろ取し、水および酢酸エチルで洗浄した。減圧下で乾燥することにより、下記物性値を有する標題化合物(8.0g)を得た。
TLC:Rf 0.49 (ヘキサン:酢酸エチル=1:1);
1H-NMR (CDCl3):δ 1.75, 3.90, 5.17, 6.76-6.85, 6.91, 7.30-7.48, 8.48, 11.2。
TLC:Rf 0.20 (酢酸エチル、NHシリカ);
1H-NMR (CDCl3):δ 2.08-2.19, 2.45-2.64, 3.73, 4.02, 4.27, 6.43, 7.25, 7.43, 7.52-7.65, 8.21, 8.47, 8.49, 9.32, 11.92。
実施例37で製造した化合物の代わりに相当する化合物を用いて、実施例38と同様の目的の操作に付すことにより、以下の実施例化合物を得た。
1H-NMR (CDCl3):δ 1.34, 2.07-2.15, 2.56-2.64, 3.28, 4.01, 4.43, 6.45, 7.25, 7.43, 7.53-7.67, 8.21, 8.48, 8.51, 9.33, 11.93。
TLC:Rf 0.28 (酢酸エチル、NHシリカ);
1H-NMR (CDCl3):δ 1.42, 1.52-1,64, 2.08-2.15, 2.38-2.45, 2.50-2.63, 4.02, 4.24, 6.42, 7.21-7.28, 7.42, 7.51, 7.55-7.66, 8.21, 8.47, 8.49, 9.32, 11.92。
1H-NMR (CDCl3):δ 1.79, 2.15, 2.56, 2.67, 4.02, 4.27, 6.42, 7.25, 7.42, 7.51, 7.53-7.65, 8.21, 8.47, 8.49, 9.32, 11.92。
TLC:Rf 0.20 (酢酸エチル,NHシリカ);
1H-NMR (CDCl3):δ 2.10, 2.55, 2.71, 3.15, 4.01, 4.26, 6.44, 7.26, 7.42, 7.51-7.67, 8.21, 8.49, 9.31, 11.92。
TLC:Rf 0.56 (酢酸エチル:メタノール=10:1);
1H-NMR (CDCl3):δ 1.86, 2.00-2.21, 2.48-2.74, 4.04, 4.90, 6.45, 7.22-7.31, 7.50-7.68, 8.22, 8.45-8.54, 9.33, 11.94。
TLC:Rf 0.16 (酢酸エチル:メタノール=10:1,NHシリカ);
1H-NMR (CDCl3):δ 2.02-2.19, 2.40-2.68, 2.99, 3.29-3.40, 4.02, 4.32, 6.45, 7.22-7.29, 7.40, 7.49-7.69, 8.22, 8.44-8.55, 9.33, 11.94。
TLC:Rf 0.20 (酢酸エチル、NHシリカ);
1H-NMR (CDCl3):δ 2.13, 2.29, 2.48-2.65, 4.02, 4.25, 6.42, 7.21-7.28, 7.42, 7.51, 7.52-7.67, 8.21, 8.47, 8.49, 9.32, 11.92。
アルゴン雰囲気下、実施例16で製造した化合物(100mg)のDMF溶液(15mL)に炭酸セシウム(94mg)、1-ブロモ-3-メチル-2-ブテン(140mg)を加え、バス温(-10℃)で2時間撹拌した。反応液に塩化アンモニウム水溶液を加え、酢酸エチルで抽出した。有機層を飽和食塩水で洗浄後、無水硫酸ナトリウムで乾燥し、濃縮した。シリカゲルカラムクロマトグラフィー(ヘキサン:酢酸エチル=1:4、NHシリカ)によって精製し、標題化合物(55mg)を得た。
TLC:Rf 0.30(酢酸エチル、NHシリカ);
1H-NMR (CDCl3):δ 1.79, 1.82, 2.08-2.17, 2.46-2.63, 4.67, 5.57, 6.39, 7.23-7.26, 7.46, 7.48-7.65, 8.18, 8.22, 8.45, 8.49, 9.29, 11.90。
TLC:Rf 0.10 (酢酸エチル、NHシリカ);
1H-NMR (CDCl3):δ1.32, 1.36, 2.11, 2.37, 2.60, 2.87, 3.92, 4.20, 4.32, 6.42, 7.23, 7.43, 7.53-7.66, 8.20, 8.23, 8.48, 8.60, 9.32, 11.93。
実施例16で製造した化合物の代わりに相当する化合物、1-ブロモ-3-メチル-2-ブテン、およびAD-mix-β、またはAD-mix-αを用いて、実施例39→実施例40と同様の目的の操作に付すことにより、以下の実施例化合物を得た。
TLC:Rf 0.41 (酢酸エチル:メタノール=10:1);
1H-NMR (CDCl3):δ 1.32, 1.36, 1.99-2.19, 2.50-2.68, 3.04, 3.15-3.23, 3.74-3.90, 4.01, 4.21-4.33, 4.37-4.48, 6.45, 7.24-7.29, 7.42, 7.54, 7.54-7.69, 8.18-8.23, 8.46-8.52, 9.32, 11.93。
TLC:Rf 0.48 (ジクロロメタン:メタノール=9:1);
1H-NMR (CDCl3):δ 1.28-1.32, 2.07-2.15, 2.56-2.64, 2.90-3.40, 3.85, 4.01, 4.27, 4.43, 6.45, 7.25-7.29, 7.42, 7.53-7.66, 8.21, 8.48, 8.50, 9.32, 11.93。
TLC:Rf 0.41 (酢酸エチル:メタノール=10:1);
1H-NMR (CDCl3):δ 1.06, 1.33, 1.37, 2.11-2.33, 2.55-2.71, 3.04, 3.06-3.15, 3.16-3.24, 3.79-3.91, 4.03, 4.21-4.33, 4.39-4.48, 6.46, 7.43, 7.53-7.61, 8.27-8.33, 8.48-8.56, 9.22, 12.18。
TLC:Rf 0.45 (ジクロロメタン:メタノール=9:1);
1H-NMR (CDCl3):δ 1.06, 1.33-1.37, 2.18-2.26, 2.63, 3.00-3.20, 3.87, 4.02, 4.28, 4.44, 6.46, 7.43, 7.55-7.60, 8.30, 8.49-8.55, 9.21, 12.18。
TLC:Rf 0.49 (ジクロロメタン:メタノール=9:1);
1H-NMR (CDCl3):δ 0.37-0.40, 0.53-0.56, 1.32-1.36, 2.41, 2.48, 2.98, 3.19, 3.85, 4.01, 4.27, 4.43, 6.46, 7.21-7.24, 7.42, 7.54-7.65, 8.22, 8.49-8.52, 9.36, 11.94。
TLC:Rf 0.56 (酢酸エチル:メタノール=10:1、DNHシリカ);
1H-NMR (CDCl3):δ 1.32, 1.36, 2.05-2.22, 2.53-2.71, 2.98-3.09, 3.11-3.26, 3.77-3.92, 4.01, 4.20-4.30, 4.39-4.47, 6.45, 7.00-7.13, 7.28-7.36, 7.42, 7.51-7.69, 8.23, 8.45-8.54, 9.32, 11.86。
ジ-tert-ブチル ジカルボナート(CAS登録番号:24424-99-5)(3.95mL)の1,3-ジメチル-3,4,5,6-テトラヒドロ-2-(1H)-ピリミジノン溶液(15mL)に、5-{[7-(ベンジルオキシ)-6-メトキシ-4-キノリニル]オキシ}-2-ピリジナミン(1.6g)を溶解し、そこへトリエチルアミン(9.37mL)、DMAP(52mg)を加えて室温で5時間撹拌した。反応液をヘキサン:酢酸エチル混合液(1:3)で希釈して水で洗浄後、有機層を濃縮してシリカゲルカラムクロマトグラフィー(ヘキサン:酢酸エチル=4:1→0:1→酢酸エチル:メタノール=50:1→20:1)によって精製し、下記物性値を有する標題化合物(2.4g)を得た。
TLC:Rf 0.51 (酢酸エチル);
1H-NMR (CDCl3):δ 1.49, 4.04, 5.33, 6.45, 7.30-7.43, 7.44-7.62, 8.41, 8.50。
アルゴン雰囲気下、実施例41で製造した化合物(1.4g)に酢酸エチル(10mL)とエタノール(30mL)を加えて溶解し、水酸化パラジウム(20wt%、420mg)を加えて水素雰囲気下にて室温で5時間撹拌した。セライトを通して水酸化パラジウムを除去し、ろ液を濃縮して標題化合物(1.2g)を得た。
TLC:Rf 0.49 (酢酸エチル);
1H-NMR (CDCl3):δ 1.50, 4.08, 6.44, 7.36, 7.46-7.60, 8.42, 8.53。
実施例42で製造した化合物(500mg)のTHF懸濁液(20mL)に3-メチル-3-ブテン-1-オール(231mg)、N,N,N’,N’-テトラメチルアゾジカルボキサミド(TMAD)(462mg)、トリ-n-ブチルホスフィン(544mg)を加えて室温で3時間撹拌した。反応液を酢酸エチルで希釈後、不溶物を除去して濃縮し、得られた残渣をシリカゲルカラムクロマトグラフィー(ヘキサン:酢酸エチル=3:2→0:1)によって精製し、下記物性値を有する標題化合物(570mg)を得た。
TLC:Rf 0.52 (ヘキサン:酢酸エチル=3:7);
1H-NMR (CDCl3):δ 1.49, 1.86, 2.68, 4.03, 4.33, 4.76-4.99, 6.46, 7.35, 7.45, 7.50, 7.55, 8.42, 8.52。
実施例43で製造した化合物(170mg)にジクロロメタン:t-ブタノール:水=1:1:1(1.5mL)を加えて溶解し、AD-mix-β(431mg)とメタンスルホンアミド(58mg)を加えて室温で終夜撹拌した。反応液を酢酸エチルで希釈して水で洗浄し、有機層を回収してシリカゲルカラムクロマトグラフィー(ヘキサン:酢酸エチル=4:1→0:1→酢酸エチル:メタノール=9:1)によって精製し、下記物性値を有する標題化合物(152mg)を得た。
TLC:Rf 0.54 (酢酸エチル:メタノール=9:1);
1H-NMR (CDCl3):δ 1.29, 1.50, 2.06-2.17, 2.19-2.36, 2.90-3.32, 3.45-3.65, 4.02, 4.28-4.51, 6.48, 7.36, 7.45, 7.51, 7.56, 8.42, 8.52。
実施例44で製造した化合物(152mg)のジクロロメタン溶液(5mL)にトリフルオロ酢酸(2mL)を加えて室温で2時間撹拌した。反応液を濃縮し、トルエンで2度共沸後、得られた残渣をシリカゲルカラムクロマトグラフィー(NHシリカ、酢酸エチル:メタノール=9:1)によって精製し、下記物性値を有する標題化合物(100mg)を得た。
TLC:Rf 0.35 (ジクロロメタン:メタノール=9:1、NHシリカ);
1H-NMR (CDCl3):δ 1.28, 2.01-2.15, 2.17-2.34, 2.74-2.94, 3.08-3.23, 3.44-3.66, 4.03, 4.26-4.46, 4.52, 6.43, 6.61, 7.31, 7.41, 7.56, 8.03, 8.48。
TLC: 0.43 (ジクロロメタン:メタノール=9:1);
1H-NMR (CDCl3):δ 1.28, 2.05-2.30, 2.56-2.64, 2.70-3.30, 3.48-3.60, 4.02, 4.31-4.45, 6.45, 7.25-7.28, 7.33, 7.43-7.67, 8.21, 8.48-8.51, 9.32, 11.93。
実施例45で製造した化合物、または実施例43で製造した化合物をAD-mix-βの代わりにAD-mix-αを用いて実施例44→実施例45と同様の目的の操作に付すことにより製造した化合物、および実施例4で製造した化合物またはその代わりに相当するカルボン酸誘導体を用いて、実施例46と同様の目的の操作に付すことにより、以下の実施例化合物を得た。
TLC: 0.40 (酢酸エチル:メタノール=10:1);
1H-NMR (CDCl3):δ 1.28, 1.97-2.17, 2.18-2.35, 2.52-2.69, 2.74-2.89, 3.13, 3.40-3.69, 4.02, 4.23-4.52, 6.45, 7.20-7.30, 7.42, 7.53, 7.54-7.70, 8.21, 8.45-8.52, 9.32, 11.93。
TLC: 0.45 (ジクロロメタン:メタノール=9:1);
1H-NMR (CDCl3):δ 0.37-0.41, 0.53-0.56, 1.28, 2.05-2.30, 2.42, 2.48, 2.70-3.30, 3.48-3.60, 4.02, 4.31-4.45, 6.45, 7.21-7.24, 7.42, 7.48-7.65, 8.21, 8.48-8.51, 9.36, 11.93。
TLC: 0.50 (酢酸エチル:メタノール=10:1、NHシリカ);
1H-NMR (CDCl3):δ 0.33-0.43, 0.50-0.61, 1.28, 1.98-2.14, 2.16-2.33, 2.42, 2.48, 2.73-2.91, 3.08-3.18, 3.42-3.68, 4.02, 4.23-4.51, 6.46, 7.19-7.25, 7.42, 7.54, 7.55-7.66, 8.22, 8.46-8.54, 9.36, 11.94。
実施例4で製造した化合物(142mg)と、ヒドロキシルアミン塩酸塩(208mg)のピリジン溶液(1.0mL)を1時間加熱還流した。室温に冷却後、反応液を酢酸エチルで希釈し、1mol/L塩酸で洗浄した。得られた有機層を濃縮し、下記物性値を有する標題化合物(151mg)を得た。
TLC:Rf 0.42 (ジクロロメタン:メタノール=9:1);
1H-NMR (DMSO-d6):δ 1.63-1.81, 2.26-2.36, 2.60, 7.38-7.46, 7.51-7.68, 8.90, 11.30, 14.03。
TLC: 0.15 (酢酸エチル、NHシリカ);
1H-NMR (CDCl3):δ 1.77-1.94, 2.38, 2.77, 4.05, 6.46, 7.20-7.25, 7.43, 7.50-7.65, 7.99-8.07, 8.22, 8.48, 8.52, 9.33, 12.23。
実施例47で製造した化合物の代わりに相当するカルボン酸誘導体と、実施例2で製造した化合物を用いて、実施例48と同様の目的の操作に付すことにより、下記物性値を有する標題化合物を得た。
TLC: 0.18 (酢酸エチル);
1H-NMR (CDCl3):δ 1.74-1.92, 2.29-2.40, 2.62-2.75, 4.00, 4.05, 6.45, 7.20-7.28, 7.42, 7.50-7.66, 8.20-8.24, 8.46-8.52, 9.36, 12.26。
6,7-ジメトキシ-キノリン-4-オールの代わりに、7-ベンジルオキシ-6-メトキシ-キノリン-4-オールを用いて実施例24と同様の目的の操作に付すことにより、下記物性値を有する標題化合物を得た。
TLC:Rf 0.76 (ヘキサン:酢酸エチル=1:1);
1H-NMR (CDCl3):δ 4.03, 5.34, 6.54, 7.28-7.43, 7.45, 7.47-7.55, 8.10-8.15, 8.19, 8.56。
実施例49で製造した化合物(1.6g)に5.1mol/L臭化水素酸-酢酸溶液(10mL)を加えて室温で5時間撹拌した。反応液にMTBE(50mL)を加えて撹拌し、生成した析出物をろ取して下記物性値を有する標題化合物(1.5g)を得た。
1H-NMR (CD3OD):δ 4.14, 7.05, 7.43, 7.76-7.85, 7.86, 8.30-8.38, 8.39-8.46, 8.69。
実施例50で製造した化合物(1.0g)のDMF溶液(9.8mL)に炭酸セシウム(4.0g)と4-(3-クロロプロピル)モルホリン(517mg)を加えて60℃で16時間撹拌した。反応液を酢酸エチルで希釈して水で洗浄し、水層を酢酸エチルで2回抽出した。有機層を合わせて無水硫酸ナトリウムで乾燥して濃縮し、得られた残渣をシリカゲルカラムクロマトグラフィー(NHシリカ、ヘキサン:酢酸エチル=1:1→0:1)によって精製し、下記物性値を有する標題化合物(600mg)を得た。
TLC:Rf 0.50 (酢酸エチル、NHシリカ);
1H-NMR (DMSO-d6):δ 1.90-2.07, 2.32-2.43, 3.25-3.35, 3.48-3.64, 3.92, 4.21, 6.77, 7.45, 7.55-7.67, 8.14-8.25, 8.41-8.50, 8.56。
アルゴン雰囲気下、実施例51で製造した化合物(300mg)を酢酸エチル:エタノール=1:1(30mL)に溶解し、水酸化パラジウム(20wt%、99mg)を加えて水素雰囲気に置換した。室温で8時間撹拌後、反応液をセライトでろ過してろ液を濃縮し、下記物性値を有する標題化合物(240mg)を得た。
1H-NMR (CDCl3):δ 2.03-2.23, 2.43-2.53, 2.57, 3.66-3.77, 3.86, 4.03, 4.26, 6.40, 6.45-6.61, 7.03, 7.42, 7.58, 8.46。
TLC:Rf 0.71 (酢酸エチル:メタノール=10:1、NHシリカ);
1H-NMR (DMSO-d6):δ 1.88-2.07, 2.34-2.41, 2.41-2.46, 2.51-2.57, 3.31-3.37, 3.52-3.64, 3.94, 4.20, 6.42-6.49, 7.39, 7.40-7.53, 7.54-7.71, 8.04, 8.46, 8.95, 11.64。
室温において2-オキソ-1,5,6,7-テトラヒドロシクロペンタ[b]ピリジン-3-カルボン酸(CAS登録番号:115122-63-9)(200mg)をメタノール(20mL)に溶解し、濃硫酸(0.006mL)を加え、バス温(70℃)で4時間撹拌した。室温まで放冷し、溶媒を減圧留去後、飽和重炭酸水素ナトリウム水溶液、ジクロロメタンを加えて分液した。有機層を飽和食塩水で洗浄後、無水硫酸ナトリウムで乾燥し、溶媒を減圧留去し、下記物性値を有する標題化合物(155mg)を得た。
TLC:Rf 0.21 (酢酸エチル);
1H-NMR (CDCl3):δ 2.13-2.20, 2.80-2.84, 2.97-3.03, 3.91, 8.10。
室温において実施例54で製造した化合物(140mg)をジクロロメタン(7mL)に溶解し、フェニルボロン酸(220mg)、酢酸銅(263mg)、ピリジン(0.234mL)を加え、20時間撹拌した。グラスフィルターにてろ過後、溶媒を減圧留去し、得られた残渣をシリカゲルカラムクロマトグラフィー(ヘキサン:酢酸エチル=8:2→酢酸エチル)で精製することで、下記物性値を有する標題化合物(131mg)を得た。
TLC:Rf 0.51 (酢酸エチル);
1H-NMR (CDCl3):δ 2.02-2.12, 2.53-2.58, 2.83-2.88, 3.88, 7.20-7.23, 7.44-7.53, 8.21。
室温において実施例55で製造した化合物(120mg)をメタノール(2mL)に溶解し、2mol/Lの水酸化ナトリウム水溶液(0.891mL)を加え、1時間撹拌した。反応液に2Nの塩酸(0.891mL)、酢酸エチルを加えて分液した。有機層を飽和食塩水で洗浄後、無水硫酸ナトリウムで乾燥し、溶媒を減圧留去し、下記物性値を有する標題化合物(109mg)を得た。
TLC:Rf 0.64 (酢酸エチル);
1H-NMR (CDCl3):δ 2.09-2.19, 2.63-2.68, 2.92-2.97, 7.25-7.30, 7.52-7.62, 8.51, 14.24。
TLC:Rf 0.65 (酢酸エチル:メタノール=9:1);
1H-NMR (DMSO-d6):δ 2.03-2.13, 2.60-2.65, 2.92-2.97, 3.97, 3.99, 6.58, 7.45, 7.47-7.52, 7.57, 7.58-7.68, 7.86-7.90, 8.38, 8.48, 8.53, 8.60, 12.58。
実施例54で製造した化合物の代わりに相当する誘導体、および実施例2で製造した化合物を用いて、実施例55→実施例56→実施例57と同様の目的の操作に付すことにより、以下の実施例化合物を得た。
TLC:Rf 0.63 (酢酸エチル、NHシリカ);
1H-NMR (CDCl3):δ 1.71-1.83, 2.20-2.29, 2.68-2.76, 4.05, 6.44, 7.19-7.24, 7.42, 7.46-7.62, 8.21, 8.44-8.50, 12.51。
TLC:Rf 0.63 (酢酸エチル:メタノール=9:1);
1H-NMR (CDCl3):δ 2.68-2.81, 4.05, 6.45, 7.35, 7.43, 7.53, 7.55-7.68, 8.24, 8.49, 8.51, 9.03, 11.91。
実施例37で製造した化合物を用いて、実施例11→実施例12→実施例13→実施例14→実施例15→実施例16と同様の目的の操作に付すことにより得られた化合物、および(S)-(2,2-ジメチル-1,3-ジオキソラン-4-イル)メタノールを用いて、実施例17と同様の目的の操作に付すことにより、下記物性値を有する標題化合物を得た。
TLC:Rf 0.60 (酢酸エチル、NHシリカ);
1H-NMR (CDCl3):δ 1.42, 1.50, 2.11, 2.60, 4.01, 4.14-4.29, 4.64, 6.44, 7.42, 7.52-7.65, 8.21, 8.47, 8.50, 9.32, 11.92。
TLC:Rf 0.55 (酢酸エチル:メタノール=5:1,NHシリカ);
1H-NMR (CDCl3):δ 2.11, 2.56-2.64, 3.89, 4.02, 4.21-4.36, 6.45, 7.25-7.28,7.44, 7.53-7.66, 8.21, 8.48-8.51, 9.32, 11.93。
実施例58で製造した化合物またはその代わりに相当する化合物を用いて、実施例59と同様の目的の操作に付すことにより、以下の実施例化合物を得た。
TLC:Rf 0.55 (酢酸エチル:メタノール=5:1,NHシリカ);
1H-NMR (CDCl3):δ 2.11, 2.56-2.64, 3.90, 4.02, 4.21-4.36, 6.44, 7.24-7.29, 7.44, 7.52-7.66, 8.22, 8.48-8.51, 9.33, 11.94。
TLC:Rf 0.35 (酢酸エチル、NHシリカ);
1H-NMR (CDCl3):δ 1.06, 2.22, 2.63, 3.09, 3.89, 4.02, 4.22, 4.34, 6.44, 7.43, 7.55, 7.58, 8.30, 8.52, 8.54, 9.21, 12.18。
TLC:Rf 0.35 (酢酸エチル、NHシリカ);
1H-NMR (CDCl3):δ 1.06, 2.22, 2.63, 3.09, 3.89, 4.02, 4.22, 4.34, 6.44, 7.43, 7.55, 7.58, 8.30, 8.52, 8.54, 9.21, 12.18。
実施例37で製造した化合物を用いて、実施例11→実施例12→実施例13→実施例14→実施例15→実施例16と同様の目的の操作に付すことにより、下記物性値を有する標題化合物を得た。
TLC:Rf 0.26 (ジクロロメタン:メタノール=19:1);
1H-NMR (CDCl3):δ 1.62-1.93, 2.27, 4.08, 4.85, 6.42, 7.23, 7.52-7.62, 8.21, 8.46, 8.51, 8.80, 12.37。
TLC:Rf 0.77 (酢酸エチル:メタノール=5:1);
1H-NMR (CDCl3):δ 1.75, 2.23, 2.72, 4.08, 6.42, 7.22, 7.51-7.60, 8.21, 8.44-8.51, 8.49, 12.51。
200mLのナスフラスコにアセト酢酸エチル(CAS登録番号:141-97-9)(17.40g)、1,3-シクロヘキサンジオン(CAS登録番号:504-02-9)(10.00g)、DMAP(0.22g)、ピリジン(30mL)を加え、バス温(140℃)で1日間撹拌した。室温まで放冷した後、溶媒を減圧留去し、得られた残渣をシリカゲルカラムクロマトグラフィー(ヘキサン:酢酸エチル=4:1)で精製することで下記物性値を有する標題化合物(4.50g)を得た。
(LC-MS/ELSD):(保持時間:0.81分);
1H-NMR (CDCl3):δ 2.11, 2.48, 2.57, 2.87, 5.99。
100mLのナスフラスコに実施例62で製造した化合物(2.00g)のDMF(40mL)溶液に、N-ブロモスクシンイミド(CAS登録番号:128-08-5)(2.00g)を加え、室温で1日間撹拌した。溶媒を減圧留去し、得られた残渣をシリカゲルカラムクロマトグラフィー(ヘキサン:酢酸エチル=9:1)で精製することで下記物性値を有する標題化合物(1.16g)を得た。
(LC-MS/ELSD):(保持時間:0.76分);
1H-NMR (CDCl3):δ 2.12, 2.59, 2.69, 2.87。
30mLのナスフラスコに実施例63で製造した化合物(1.15g)とアニリン(1.25g)を加え、バス温(70℃)で20時間撹拌した。反応溶液に1mol/Lの塩酸を加え、酢酸エチルで抽出し、水、飽和食塩水の順で洗浄後、無水硫酸ナトリウムで乾燥した。溶媒を減圧留去し、得られた残渣をシリカゲルカラムクロマトグラフィー(ヘキサン:酢酸エチル=7:3)で精製することで下記物性値を有する標題化合物(1.31g)を得た。
(LC-MS/ELSD):(保持時間:1.12分);
1H-NMR (CDCl3):δ 1.96, 2.43, 2.54, 2.79, 7.16-7.20, 7.49-7.58。
200mLのナスフラスコに実施例64で製造した化合物(1.11g)、酢酸カリウム(0.66g)、DMF(11mL)、メタノール(11mL)を、続いて脱気操作後に[1,1’-ビス(ジフェニルホスフィノ)フェロセン]パラジウム(II)ジクロリド ジクロロメタン錯体(1:1)[PdCl2(dppf)2 CH2Cl2](0.27g)を加えた。一酸化炭素で置換した後、バス温(70℃)で17時間撹拌した。反応溶液に1mol/Lの塩酸を加え、酢酸エチルで抽出し、水、飽和食塩水の順で洗浄後、無水硫酸ナトリウムで乾燥した。溶媒を減圧留去し、得られた残渣をシリカゲルカラムクロマトグラフィー(ヘキサン:酢酸エチル=7:3)で精製することで下記物性値を有する標題化合物(0.51g)を得た。
(LC-MS/ELSD):(保持時間:0.75分);
1H-NMR (CDCl3):δ 1.97, 2.48, 2.53, 2.56, 3.89, 7.17-7.20, 7.48-7.56。
50mLのナスフラスコに実施例65で製造した化合物(1.85g)と5mol/Lの塩酸(19mL)を加え、バス温(50℃)で26時間撹拌した。析出物をろ過で除き、ろ液を減圧留去し、得られた残渣をメタノールと酢酸エチルでスラリー洗浄することで下記物性値を有する標題化合物(0.89g)を得た。
(LC-MS/ELSD):(保持時間:0.66分);
1H-NMR (CD3OD):δ 1.97, 2.54, 2.63, 7.29-7.32,7.54-7.63。
TLC:Rf 0.62 (ジクロロメタン:メタノール=9:1);
1H-NMR (CDCl3):δ 2.01, 2.53, 2.58, 2.86, 4.05, 6.42, 7.22, 7.42, 7.49-7.61, 8.20, 8.45, 8.50, 9.73。
実施例66で製造した化合物と、実施例22で製造した化合物を用いて、実施例67と同様の目的の操作に付すことにより、下記物性値を有する標題化合物を得た。
TLC:Rf 0.48 (酢酸エチル:メタノール=19:1);
1H-NMR (CDCl3):δ 2.01, 2.52, 2.59, 2.93, 4.04, 6.45, 7.14, 7.23, 7.41, 7.55-7.68, 7.72, 8.47, 9.79。
以下に生物学的実験例を示し、これらの実験方法に基づいて、本発明化合物の効果を確認した。
生物学的実験例1:Axl阻害活性の測定(in vitro試験)
Axl酵素阻害活性の測定は、LanthaScreen(登録商標)system(Invitrogen社)により、添付の説明書に準じて実施した。使用した試薬を以下に示した。
反応緩衝液:50mmol/L HEPES(pH7.5)、0.01%Brij35、10mmol/L MgCl2及び1mmol/L EGTAを含む溶液を、精製水を用いて調製した。
被験物質溶液:各濃度の被験化合物のDMSO溶液を反応緩衝液にて20倍希釈し、最終濃度の5倍濃度の被験化合物を含む溶液を調製した。
酵素液:400ng/mL Axl酵素を含む溶液を、反応緩衝液を用いて調製した。
基質液:45μmmol/L ATP及び500nmmol/L Fluorescein-Poly GT(Invitrogen社)を含む溶液を、反応緩衝液を用いて調製した。
検出液:20mM EDTA及び4nM PY20(Invitrogen社)を含む溶液をDilution B(Invitrogen社)を用いて調製した。
96ウェルプレート(Nunc社)に10mmol/Lの被験化合物のDMSO溶液を分注し、さらにDMSOで3倍公比の希釈系列を調製した。測定用の96ウェルプレートの各ウェルに、Blank群及び媒体群にはDMSOを含む反応緩衝液を、被験物質群には被験物質溶液を5μLずつ添加した。次に、Blank群には反応緩衝液を、媒体群及び被験化合物群には酵素液を各ウェル10μLずつ添加後、室温にて10分間撹拌した。撹拌終了後、基質液を各ウェルに10μLずつ添加し、室温・遮光下にて1時間撹拌した。反応終了後、各ウェルに検出液を25μLずつ添加し、室温・遮光下にて30分間静置した。静置後、Analyst GT(Molecular Devices社)を用いて励起光340nmを照射した時の520nm及び495nmの蛍光強度を測定し、人工基質のリン酸化を時間分解蛍光共鳴エネルギー転移(TR-FRET)により定量化した。ウェル毎に520nm蛍光シグナルを495nm蛍光シグナルで除算してTR-FRET比を算出し、以下の式により被験化合物群での阻害率(%)を算出した。
その結果、本発明化合物において、例えば、実施例5、実施例5(1)、実施例5(6)、実施例17(2)、および実施例23(2)の化合物のIC50値は、それぞれ0.0022μM、0.0056μM、0.0043μM、0.0044μMおよび0.0011μMであった。
一方、比較化合物として、下記構造を有する特許文献1記載の実施例8の化合物(比較化合物A)、および特許文献3記載の化合物2(比較化合物B)のAxl阻害活性を測定したところ、いずれもそのIC50値は10μMより大きかった。
96ウェルプレートに0.1mmol/Lの被験化合物のDMSO溶液を分注し、さらにDMSOで3倍公比の希釈系列を調製した。各濃度の被験化合物のDMSO溶液をRPMI1640培地(10%HI-FBS、1%ペニシリン含有)でさらに500倍希釈して最終濃度の500倍濃度の被験化合物を含む被験化合物希釈溶液を調製した。測定用の96ウェルプレート(BD Bioscience社)の各ウェルに、Blank群にはRPMI培地を、媒体群には0.2%DMSOを含むRPMI培地を、被験化合物群には被験化合物希釈溶液をそれぞれ50μLずつ添加した。Ba/F3 Axlを、2×105細胞数/mLの密度になるよう培地で希釈し、細胞懸濁液を調製した。測定用の96ウェルプレートの各ウェルに、Blank群にはRPMI培地を、媒体群及び被験化合物群には細胞懸濁液をそれぞれ50μLずつ添加し、37℃、5%CO2で48時間静置した。静置終了後、CELLTITER-GLO(登録商標)LUMINESCENT CELL VIABILITY ASSAY(Promega社)を使用して相対発光単位(RLU;Relative Light Unit)を測定した。測定は添付の説明書に準じて実施した。各ウェルに100μLの発光液を添加し室温にて3分間プレートを撹拌後、室温・遮光下にて10分間静置し、マイクロプレートリーダー(SpectraMax M5e、Molecular Devices社)を用いてRLUを測定した。Blank群及び媒体群のRLUの平均値を算出し、以下の式で被験化合物群の増殖抑制率を算出した。
その結果、本発明化合物において、例えば、実施例5、実施例5(1)、実施例5(6)、実施例17(2)、および実施例23(2)の化合物のIC50値は、それぞれ0.0007μM、0.0008μM、0.0078μM、0.0012μMおよび0.0012μMであった。
一方、比較化合物Aおよび比較化合物BのIC50値は、それぞれ0.62μMおよび>10μMであった。
生物学的実施例1と同様に、被験化合物の各種キナーゼ(KDR、DDR1、FLT4、ROS)に対する50%阻害率の値(IC50値)を測定した。被験化合物のこれらキナーゼ、例えばKDRに対するAxl選択的な阻害活性は、上記IC50値の比に基づいて算出し、以下の表1に示す通りであった。被験化合物として、本発明化合物は実施例5、実施例5(1)、実施例17(2)、および実施例23(2)を用い、比較化合物は下記構造を有する特許文献5記載の実施例74の化合物(比較化合物C)、および実施例92(比較化合物D)の化合物を用いた。
反応は384ウェルプレート上にて行った。陽性対照物質(CYP2C8:クェルセチン)は最終濃度の300倍の濃度にDMSOで調整し(CYP2C8:22.5および225μmol/L)、2.7%のアセトニトリルを含む精製水で75倍希釈した溶液を準備した(CYP2C8:0.3および3μmol/L)。被験化合物はDMSOで0.3および3mmol/Lに調製後、2.7%アセトニトリルを含む精製水で75倍希釈し、4および40μmol/Lに調製した。次にリン酸カリウム緩衝液(pH7.4)、塩化マグネシウム(5mol/L)、基質(CYP2C8:Luciferin-ME、150μmol/L)および大腸菌発現系肝ミクロソームのCYP2C8(Cypex、30pmol/L)を加えた反応混合液を調製した(数値は最終濃度)。この反応混合液8μLと前述で準備した被験化合物および陽性対照物質溶液を各ウェルに4μL、NADPH産生系溶液(5.2mM NADP、13.2mM グルコース6リン酸、1.6 U/mL グルコース6リン酸デヒドロゲナーゼ)を4μL加えて反応を開始し、37℃で30分間インキュベーションを行った。その後、ルシフェラーゼ溶液 16μLを添加して反応停止とともにルシフェリンを発光させ、反応液の発光強度を測定した。阻害率は被験化合物溶液の代わりにDMSOを添加して反応をおこなったコントロールと比較した時の発光強度の減少率(阻害率)とし、以下の式により算出した。
阻害率(%)=100-{(被験化合物の発光強度-バックグランドの発光強度)/(コントロールの発光強度-バックグランドの発光強度)×100}
IC50値は、1μmol/Lで阻害率が50%以上の時は<1μM、10μmol/Lで阻害率が50%以下の場合は>10μMとし、その間(1μmol/Lで50%以下かつ10μmol/Lで50%以上の場合)については以下の式により算出した。
IC50=(50-b)/a
ただし、a、bは、1μmol/Lの濃度と阻害率および10μmol/Lの濃度と阻害率の2点を通る線形回帰直線y=ax+bの傾きと切片とした。
上記の測定方法で、比較化合物および本発明化合物のIC50値を測定した。
その結果、比較化合物E(特許文献4記載の実施例133)は、CYP2C8のIC50値が、2.6μMであった。一方、本発明化合物では、例えば、実施例5、実施例5(1)、実施例17(2)、および実施例23(2)の化合物は、CYP2C8のIC50値がいずれも>10μMであった。したがって、本発明化合物は比較化合物に対してCYP阻害作用が低いことがわかった。
製剤例1
以下の各成分を常法により混合した後打錠して、一錠中に10mgの活性成分を含有する錠剤1万錠を得た。
・N-{5-[(6,7-ジメトキシ-4-キノリニル)オキシ]-2-ピリジニル}-2,5-ジオキソ-1-フェニル-1,2,5,6,7,8-ヘキサヒドロ-3-キノリンカルボキサミド…100g
・カルボキシメチルセルロースカルシウム(崩壊剤) … 20g
・ステアリン酸マグネシウム(潤滑剤) … 10g
・微結晶セルロース … 870g
以下の各成分を常法により混合した後、除塵フィルターでろ過し、5mlずつアンプルに充填し、オートクレーブで加熱滅菌して、1アンプル中20mgの活性成分を含有するアンプル1万本を得た。
・N-{5-[(6,7-ジメトキシ-4-キノリニル)オキシ]-2-ピリジニル}-7,7-ジメチル-2,5-ジオキソ-1-フェニル-1,2,5,6,7,8-ヘキサヒドロ-3-キノリンカルボキサミド…200g
・マンニトール … 20g
・蒸留水 … 50L
Claims (15)
- 一般式(I)
ここで、R1で表されるC1~8アルキル基が分枝鎖アルキル基の場合、同一の炭素原子から分枝したC1~3アルキル基は結合する炭素原子と一緒になってC3~7の飽和炭素環を形成してもよく、
R2は(1)C1~4アルキル基、(2)ハロゲン原子、(3)C1~4ハロアルキル基、(4)オキソ基、(5)-OR21基、または(6)=NR22基を表し、
R3は(1)C1~4アルキル基、(2)ハロゲン原子、または(3)C1~4ハロアルキル基を表し、
R4は(1)C1~4アルコキシ基、(2)C1~4ハロアルキル基、(3)-OR41基、(4)C1~4アルキル基、(5)C2~4アルケニルオキシ基、または(6)C2~4アルキニルオキシ基を表し、
R5は(1)水素原子、(2)C1~4アルキル基、(3)ハロゲン原子、(4)C1~4ハロアルキル基、または(5)-OR21基を表し、
R11は(1)-OR101基、(2)SO2R102基、(3)NR103R104基、または(4)1~3個のハロゲン原子で置換されていてもよいC3~7の炭素環を表し、
R12は(1)水酸基で置換されていてもよいC1~8アルキル基、または(2)ハロゲン原子を表し、
R13は(1)水酸基で置換されていてもよいC1~8アルキル基、または(2)ハロゲン原子を表し、
R21は(1)水素原子、または(2)C1~4アルキル基を表し、
R22は(1)水酸基、または(2)C1~4アルコキシ基を表し、
R41は、
(1)水素原子、
(2)(a)(i)C1~4アルキル基、(ii)C1~4ハロアルキル基、および(iii)ハロゲン原子からなる群から選択される1~2個の置換基で置換されていてもよい5~7員の環状基、(b)NR401R402、(c)水酸基、および(d)SO2R403基からなる群から選択される1~2個の置換基で置換されたC1~8アルキル基、
(3)(a)(i)C1~4アルキル基、(ii)C1~4ハロアルキル基、および(iii)ハロゲン原子からなる群から選択される1~2個の置換基で置換されていてもよい5~7員の環状基、(b)NR401R402、(c)水酸基、および(d)SO2R403基からなる群から選択される1~2個の置換基で置換されたC2~8アルケニル基、
または
(4)(a)(i)C1~4アルキル基、(ii)C1~4ハロアルキル基、および(iii)ハロゲン原子からなる群から選択される1~2個の置換基で置換されていてもよい5~7員の環状基、(b)NR401R402、(c)水酸基、および(d)SO2R403基からなる群から選択される1~2個の置換基で置換されたC2~8アルキニル基を表し、
R101は(1)水素原子、または(2)C1~4アルキル基を表し、
R102は(1)水素原子、または(2)C1~4アルキル基を表し、
R103およびR104はそれぞれ独立して、(1)水素原子、または(2)C1~4アルキル基を表し、
R401およびR402はそれぞれ独立して、(1)水素原子、または(2)C1~4アルキル基を表し、
R403は(1)水素原子、または(2)C1~4アルキル基を表し、
Aは(1)CH、または(2)窒素原子を表し、
Lは(1)-O-、(2)-NH-、(3)-C(O)-、(4)-CR6R7-、(5)-S-、(6)-S(O)-、または(7)-S(O)2-を表し、
R6およびR7はそれぞれ独立して、(1)水素原子、(2)ハロゲン原子、(3)C1~4アルキル基、(4)水酸基、または(5)NH2を表し、
ring1は5~7員の環状基を表し、
mは0~5の整数を表し、
nは0~5の整数を表し、
pは0~2の整数を表し、
qは0~4の整数を表し、
mが2以上のとき、複数のR2は同じでも異なっていてもよく、ここで、2個のR2がC1~3アルキル基を表し、かつ同一の炭素原子上にあるとき、当該R2と結合する炭素原子が一緒になってC3~7の飽和炭素環を形成してもよく、
nが2以上のとき、複数のR3は同じでも異なっていてもよく、
qが2以上のとき、複数のR4は同じでも異なっていてもよい。]で示される化合物、その塩、その溶媒和物、そのN-オキシド体、またはそれらのプロドラッグ。 - mが1以上であり、かつR2の1つが必ずオキソ基である請求項1記載の化合物。
- ring1がベンゼン、またはピリジンである請求項1または2に記載の化合物。
- Lが(1)-O-、(2)-NH-、または(3)-C(O)-である請求項1~3のいずれかに記載の化合物。
- 一般式(I-1)
m-1は0~4の整数を表し、
L1は(1)-O-、(2)-NH-、または(3)-C(O)-を表し、
ring1-1はベンゼン、またはピリジンを表し、
m-1が2以上のとき、複数のR2-1は同じでも異なっていてもよく、
ここで、2個のR2-1がC1~3アルキル基を表し、かつ同一の炭素原子上にあるとき、当該R2-1と結合する炭素原子が一緒になってC3~7の飽和炭素環を形成してもよく、
その他の記号は請求項1記載と同じ意味を表す。]で示される請求項1記載の化合物。 - (1)N-{5-[(6,7-ジメトキシ-4-キノリニル)オキシ]-2-ピリジニル}-2,5-ジオキソ-1-フェニル-1,2,5,6,7,8-ヘキサヒドロ-3-キノリンカルボキサミド、(2)N-{5-[(6,7-ジメトキシ-4-キノリニル)オキシ]-2-ピリジニル}-7,7-ジメチル-2,5-ジオキソ-1-フェニル-1,2,5,6,7,8-ヘキサヒドロ-3-キノリンカルボキサミド、(3)N-{5-[(6,7-ジメトキシ-4-キノリニル)オキシ]-2-ピリジニル}-1-(2,2-ジメチルプロピル)-2,5-ジオキソ-1,2,5,6,7,8-ヘキサヒドロ-3-キノリンカルボキサミド、(4)N-[5-({7-[3-(4-モルホリニル)プロポキシ]-4-キノリニル}オキシ)-2-ピリジニル]2,5-ジオキソ-1-フェニル-1,2,5,6,7,8-ヘキサヒドロ-3-キノリンカルボキサミド、(5)N-{4-[(6,7-ジメトキシ-4-キノリニル)オキシ]-3-フルオロフェニル}-2,5-ジオキソ-1-フェニル-1,2,5,6,7,8-ヘキサヒドロ-3-キノリンカルボキサミド、(6)N-{4-[(6,7-ジメトキシ-4-キノリニル)オキシ]フェニル}-2,5-ジオキソ-1-フェニル-1,2,5,6,7,8-ヘキサヒドロ-3-キノリンカルボキサミド、(7)N-{5-[(6,7-ジメトキシ-4-キノリニル)オキシ]-2-ピリジニル}-1-(4-フルオロフェニル)-2,5-ジオキソ-1,2,5,6,7,8-ヘキサヒドロ-3-キノリンカルボキサミド、(8)N-{5-[(6,7-ジメトキシ-4-キノリニル)オキシ]-2-ピリジニル}-1-(3-フルオロフェニル)-2,5-ジオキソ-1,2,5,6,7,8-ヘキサヒドロ-3-キノリンカルボキサミド、(9)N-{5-[(6,7-ジメトキシ-4-キノリニル)オキシ]-2-ピリジニル}-1-(2-フルオロフェニル)-2,5-ジオキソ-1,2,5,6,7,8-ヘキサヒドロ-3-キノリンカルボキサミド、(10)N-{5-[(6,7-ジメトキシ-4-キナゾリニル)オキシ]-2-ピリジニル}-2,5-ジオキソ-1-フェニル-1,2,5,6,7,8-ヘキサヒドロ-3-キノリンカルボキサミド、(11)N-{5-[(6,7-ジメトキシ-4-キナゾリニル)オキシ]-2-ピリジニル}-1-(4-フルオロフェニル)-2,5-ジオキソ-1,2,5,6,7,8-ヘキサヒドロ-3-キノリンカルボキサミド、(12)N-{5-[(6,7-ジメトキシ-4-キノリニル)オキシ]-2-ピリジニル}-1-[(2S)-1-ヒドロキシ-3-メチル-2-ブタニル]-2,5-ジオキソ-1,2,5,6,7,8-ヘキサヒドロ-3-キノリンカルボキサミド、(13)N-{4-[(6,7-ジメトキシ-4-キノリニル)オキシ]-3-フルオロフェニル}-1-(3-フルオロフェニル)-2,5-ジオキソ-1,2,5,6,7,8-ヘキサヒドロ-3-キノリンカルボキサミド、(14)N-{5-[(6,7-ジメトキシ-4-キノリニル)オキシ]-2-ピリジニル}-6,6-ジメチル-2,5-ジオキソ-1-フェニル-1,2,5,6,7,8-ヘキサヒドロ-3-キノリンカルボキサミド、(15)N-[5-({6-メトキシ-7-[3-(4-モルホリニル)プロポキシ]-4-キノリニル}オキシ)-2-ピリジニル]-2,5-ジオキソ-1-フェニル-1,2,5,6,7,8-ヘキサヒドロ-3-キノリンカルボキサミド、(16)N-(5-{[7-(3-ヒドロキシ-3-メチルブトキシ)-6-メトキシ-4-キノリニリル]オキシ}-2-ピリジニル)-2,5-ジオキソ-1-フェニル-1,2,5,6,7,8-ヘキサヒドロ-3-キノリンカルボキサミド、または(17)N-[5-({6-メトキシ-7-[3-(1-ピロリジニル)プロポキシ]-4-キノリニル}オキシ)-2-ピリジニル]-2,5-ジオキソ-1-フェニル-1,2,5,6,7,8-ヘキサヒドロ-3-キノリンカルボキサミドである請求項1~5のいずれかに記載の化合物。
- 請求項1記載の一般式(I)で示される化合物、その塩、その溶媒和物、そのN-オキシド体、またはそれらのプロドラッグを含有してなる医薬組成物。
- Axl阻害剤である請求項7記載の医薬組成物。
- Axl関連疾患の予防および/または治療剤である請求項7記載の医薬組成物。
- Axl関連疾患が、癌、腎臓疾患、免疫系疾患、または循環器系疾患である請求項9記載の医薬組成物。
- 癌が、急性骨髄性白血病、慢性骨髄性白血病、急性リンパ性白血病、メラノーマ、乳癌、膵臓癌、神経膠腫、食道腺癌、大腸癌、腎細胞癌、甲状腺癌、非小細胞肺癌、前立腺癌、胃癌、肝癌、ブドウ膜悪性黒色腫、卵巣癌、子宮内膜癌、リンパ腫、頭頸部癌、または肉腫である請求項10記載の医薬組成物。
- 癌細胞の転移抑制剤である請求項7記載の医薬組成物。
- 請求項1記載の一般式(I)で示される化合物、その塩、その溶媒和物、そのN-オキシド、またはそれらのプロドラッグの有効量を哺乳動物に投与することを特徴とする、Axl関連疾患の予防および/または治療方法。
- Axl関連疾患の予防および/または治療のための請求項1記載の一般式(I)で示される化合物、その塩、その溶媒和物、そのN-オキシド、またはそれらのプロドラッグ。
- Axl関連疾患の予防および/または治療剤を製造するための請求項1記載の一般式(I)で示される化合物、その塩、その溶媒和物、そのN-オキシド、またはそれらのプロドラッグの使用。
Priority Applications (26)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MYPI2016700235A MY191433A (en) | 2013-07-24 | 2014-07-23 | Quinoline derivative |
MX2016000989A MX365377B (es) | 2013-07-24 | 2014-07-23 | Derivado de quinolina. |
RU2016102036A RU2666895C2 (ru) | 2013-07-24 | 2014-07-23 | ПРОИЗВОДНОЕ ХИНОЛИНА ИЛИ ХИНАЗОЛИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРА Axl |
BR112016001515-0A BR112016001515B1 (pt) | 2013-07-24 | 2014-07-23 | Compostos derivados de quinolina, composição farmacêutica compreendendo ditos compostos e uso dos mesmos para prevenir e/ou tratar uma doença relacionada ao axl |
AU2014294109A AU2014294109B2 (en) | 2013-07-24 | 2014-07-23 | Quinoline derivative |
KR1020167002008A KR102251609B1 (ko) | 2013-07-24 | 2014-07-23 | 퀴놀린 유도체 |
DK14828976.2T DK3026045T3 (da) | 2013-07-24 | 2014-07-23 | Quinolinderivat |
ES14828976.2T ES2694513T3 (es) | 2013-07-24 | 2014-07-23 | Derivado de quinolina |
EP14828976.2A EP3026045B1 (en) | 2013-07-24 | 2014-07-23 | Quinoline derivative |
JP2015528303A JP6213564B2 (ja) | 2013-07-24 | 2014-07-23 | キノリン誘導体 |
PL14828976T PL3026045T3 (pl) | 2013-07-24 | 2014-07-23 | Pochodna chinoliny |
NZ716244A NZ716244B2 (en) | 2013-07-24 | 2014-07-23 | Quinoline derivative |
EP18185739.2A EP3415501B9 (en) | 2013-07-24 | 2014-07-23 | Quinoline derivative |
US14/906,993 US9573935B2 (en) | 2013-07-24 | 2014-07-23 | Quinoline derivative |
CA2918888A CA2918888C (en) | 2013-07-24 | 2014-07-23 | Quinoline derivative |
SG11201600533XA SG11201600533XA (en) | 2013-07-24 | 2014-07-23 | Quinoline derivative |
CN201480041780.2A CN105408312B (zh) | 2013-07-24 | 2014-07-23 | 喹啉衍生物 |
IL243743A IL243743B (en) | 2013-07-24 | 2016-01-21 | A consequence of quinoline |
PH12016500150A PH12016500150A1 (en) | 2013-07-24 | 2016-01-21 | Quinoline derivative |
ZA2016/00514A ZA201600514B (en) | 2013-07-24 | 2016-01-22 | Quinoline derivative |
HK16107769.6A HK1219735A1 (zh) | 2013-07-24 | 2016-07-05 | 喹啉誘導體 |
US15/373,091 US9994549B2 (en) | 2013-07-24 | 2016-12-08 | Quinoline derivative |
US15/975,999 US10208022B2 (en) | 2013-07-24 | 2018-05-10 | Quinoline derivative |
US16/237,275 US10501442B2 (en) | 2013-07-24 | 2018-12-31 | Quinoline derivative |
US16/540,306 US10676462B2 (en) | 2013-07-24 | 2019-08-14 | Quinoline derivative |
US16/858,244 US20200392110A1 (en) | 2013-07-24 | 2020-04-24 | Quinoline derivative |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013153350 | 2013-07-24 | ||
JP2013-153350 | 2013-07-24 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/906,993 A-371-Of-International US9573935B2 (en) | 2013-07-24 | 2014-07-23 | Quinoline derivative |
US15/373,091 Continuation US9994549B2 (en) | 2013-07-24 | 2016-12-08 | Quinoline derivative |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015012298A1 true WO2015012298A1 (ja) | 2015-01-29 |
Family
ID=52393331
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2014/069419 WO2015012298A1 (ja) | 2013-07-24 | 2014-07-23 | キノリン誘導体 |
Country Status (23)
Country | Link |
---|---|
US (6) | US9573935B2 (ja) |
EP (2) | EP3026045B1 (ja) |
JP (2) | JP6213564B2 (ja) |
KR (1) | KR102251609B1 (ja) |
CN (1) | CN105408312B (ja) |
AU (1) | AU2014294109B2 (ja) |
BR (1) | BR112016001515B1 (ja) |
CA (1) | CA2918888C (ja) |
DK (1) | DK3026045T3 (ja) |
ES (2) | ES2798150T3 (ja) |
HK (1) | HK1219735A1 (ja) |
HU (1) | HUE040238T2 (ja) |
IL (1) | IL243743B (ja) |
MX (1) | MX365377B (ja) |
MY (1) | MY191433A (ja) |
PH (1) | PH12016500150A1 (ja) |
PL (1) | PL3026045T3 (ja) |
PT (1) | PT3026045T (ja) |
RU (1) | RU2666895C2 (ja) |
SG (1) | SG11201600533XA (ja) |
TW (1) | TWI649308B (ja) |
WO (1) | WO2015012298A1 (ja) |
ZA (1) | ZA201600514B (ja) |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016104617A1 (ja) * | 2014-12-25 | 2016-06-30 | 小野薬品工業株式会社 | キノリン誘導体 |
WO2016193680A1 (en) * | 2015-05-29 | 2016-12-08 | Bergenbio As | Combination therapy with axl inhibitor and immune checkpoint modulator or oncolytic virus |
WO2017028797A1 (zh) * | 2015-08-18 | 2017-02-23 | 暨南大学 | 取代喹诺酮类衍生物或其药学上可接受的盐或立体异构体及其药用组合物和应用 |
US9708333B2 (en) | 2015-08-12 | 2017-07-18 | Incyte Corporation | Fused bicyclic 1,2,4-triazine compounds as TAM inhibitors |
WO2017146236A1 (ja) | 2016-02-26 | 2017-08-31 | 小野薬品工業株式会社 | Axl阻害剤と免疫チェックポイント阻害剤とを組み合わせて投与することを特徴とする癌治療のための医薬 |
US9840503B2 (en) | 2015-05-11 | 2017-12-12 | Incyte Corporation | Heterocyclic compounds and uses thereof |
US9981975B2 (en) | 2016-03-28 | 2018-05-29 | Incyte Corporation | Pyrrolotriazine compounds as tam inhibitors |
US9994549B2 (en) | 2013-07-24 | 2018-06-12 | Ono Pharmaceutical Co., Ltd. | Quinoline derivative |
WO2018139527A1 (ja) | 2017-01-26 | 2018-08-02 | 小野薬品工業株式会社 | キノリン誘導体のエタンスルホン酸塩 |
US10053465B2 (en) | 2015-08-26 | 2018-08-21 | Incyte Corporation | Pyrrolopyrimidine derivatives as TAM inhibitors |
WO2019039525A1 (ja) | 2017-08-23 | 2019-02-28 | 小野薬品工業株式会社 | Axl阻害剤を有効成分として含むがん治療剤 |
WO2019074116A1 (ja) | 2017-10-13 | 2019-04-18 | 小野薬品工業株式会社 | Axl阻害剤を有効成分として含む固形がん治療剤 |
US10633387B2 (en) | 2017-09-27 | 2020-04-28 | Incyte Corporation | Salts of TAM inhibitors |
US10744134B2 (en) | 2015-11-04 | 2020-08-18 | Astellas Pharma Inc. | Pharmaceutical composition for cancer immunotherapy and/or immunological activation containing diamino heterocyclic carboxamide compound as active ingredient |
WO2020188015A1 (en) | 2019-03-21 | 2020-09-24 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
CN112513030A (zh) * | 2018-06-01 | 2021-03-16 | 里格尔药品股份有限公司 | 用作酪氨酸激酶抑制剂的喹啉衍生物 |
WO2021089791A1 (en) | 2019-11-08 | 2021-05-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
US11241438B2 (en) | 2018-06-29 | 2022-02-08 | Incyte Corporation | Formulations of an AXL/MER inhibitor |
WO2022220227A1 (ja) * | 2021-04-14 | 2022-10-20 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | テトラヒドロピリドピリミジン化合物 |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150299219A1 (en) | 2014-04-22 | 2015-10-22 | Calitor Sciences, Llc | Bicyclic pyrazolone compounds and methods of use |
AR103726A1 (es) | 2015-02-27 | 2017-05-31 | Merck Sharp & Dohme | Cristales de anticuerpos monoclonales anti-pd-1 humanos |
US10550135B2 (en) | 2016-03-30 | 2020-02-04 | Council Of Scientific & Industrial Research | Silicon incorporated quinolines with anti-malarial and anti-toxoplasmosis activity |
CN108250200A (zh) * | 2016-12-28 | 2018-07-06 | 中国科学院上海药物研究所 | 一种具有Axl抑制活性的化合物及其制备和应用 |
JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
US11845798B2 (en) | 2017-05-02 | 2023-12-19 | Merck Sharp & Dohme Llc | Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies |
CN109232416B (zh) * | 2018-10-24 | 2021-09-24 | 福州大学 | 一种合成4-三氟甲基-2-吡喃酮/吡啶酮化合物的方法 |
CN110078675B (zh) * | 2019-04-25 | 2022-09-23 | 郑州大学 | 4-芳基喹唑啉类化合物及其制备方法 |
WO2021062245A1 (en) * | 2019-09-26 | 2021-04-01 | Exelixis, Inc. | Pyridone compounds and methods of use in the modulation of a protein kinase |
CN115605478A (zh) * | 2020-02-24 | 2023-01-13 | 埃克塞里艾克西斯公司(Us) | 化合物和使用方法 |
CN116390729A (zh) * | 2020-05-18 | 2023-07-04 | 伟迈可生物有限公司 | 用于预防或治疗与ron突变相关的非小细胞肺癌的药物组合物及其使用方法 |
US20230202992A1 (en) * | 2020-05-18 | 2023-06-29 | Wellmarker Bio Co., Ltd. | Pharmaceutical composition for preventing or treating small-cell lung cancer associated with ron mutants and method using same |
WO2021235813A1 (ko) * | 2020-05-18 | 2021-11-25 | 웰마커바이오 주식회사 | Ron 돌연변이와 관련된 췌장암 예방 또는 치료용 약학 조성물 및 이를 이용한 방법 |
JP2024507794A (ja) * | 2021-02-19 | 2024-02-21 | エグゼリクシス, インコーポレイテッド | ピリドン化合物および使用方法 |
WO2022237843A1 (zh) * | 2021-05-12 | 2022-11-17 | 微境生物医药科技(上海)有限公司 | Axl抑制剂 |
AR126963A1 (es) * | 2021-09-13 | 2023-12-06 | Lilly Co Eli | Agonistas de ahr |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006116713A1 (en) | 2005-04-27 | 2006-11-02 | Amgen Inc. | Substituted amide derivatives as protein kinase inhibitors |
WO2007146824A2 (en) | 2006-06-08 | 2007-12-21 | Array Biopharma Inc. | Quinoline compounds and methods of use |
WO2009137429A1 (en) * | 2008-05-05 | 2009-11-12 | Smithkline Beecham Corporation | Method of treating cancer using a cmet and axl inhibitor and an erbb inhibitor |
WO2012011548A1 (ja) | 2010-07-23 | 2012-01-26 | 国立大学法人 東京大学 | 含窒素複素環誘導体 |
WO2012028332A1 (en) | 2010-08-28 | 2012-03-08 | Lead Discovery Center Gmbh | Pharmaceutically active compounds as axl inhibitors |
WO2013074633A1 (en) | 2011-11-14 | 2013-05-23 | Cephalon, Inc. | Uracil derivatives as axl and c-met kinase inhibitors |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4656174A (en) * | 1982-07-24 | 1987-04-07 | Pfizer Inc. | Quinoline therapeutic agents |
RU2240313C2 (ru) * | 1999-10-25 | 2004-11-20 | Эктив Байотек Аб | Лекарственные средства для лечения злокачественных опухолей |
CZ20022332A3 (cs) | 2000-01-07 | 2003-01-15 | Transform Pharmaceuticals, Inc. | Sestava vzorků |
WO2007033196A1 (en) | 2005-09-14 | 2007-03-22 | Bristol-Myers Squibb Company | Met kinase inhibitors |
EP2023926B1 (en) | 2006-05-19 | 2011-10-12 | Bayer Pharma Aktiengesellschaft | Pyridonecarboxamide derivatives useful in treating hyper-proliferative and angiogenesis disorders |
RU2010146474A (ru) | 2008-04-16 | 2012-05-27 | Макс-Планк-Гезелльшафт Цур Фердерунг Дер Виссеншафтен Е.Ф. (De) | Производные хинолина в качестве ингибиторов axl киназ |
WO2009140549A1 (en) | 2008-05-14 | 2009-11-19 | Amgen Inc. | Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer |
CA2738583A1 (en) | 2008-10-01 | 2010-04-08 | Ludwig Institute For Cancer Research | Methods for the treatment of cancer |
JP2010178651A (ja) | 2009-02-04 | 2010-08-19 | Eisai R & D Management Co Ltd | Hgfr阻害物質の作用検定方法 |
CA2818903C (en) | 2010-12-14 | 2021-03-23 | Electrophoretics Limited | 5-(1,3-benzoxazol-2-yl)-4-(pyridin-4-yl)pyrimidin-2-amine and its use as a casein kinase 1delta inhibitor |
CN102816175B (zh) | 2011-06-09 | 2015-12-16 | 上海汇伦生命科技有限公司 | 一种杂环并吡啶酮类化合物,其中间体、制备方法和用途 |
TWI649308B (zh) | 2013-07-24 | 2019-02-01 | 小野藥品工業股份有限公司 | 喹啉衍生物 |
-
2014
- 2014-07-22 TW TW103125057A patent/TWI649308B/zh active
- 2014-07-23 ES ES18185739T patent/ES2798150T3/es active Active
- 2014-07-23 ES ES14828976.2T patent/ES2694513T3/es active Active
- 2014-07-23 WO PCT/JP2014/069419 patent/WO2015012298A1/ja active Application Filing
- 2014-07-23 BR BR112016001515-0A patent/BR112016001515B1/pt active IP Right Grant
- 2014-07-23 RU RU2016102036A patent/RU2666895C2/ru active
- 2014-07-23 HU HUE14828976A patent/HUE040238T2/hu unknown
- 2014-07-23 MX MX2016000989A patent/MX365377B/es active IP Right Grant
- 2014-07-23 PL PL14828976T patent/PL3026045T3/pl unknown
- 2014-07-23 PT PT14828976T patent/PT3026045T/pt unknown
- 2014-07-23 US US14/906,993 patent/US9573935B2/en active Active
- 2014-07-23 EP EP14828976.2A patent/EP3026045B1/en active Active
- 2014-07-23 MY MYPI2016700235A patent/MY191433A/en unknown
- 2014-07-23 JP JP2015528303A patent/JP6213564B2/ja active Active
- 2014-07-23 EP EP18185739.2A patent/EP3415501B9/en active Active
- 2014-07-23 CN CN201480041780.2A patent/CN105408312B/zh active Active
- 2014-07-23 DK DK14828976.2T patent/DK3026045T3/da active
- 2014-07-23 KR KR1020167002008A patent/KR102251609B1/ko active IP Right Grant
- 2014-07-23 SG SG11201600533XA patent/SG11201600533XA/en unknown
- 2014-07-23 AU AU2014294109A patent/AU2014294109B2/en active Active
- 2014-07-23 CA CA2918888A patent/CA2918888C/en active Active
-
2016
- 2016-01-21 IL IL243743A patent/IL243743B/en active IP Right Grant
- 2016-01-21 PH PH12016500150A patent/PH12016500150A1/en unknown
- 2016-01-22 ZA ZA2016/00514A patent/ZA201600514B/en unknown
- 2016-07-05 HK HK16107769.6A patent/HK1219735A1/zh unknown
- 2016-12-08 US US15/373,091 patent/US9994549B2/en active Active
-
2017
- 2017-09-15 JP JP2017177943A patent/JP6436205B2/ja active Active
-
2018
- 2018-05-10 US US15/975,999 patent/US10208022B2/en active Active
- 2018-12-31 US US16/237,275 patent/US10501442B2/en active Active
-
2019
- 2019-08-14 US US16/540,306 patent/US10676462B2/en active Active
-
2020
- 2020-04-24 US US16/858,244 patent/US20200392110A1/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006116713A1 (en) | 2005-04-27 | 2006-11-02 | Amgen Inc. | Substituted amide derivatives as protein kinase inhibitors |
WO2007146824A2 (en) | 2006-06-08 | 2007-12-21 | Array Biopharma Inc. | Quinoline compounds and methods of use |
WO2009137429A1 (en) * | 2008-05-05 | 2009-11-12 | Smithkline Beecham Corporation | Method of treating cancer using a cmet and axl inhibitor and an erbb inhibitor |
WO2012011548A1 (ja) | 2010-07-23 | 2012-01-26 | 国立大学法人 東京大学 | 含窒素複素環誘導体 |
WO2012028332A1 (en) | 2010-08-28 | 2012-03-08 | Lead Discovery Center Gmbh | Pharmaceutically active compounds as axl inhibitors |
WO2013074633A1 (en) | 2011-11-14 | 2013-05-23 | Cephalon, Inc. | Uracil derivatives as axl and c-met kinase inhibitors |
Non-Patent Citations (11)
Title |
---|
"Molecular Design", vol. 7, 1990, HIROKAWA SHOTEN, article "Development of Medicaments", pages: 163 - 198 |
BLOOD, vol. 121, 2013, pages 2064 - 2073 |
CLINICAL SCIENCE, vol. 122, 2012, pages 361 - 368 |
DATABASE REGISTRY [online] 16 January 2001 (2001-01-16), "3-QUINOLINECARBOXAMIDE, N-[5-[(7-CHLORO-4-QUINOLINYL)THIO]-1,3,4- THIADIAZOL-2-YL]-1,2-DIHYDRO-4-HYDROXY-2-OXO- (CA INDEX NAME)", XP055311240, retrieved from STN Database accession no. 314026-41-0 * |
HYPERTENSION, vol. 39, 2002, pages 1095 - 1100 |
ORGANIC LETTERS, vol. 3, no. 17, 2001, pages 2729 - 2732 |
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 107, no. 3, 2010, pages 1124 - 1129 |
RICHARD C. LAROCK: "Comprehensive Organic Transformations: A Guide to Functional Group Preparations", 1999, JOHN WILEY & SONS INC |
See also references of EP3026045A4 |
T. W. GREENE: "Protective Groups in Organic Synthesis", 1999, JOHN WILEY & SONS INC. |
T. W. GREENE: "Protective Groups in Organic Synthesis", 1999, WILEY |
Cited By (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10501442B2 (en) | 2013-07-24 | 2019-12-10 | Ono Pharmaceuticals Co., Ltd. | Quinoline derivative |
US10676462B2 (en) | 2013-07-24 | 2020-06-09 | Ono Pharmaceutical Co., Ltd. | Quinoline derivative |
US10208022B2 (en) | 2013-07-24 | 2019-02-19 | Ono Pharmaceutical Co., Ltd. | Quinoline derivative |
US9994549B2 (en) | 2013-07-24 | 2018-06-12 | Ono Pharmaceutical Co., Ltd. | Quinoline derivative |
WO2016104617A1 (ja) * | 2014-12-25 | 2016-06-30 | 小野薬品工業株式会社 | キノリン誘導体 |
US10208034B2 (en) | 2014-12-25 | 2019-02-19 | Ono Pharmaceutical Co., Ltd. | Quinoline derivative |
US9840503B2 (en) | 2015-05-11 | 2017-12-12 | Incyte Corporation | Heterocyclic compounds and uses thereof |
JP2020105211A (ja) * | 2015-05-29 | 2020-07-09 | ベルゲンビオ エイエスエイBerGenBio ASA | Axlインヒビタおよび免疫チェックポイントモジュレータまたは腫瘍溶解性ウィルスによる併用療法 |
US11534440B2 (en) | 2015-05-29 | 2022-12-27 | Bergenbio Asa | Combination therapy with Axl inhibitor and immune checkpoint modulator or oncolytic virus |
JP7229194B2 (ja) | 2015-05-29 | 2023-02-27 | ベルゲンビオ エイエスエイ | Axlインヒビタおよび免疫チェックポイントモジュレータまたは腫瘍溶解性ウィルスによる併用療法 |
WO2016193680A1 (en) * | 2015-05-29 | 2016-12-08 | Bergenbio As | Combination therapy with axl inhibitor and immune checkpoint modulator or oncolytic virus |
JP2018521116A (ja) * | 2015-05-29 | 2018-08-02 | ベルゲンビオ エイエスエイBerGenBio ASA | Axlインヒビタおよび免疫チェックポイントモジュレータまたは腫瘍溶解性ウィルスによる併用療法 |
EP3804723A1 (en) * | 2015-05-29 | 2021-04-14 | BerGenBio ASA | Combination therapy |
US10005788B2 (en) | 2015-08-12 | 2018-06-26 | Incyte Corporation | Bicyclic fused pyrimidine compounds as TAM inhibitors |
US9708333B2 (en) | 2015-08-12 | 2017-07-18 | Incyte Corporation | Fused bicyclic 1,2,4-triazine compounds as TAM inhibitors |
JP2018528195A (ja) * | 2015-08-18 | 2018-09-27 | 曁南大学 | 置換キノロン誘導体またはその薬学的に許容される塩もしくはその立体異性体、並びにその医薬組成物及び応用 |
KR102237707B1 (ko) * | 2015-08-18 | 2021-04-08 | 상하이 인스티튜트 오브 마테리아 메디카 차이니즈 아카데미 오브 싸이언시즈 | 퀴놀론계를 대체하는 유도체 또는 그의 약학적으로 수용가능한 염 또는 입체이성체 및 이들의 의약용 조성물과 응용 |
KR20180052640A (ko) * | 2015-08-18 | 2018-05-18 | 상하이 인스티튜트 오브 마테리아 메디카 차이니즈 아카데미 오브 싸이언시즈 | 퀴놀론계를 대체하는 유도체 또는 그의 약학적으로 수용가능한 염 또는 입체이성체 및 이들의 의약용 조성물과 응용 |
CN108473434A (zh) * | 2015-08-18 | 2018-08-31 | 暨南大学 | 取代喹诺酮类衍生物或其药学上可接受的盐或立体异构体及其药用组合物和应用 |
CN106467541A (zh) * | 2015-08-18 | 2017-03-01 | 暨南大学 | 取代喹诺酮类衍生物或其药学上可接受的盐或立体异构体及其药用组合物和应用 |
US10683278B2 (en) | 2015-08-18 | 2020-06-16 | Shanghai Haihe Pharmaceutical Co., Ltd. | Substituted quinolone derivatives, or pharmaceutically acceptable salts or stereoisomers thereof, and pharmaceutical compositions and use thereof |
CN106467541B (zh) * | 2015-08-18 | 2019-04-05 | 暨南大学 | 取代喹诺酮类衍生物或其药学上可接受的盐或立体异构体及其药用组合物和应用 |
WO2017028797A1 (zh) * | 2015-08-18 | 2017-02-23 | 暨南大学 | 取代喹诺酮类衍生物或其药学上可接受的盐或立体异构体及其药用组合物和应用 |
CN108473434B (zh) * | 2015-08-18 | 2021-11-23 | 上海海和药物研究开发股份有限公司 | 取代喹诺酮类衍生物或其药学上可接受的盐或立体异构体及其药用组合物和应用 |
US10519163B2 (en) | 2015-08-26 | 2019-12-31 | Incyte Corporation | Pyrrolopyrimidine derivatives as TAM inhibitors |
US11136326B2 (en) | 2015-08-26 | 2021-10-05 | Incyte Corporation | Pyrrolopyrimidine derivatives as TAM inhibitors |
US10053465B2 (en) | 2015-08-26 | 2018-08-21 | Incyte Corporation | Pyrrolopyrimidine derivatives as TAM inhibitors |
US10744134B2 (en) | 2015-11-04 | 2020-08-18 | Astellas Pharma Inc. | Pharmaceutical composition for cancer immunotherapy and/or immunological activation containing diamino heterocyclic carboxamide compound as active ingredient |
JPWO2017146236A1 (ja) * | 2016-02-26 | 2018-12-20 | 小野薬品工業株式会社 | Axl阻害剤と免疫チェックポイント阻害剤とを組み合わせて投与することを特徴とする癌治療のための医薬 |
WO2017146236A1 (ja) | 2016-02-26 | 2017-08-31 | 小野薬品工業株式会社 | Axl阻害剤と免疫チェックポイント阻害剤とを組み合わせて投与することを特徴とする癌治療のための医薬 |
EP3421039A4 (en) * | 2016-02-26 | 2019-01-02 | ONO Pharmaceutical Co., Ltd. | Drug for cancer therapy characterized by administering combination between axl inhibitor and immune checkpoint inhibitor |
US10844069B2 (en) | 2016-03-28 | 2020-11-24 | Incyte Corporation | Pyrrolotriazine compounds as TAM inhibitors |
US9981975B2 (en) | 2016-03-28 | 2018-05-29 | Incyte Corporation | Pyrrolotriazine compounds as tam inhibitors |
US10442810B2 (en) | 2016-03-28 | 2019-10-15 | Incyte Corporation | Pyrrolotriazine compounds as TAM inhibitors |
US11591338B2 (en) | 2016-03-28 | 2023-02-28 | Incyte Corporation | Pyrrolotriazine compounds as TAM inhibitors |
WO2018139527A1 (ja) | 2017-01-26 | 2018-08-02 | 小野薬品工業株式会社 | キノリン誘導体のエタンスルホン酸塩 |
AU2018211801B2 (en) * | 2017-01-26 | 2021-07-08 | Ono Pharmaceutical Co., Ltd. | Ethane-sulfonate salt of quinoline derivative |
JPWO2018139527A1 (ja) * | 2017-01-26 | 2019-06-27 | 小野薬品工業株式会社 | キノリン誘導体のエタンスルホン酸塩 |
US10836747B2 (en) | 2017-01-26 | 2020-11-17 | Ono Pharmaceutical Co., Ltd. | Ethane-sulfonate salt of quinoline derivative |
KR20190111035A (ko) | 2017-01-26 | 2019-10-01 | 오노 야꾸힝 고교 가부시키가이샤 | 퀴놀린 유도체의 에탄술폰산염 |
KR102571911B1 (ko) | 2017-01-26 | 2023-08-28 | 오노 야꾸힝 고교 가부시키가이샤 | 퀴놀린 유도체의 에탄술폰산염 |
JP7156287B2 (ja) | 2017-08-23 | 2022-10-19 | 小野薬品工業株式会社 | Axl阻害剤を有効成分として含むがん治療剤 |
WO2019039525A1 (ja) | 2017-08-23 | 2019-02-28 | 小野薬品工業株式会社 | Axl阻害剤を有効成分として含むがん治療剤 |
JPWO2019039525A1 (ja) * | 2017-08-23 | 2020-07-30 | 小野薬品工業株式会社 | Axl阻害剤を有効成分として含むがん治療剤 |
US11104682B2 (en) | 2017-09-27 | 2021-08-31 | Incyte Corporation | Salts of TAM inhibitors |
US10633387B2 (en) | 2017-09-27 | 2020-04-28 | Incyte Corporation | Salts of TAM inhibitors |
WO2019074116A1 (ja) | 2017-10-13 | 2019-04-18 | 小野薬品工業株式会社 | Axl阻害剤を有効成分として含む固形がん治療剤 |
US11826363B2 (en) | 2017-10-13 | 2023-11-28 | Ono Pharmaceutical Co., Ltd. | Therapeutic agent for solid cancers, which comprises Axl inhibitor as active ingredient |
JP7223998B2 (ja) | 2017-10-13 | 2023-02-17 | 小野薬品工業株式会社 | Axl阻害剤を有効成分として含む固形がん治療剤 |
JPWO2019074116A1 (ja) * | 2017-10-13 | 2020-11-05 | 小野薬品工業株式会社 | Axl阻害剤を有効成分として含む固形がん治療剤 |
CN112513030A (zh) * | 2018-06-01 | 2021-03-16 | 里格尔药品股份有限公司 | 用作酪氨酸激酶抑制剂的喹啉衍生物 |
US11918585B2 (en) | 2018-06-29 | 2024-03-05 | Incyte Corporation | Formulations of an AXL/MER inhibitor |
US11241438B2 (en) | 2018-06-29 | 2022-02-08 | Incyte Corporation | Formulations of an AXL/MER inhibitor |
WO2020188015A1 (en) | 2019-03-21 | 2020-09-24 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
WO2021089791A1 (en) | 2019-11-08 | 2021-05-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
WO2022220227A1 (ja) * | 2021-04-14 | 2022-10-20 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | テトラヒドロピリドピリミジン化合物 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6436205B2 (ja) | キノリン誘導体 | |
JP6708130B2 (ja) | キノリン誘導体 | |
JP6493218B2 (ja) | ピロロピリミジン誘導体 | |
KR20130098269A (ko) | 테트라히드로카르볼린 유도체 | |
NZ716244B2 (en) | Quinoline derivative |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201480041780.2 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14828976 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2015528303 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2918888 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 243743 Country of ref document: IL Ref document number: 12016500150 Country of ref document: PH Ref document number: 2014828976 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20167002008 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14906993 Country of ref document: US Ref document number: IDP00201600443 Country of ref document: ID Ref document number: MX/A/2016/000989 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112016001515 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2014294109 Country of ref document: AU Date of ref document: 20140723 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2016102036 Country of ref document: RU Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 112016001515 Country of ref document: BR Kind code of ref document: A2 Effective date: 20160122 |